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Emily G. Werth: Exploration of kinase-regulated cellular signaling in Chlamydomonas 
reinhardtii 
(Under the direction of Leslie M. Hicks) 
Post-translational modifications (PTMs) on proteins to form functional protein products 
are a key level of cellular signaling regulation. Because of this, there has been an immense effort 
in the proteomics community to improve quantitative enrichment, acquisition, and bioinformatics 
strategies for the analysis of PTMs to probe metabolic pathways. The identification of dynamic 
protein phosphorylation events, a vital PTM, is especially important for understanding kinase/ 
phosphatase-regulated signaling pathways, and is the focus of this dissertation. The aim of this 
dissertation is to develop and apply phosphoproteomic strategies in the alga Chlamydomonas 
reinhardtii to characterize the role of protein phosphorylation on cellular regulation in a diverse 
array of signaling networks. 
Techniques for algal cell culturing, protein extraction, quantitative enrichment, 
acquisition and bioinformatics processing developed and adapted for Chlamydomonas are 
discussed (Chapter 2). Using these techniques, a quantitative workflow for a dual enrichment 
strategy to target intact protein kinases via capture on immobilized multiplexed inhibitor beads 
with subsequent proteolytic digestion of unbound proteins and peptide-based phosphorylation 
enrichment was developed (Chapter 3). This workflow obtained quantitative coverage on 115 
protein kinases and 2,304 phosphopeptides. Application of the quantitative phosphoproteomic 
pipeline was employed to study the effect of Target of Rapamycin (TOR) kinase inhibition on 
the Chlamydomonas phosphoproteome in wild-type (Chapter 4) and extension into a rapamycin
iv 
hypersensitive mutant line (Chapter 5). From the wild-type study, three TOR inhibitors with 
varying mechanisms of inhibition were used to obtain quantitative coverage on 2,547 unique 
phosphosites with 258 phosphosites differentially changing following inhibition. This approach 
identified Chlamydomonas homologs of TOR signaling-related proteins such as RPS6 and 
LARP1 that had decreased phosphorylation upon TORC1 inhibition. Additionally, this led to 
follow-up experiments guided by our phosphoproteomic findings showing that carotenoid levels 
are affected by TORC1 inhibition, the first evidence that carotenoid production is under TOR 
control. From the rapamycin hypersensitive mutant study, the workflow obtained quantitative 
coverage on 2,699 phosphosites with 316 sites changing following rapamycin treatment. This 
study showed similarities with the sites modulated in the wild-type study described in Chapter 4 




I would like to thank my advisor, Leslie M. Hicks, for her mentorship and research 
guidance. Leslie gave me the freedom to be curious and to take ownership over my project while 
always giving insightful ideas and feedback to move the work forward. Her leadership and 
passion has made the Hicks group a special place to work and I look back at my time at UNC 
fondly because of it. Thank you to the members of the Hicks group that I’ve spent every day 
(and some nights) working alongside, I am grateful for your edits, advice, coffee breaks, and the 
laughter. Christine, I don’t think I would have made it through if you weren’t there alongside. 
Seriously, I question if I would have missed a final admin deadline and been kicked out if it 
weren’t for you. Evan, I think we’ve talked through more problems and come up with more ideas 
on walks to lunch than I can count, so thank you for being my PTM person. Megan and Anthony, 
I am excited to see where you take your projects from here and how you will move the TOR 
work along. Nicole and Tessa, I appreciate your friendship and getting to know you.  
This experience wouldn’t be nearly as much fun or possible without the friendships I’ve 
made during my time at Carolina. I want to thank my classmates and peers, especially Christine, 
Rima, Alex, Micah, Nate, Jake, Jenn, Matt Campbell, and Matt Boyce for the memories. 
Whether it was the beach trips, game nights, or potlucks, I always looked forward to the 
conversations. 
To my family, I am endlessly grateful for your support and encouragement. To my mom 
and dad, you never let myself or others set limits on who I can become. Thank you. To my sister, 
vi 
I could not have imagined how close we would become as adults when we were younger. I’m 
glad four years doesn’t seem so different now and you, Jason, Benjamin, and Addison mean the 
world to me. I would also like to thank my grandma, Regina Flood Callahan, for being the 
original chemist in the family. I have always been in awe of your experience as a female chemist 
in the 1940’s, you inspire me. And of course, I want to end with the canine members of my 
family, Ella and Fitz. Their ability to brighten my day, without fail, is the best way to brush off 




TABLE OF CONTENTS 
LIST OF TABLES ....................................................................................................................... xiii 
LIST OF FIGURES ...................................................................................................................... xv 
LIST OF ABBREVIATIONS ...................................................................................................... xxi 
CHAPTER 1: Chlamydomonas reinhardtii Phosphoproteomics .................................................... 1 
1.1 Phosphoproteomics .......................................................................................................... 1 
1.2 Label-Free Quantitation ................................................................................................... 3 
1.2.1 Label-Free Quantitative Proteomics ......................................................................... 3 
1.2.2 Label-Free Quantitative Phosphoproteomics ............................................................ 6 
1.3 Phosphoproteomics for Studying Cellular Signaling in 
Chlamydomonas reinhardtii ............................................................................................... 7 
1.4 Target of Rapamycin Signaling in Chlamydomonas reinhardtii ..................................... 8 
1.5 Scope of Dissertation ....................................................................................................... 9 
1.6 Figures ............................................................................................................................ 11 
REFERENCES .......................................................................................................................... 14 
CHAPTER 2: SOPs for Culturing, Extraction, Digestion, Enrichment, 
Data Analysis Techniques for Algal-based Phosphoproteomics .................................................. 20 
2.1 Introduction .................................................................................................................... 20 
2.2 Strain Selection and Algal Culturing ............................................................................. 20 
2.3 Plant-based Extraction Techniques ................................................................................ 23
viii 
2.3.1 Native Extraction .................................................................................................... 24 
2.3.2 Denaturing Extraction ............................................................................................. 25 
2.4 Kinome Enrichment ....................................................................................................... 27 
2.5 Digestion and C18 Clean-Up Techniques ...................................................................... 29 
2.6 Phosphoproteomic Techniques ...................................................................................... 31 
2.7 LC-MS/MS Analysis ...................................................................................................... 33 
2.7.1 DDA and SWATH (DIA) Acquisition Parameters ................................................. 34 
2.8 Label-Free Quantitative Data Processing and Analysis Techniques ................................ 34 
2.8.1 DDA Data Processing and Analysis ....................................................................... 35 
2.8.2 SWATH Data Processing and Analysis .................................................................. 36 
2.9 Data Visualization and Biological Inference Techniques .............................................. 38 
2.10 Tables ............................................................................................................................. 40 
2.11 Figures ............................................................................................................................ 42 
REFERENCES .......................................................................................................................... 48 
CHAPTER 3: Probing the Global Kinome and Phosphoproteome in 
Chlamydomonas reinhardtii via Sequential Enrichment and      
Quantitative Proteomics ................................................................................................................ 50 
3.1 Introduction .................................................................................................................... 50 
3.2 Materials and Methods ................................................................................................... 52 
3.2.1 Cell Growth and Native Extraction......................................................................... 52 
3.2.2 Kinome Enrichment ................................................................................................ 52 
3.2.3 Protein Digestion and Reduction ............................................................................ 53 
3.2.4 Solid-Phase Extraction ............................................................................................ 53 
ix 
3.2.5 Phosphopeptide Enrichment ................................................................................... 54 
3.2.6 DDA and SWATH MS Acquisition ....................................................................... 54 
3.2.7 DDA Data Processing ............................................................................................. 55 
3.2.8 Ion Library Generation ........................................................................................... 56 
3.2.9 SWATH Data Processing ....................................................................................... 56 
3.3 Results and Discussion ................................................................................................... 57 
3.3.1 Native Protein Extraction of Chlamydomonas ....................................................... 57 
3.3.2 Kinome DDA and SWATH Data Acquisition ........................................................ 58 
3.3.3 Phosphopeptide Enrichment ................................................................................... 59 
3.3.4 Kinome and Phosphoproteome Coverage Using MIBs and 
TiO2 Enrichment ..................................................................................................... 61 
3.4 Conclusion/Summary ..................................................................................................... 63 
3.5 Tables ............................................................................................................................. 65 
3.6 Figures ............................................................................................................................ 67 
REFERENCES .......................................................................................................................... 74 
CHAPTER 4: Investigating the Effect of Target of Rapamycin Kinase 
Inhibition on the Chlamydomonas reinhardtii Phosphoproteome: From 
Known Homologs to New Targets. .............................................................................................. 78 
4.1 Introduction .................................................................................................................... 78 
4.2 Materials and Methods ................................................................................................... 80 
4.2.1 Cell Culturing and Drug Treatment ........................................................................ 80 
4.2.2 Protein Extraction ................................................................................................... 81 
4.2.3 Protein Digestion and Reduction. ........................................................................... 81 
x 
4.2.4 Solid-Phase Extraction. ........................................................................................... 81 
4.2.5 Phosphopeptide Enrichment and Clean-Up. ........................................................... 82 
4.2.6 LC-MS/MS Acquisition and Data Processing. ....................................................... 82 
4.2.7 Downstream Bioinformatics Analysis. ................................................................... 83 
4.2.8 Carotenoid Analysis. ............................................................................................... 84 
4.2.9 Dry Weight Determination ..................................................................................... 85 
4.2.10 SDS-PAGE and Western Blotting .......................................................................... 85 
4.3 Results and Discussion ................................................................................................... 86 
4.3.1 Parameter Selection for TORC1-Specific Inhibition .............................................. 86 
4.3.2 Quantitative Coverage of the TOR-Inhibited 
Phosphoproteome .................................................................................................... 87 
4.3.3 Cluster Analysis and Phosphosite Motif Identification .......................................... 88 
4.3.4 Phosphosites in TORC1 Complex Proteins ............................................................ 89 
4.3.5 Sites Modulated by TORC1 Inhibition – Known and 
Putative Substrates. ................................................................................................. 90 
4.3.6 Sites Modulated by TORC1 Inhibition – Known TOR 
Pathway Association. .............................................................................................. 91 
4.3.7 Additional Proteins with Phosphosites Altered by TORC1      
Inhibition ................................................................................................................. 93 
4.4 Conclusion/Summary ..................................................................................................... 95 
4.5 Tables ............................................................................................................................. 96 
4.6 Figures ............................................................................................................................ 98 
REFERENCES ........................................................................................................................ 107 
xi 
CHAPTER 5: Pathway Inhibition of Rapamycin-Hypersensitive Vip-1 
Mutant Chlamydomonas Strain Revealed via Phosphoproteomics ............................................ 115 
5.1 Introduction .................................................................................................................. 115 
5.2 Materials and Methods ................................................................................................. 117 
5.2.1 Cell Culturing and Rapamycin Treatment. ........................................................... 117 
5.2.2 Protein Extraction. ................................................................................................ 118 
5.2.3 Protein Digestion and Reduction. ......................................................................... 118 
5.2.4 Solid-Phase Extraction. ......................................................................................... 118 
5.2.5 Phosphopeptide Enrichment and Clean-Up. ......................................................... 119 
5.2.6 LC-MS/MS Acquisition and Data Processing ...................................................... 119 
5.2.7 Downstream Bioinformatic Analysis. ................................................................... 121 
5.3 Results and Discussion ................................................................................................. 122 
5.3.1 Experimental Design ............................................................................................. 122 
5.3.2 Quantitative Coverage of the TOR-Inhibited 
Phosphoproteome in vip1-1 Mutant ...................................................................... 122 
5.3.3 Cluster Analysis and Phosphosite Motif Identification. ....................................... 123 
5.3.4 Phosphosites Modulated by TORC1 Inhibition in vip1-1 
Strain– Known and Putative Substrates ................................................................ 124 
5.3.5 Comparison of vip1-1 Mutant Study to Wild-Type TOR 
Inhibited Phosphoproteome Study ........................................................................ 125 
5.3.6 Additional Proteins with Phosphosites Altered by TORC1 
Inhibition ............................................................................................................... 126 
5.3.7 Glycolysis-Related Enzymes Modulated by TOR Inhibition ............................... 127 
5.4 Conclusion/Summary ................................................................................................... 128 
xii 
5.5 Tables ........................................................................................................................... 129 
5.6 Figures .......................................................................................................................... 131 
REFERENCES ........................................................................................................................ 134 
CHAPTER 6: Conclusions and Future Directions ...................................................................... 141 
6.1 Conclusions .................................................................................................................. 141 
REFERENCES ........................................................................................................................ 144 
xiii 
LIST OF TABLES  
Table 2.1 Sequential window m/z values across Q1 mass range from 
350.0-1250.0 m/z for SWATH acquisition employed during 
kinome analysis in Chapter 3. ........................................................................................... 40 
Table 2.2 Overview of processing settings for SWATH data processing. ................................... 41 
Table 3.1 Phosphosite coverage on MIBs-identified kinases. * previously 
undetected. Based on phosphopeptide enrichment on the MIBs 
flow through, 71 phosphosites were localized from 36 protein 
kinases identified in the kinome enrichment dataset and 9 sites 
were not previously detected. ........................................................................................... 65 
Table 3.2 Identified proteins in the cell cycle signaling pathway in 
Chlamydomonas. * indicates Chlamydomonas cell-cycle 
regulatory genes with available Chlamydomonas mutants based on 
(Cross and Umen 2015). Bolded accessions indicate proteins 
unique to the kinome enrichment and italicized rows indicate 
proteins unique to phosphopeptide enrichment. ............................................................... 66 
Table 4.1 TOR targets identified with fold change values for drug 
condition versus control. Fold change values shaded red indicate a 
statistically significant increase in phosphopeptide abundance for 
specified drug treatment versus control. Fold change values shaded 
blue indicate a statistically significant decrease in phosphopeptide 
abudance for specified drug treatment versus control. Level of p-
value statistical significance is denoted by p-value ≤ 0.05 (*) and ≤ 
0.01 (**) ............................................................................................................................ 96 
Table 4.2 Carotenoid content in WT Chlamydomonas after 8 hours of 
treatment with Rapamycin, Torin1, and AZD8055 compared to 
control. .............................................................................................................................. 97 
Table 5.1 TOR targets identified with fold change values for rapamycin 
vs. control in the vip1-1 mutant study compared to wild-type 
values from the study performed in wild-type24. Fold change 
values shaded red indicate a statistically signficant increase in 
phosphopeptide abundance for rapamycin versus control. Fold 
change values shaded blue indicate a statistically significant 
decrease in phosphopeptide abundance for rapamycin versus 
control. Sites that do not have a corresponding fold-change in the 
wild-type study because they were not identified are denoted with 
“n/a”. Level of p-value statistical significance is denoted by p-
value ≤ 0.05 (*) and ≤ 0.01 (**). .................................................................................... 129 
xiv 
Table 5.2 TOR inhibited sites in vip1-1 mutant with opposite trends from 
sites identified in the rapamycin study performed in the wild-
type24. Fold change values shaded red indicate a statistically 
signficant increase in phosphopeptide abundance for rapamycin 
versus control. Fold change values shaded blue indicate a 
statistically significant decrease in phosphopeptide abundance for 
rapamycin versus control. Level of p-value statistical significance 




LIST OF FIGURES 
Figure 1.1 Schematic of a label-free quantitative workflow showing n=5 
replicates per condition. Chlamydomonas cells were cultured 
photoheterotrophically with subsequent protein extraction, 
digestion, and LC-MS/MS acquisition. Following acquisition, 
relative quantification using area under the curve (AUC) 
abundance at the MS1 level occurs between control and treatment 
samples to determine differentially changing proteins and protein 
identification is done through database searching using MS2 
spectra. .............................................................................................................................. 11 
Figure 1.2 DDA and DIA acquisition workflows for AB Sciex TripleTOF 
5600 instrument platform. For DDA, first 20 peptide precursors are 
selected for fragmentation every 2 second cycle based on 
optimized proteomic parameters70. For DIA, 20 MS/MS are 
selected for fragmentation based on windows of varying widths 
optimized to effectively cover the entire mass range while 
concurrently focusing on dense m/z regions with smaller Q1 
windows and larger Q1 windows on less dense m/z regions. ........................................... 12 
Figure 1.3 Standard bottom-up phosphoproteomic workflow including cell 
culturing, protein extraction, protein digestion, TiO2 
phosphopeptide enrichment, LC-MS/MS acquisition, and label free 
quantitative analysis. ......................................................................................................... 13 
Figure 2.1 Figure reproduced from [5]. Overview of coverage of 
phosphopeptides identified and phosphopeptide efficiency using 
600, 1000, 1200, 1500, 2000 µg of digested protein lysate starting 
material ............................................................................................................................. 42 
Figure 2.2 Variable windows used for SWATH acquisition. Window sizes 
are based on generating a peak list from DDA LC-MS/MS run 
representative of SWATH samples. Smaller Q1 windows are used 
for regions of the mass range where many peptide precursors are 
measured. Wider windows used where there are less precursors 
while still interrogating the entire mass range. ................................................................. 43 
Figure 2.3 Overview of database searching requirements employed in LFQ 
proteomic experiments. Searches of MS/MS data used a trypsin 
protease specificity with the possibility of two missed cleavages, 
peptide/fragment mass tolerances of 20ppm/0.1 Da, and variable 
modifications of acetylation at the protein N-terminus, 
carbamidomethylation at cysteine, oxidation at methionine, and 
deamidation at asparagine or glutamine. Variable modifications of 
phosphorylation at serine or threonine and phosphorylation at 
xvi 
tyrosine were appended to this list when working with 
phosphorylation enriched datasets. ................................................................................... 44 
Figure 2.4 Example Python output following custom scripts written 
implemented to parse results. ............................................................................................ 45 
Figure 2.5 Overview of filtering steps in phosphoproteomic experiments 
required following Progenesis QI for Proteomics and Mascot 
database searching workflows described in Section 2.8.1. ............................................... 46 
Figure 2.6 Block diagram of Perseus v.1.6.0.0 workflow highlighted in 
Section 2.9......................................................................................................................... 47 
Figure 3.1 Figure reproduced from ref [36]. Overview of kinome and 
phosphoproteome workflow. (A) Schematic highlighting the 
focused ultrasonication performed during native protein extraction 
before MIBs kinome enrichment. (B) Following protein extraction, 
5.5 mg of cell lysate is incubated with Sepharose beads covalently 
bound to a mixture of moderate and pan-kinase inhibitors. Proteins 
that are not bound to the MIBs beads (flow through) are saved for 
subsequent phosphopeptide enrichment. After washes, intact 
kinases and additional ATP-binding proteins are eluted from the 
columns and subjected to DDA and SWATH-MS analysis. (C) For 
the proteins collected in the flow through of the MIBs enrichment, 
phosphopeptide enrichment using TiO2 is performed on 2 mg of 
each of the cell lysates. ..................................................................................................... 67 
Figure 3.2 Figure reproduced from [36]. SWATH ion library generation. 
Schematic depicting ion library generation for SWATH data 
spectral matching and protein identification. An ion library was 
generated from a combination of 15 fractions derived from 
digested whole cell lysate separated by SCX and acquired via 
DDA. Additionally, 8 DDA runs of MIBs-enriched samples were 
included to assure exhaustive coverage of proteins in the ion 
library. After acquisition of all DDA runs, database searching was 
performed using ProteinPilot v5.0 and the result file (*.group file) 
was imported into PeakView v2.1 for SWATH data analysis. ......................................... 68 
Figure 3.3 Figure reproduced from [36]. Comparison of data independent 
(SWATH) and data dependent acquisition (DDA) methods for 
kinome identification. Venn diagram showing overlap of proteins 
identified between SWATH and DDA acquisition strategies for 
kinome enrichment (A) and no kinome enrichment (B) datasets. 
(C) Box-whisker plot showing distribution of CV values for 90% 
of proteins identified using DDA and SWATH acquisition 
strategies with and without enrichment. (D) Breakdown of 
coverage for both SWATH and DDA MS acquisition for kinome 
xvii 
and no enrichment along with total unique proteins identified for 
each. .................................................................................................................................. 69 
Figure 3.4 Figure reproduced from [36]. Chemical characteristics of the 
peptides identified in the MIBs dataset including (A) Amino acid 
length, (B) Molecular Weight, (C) pI, (D) amount of basic 
residues, (E) amount of acidic residues and (F) Hydrophobicity. .................................... 70 
Figure 3.5 Figure reproduced from [36]. Comparison of proteins identified 
in MIBs and phosphopeptide enrichments. (A) Venn diagram 
comparing the overlap and unique proteins identified from kinome 
enrichment versus phosphopeptide enrichment. 243 proteins were 
found in both data sets, with 1307 identified solely in MIBs and 
834 via phosphopeptide enrichment. (B) Of the phosphorylation 
sites confidently localized, 86.6% were pSer, 12.8% were pThr, 
and 0.6% were pTyr. (C) Box-whisker plot showing distribution of 
%CV of each protein for DDA from TiO2 enrichment. (D) 
Distribution of phophosites among peptides showing that 80% 
(1394/1765) were singly phosphorylated.......................................................................... 71 
Figure 3.6 Figure reproduced from ref [36]. Chemical characteristics of the 
peptides identified in the phosphopeptide dataset including (A) 
Amino acid length, (B) Molecular Weight, (C) pI, (D) amount of 
basic residues, (E) amount of acidic residues and (F) 
Hydrophobicity. ................................................................................................................ 72 
Figure 3.7 Figure reproduced from [36]. Comparison of proteins identified 
and enriched GO terms from MIBs. (A) Venn diagram comparing 
the overlap and unique proteins identified with and without 
enrichment in addition to a table highlighting protein groups of 
interest in the 229 proteins unique to MIBs enrichment. (B) Bar 
graph highlighting the GO terms enriched following enrichment of 
Gene Ontology terms for biological processes, molecular 
functions, and cellular processes using default parameters in 
Blast2GO (http://www.Blast2GO.com/b2ghome, BioBam, 
Valencia, Spain) using the Fisher method with multiple testing 
correction based on Benjamani Hochberg FDR cutoff of 0.05 with 
the Phytozome v11 C. reinhardtii predicted proteome as 
background. ....................................................................................................................... 73 
Figure 4.1 Figure reproduced from ref [83]. Drug treatment and cell 
harvesting workflow in Chlamydomonas cells. Replicate “n” (1-5) 
of each drug condition and control were harvested together prior to 
downstream processing. To minimize inter-condition batch effects, 
“n” replicate of each condition was harvested together and frozen 
until protein extraction. ..................................................................................................... 98 
xviii 
Figure 4.2 Figure reproduced from ref [83]. Titration experiment for 
AZD8055 and Torin1 to determine drug concentrations required 
for saturation ..................................................................................................................... 99 
Figure 4.3 Figure reproduced from ref [83]. Pearson correlation coefficient 
between replicates of control and rapamycin-treated cells 
following protein-level analysis. Logarithmized protein 
abundances across 4 replicates for control and 15 min. rapamycin-
treated cells showing high correlation regardless of treatment with 
no significant differences in protein abundances between control 
and treatment replicates. ................................................................................................. 100 
Figure 4.4 Figure reproduced from ref [83]. Sites modulated by chemical 
inhibition. Results of differential analysis between each chemical 
inhibitor drug treatment compared to control for both wild-type 
(A) and AZD-insensitive (B) Chlamydomonas strains. For 
comparison of overlap between the drug conditions in the WT 
dataset, a Pearson’s correlation was performed comparing all 
condition types. From this, the highest correlation among 
conditions was between AZD8055 and Torin1 at 0.986 and the 
lowest 3 were all drug inhibitor vs. controls. .................................................................. 101 
Figure 4.5 Figure reproduced from ref [83]. Spot test for comparison of 
growth between WT and AZD-insensitive Chlamydomonas 
cultures after 3 and 5 days of growth. WT and AZD-insensitive 
strains were grown on solid TAP media and cultures were diluted 
1/5 and 1/25. Additionally, after 5 days of growth, spot tests for 0.5 
uM- 2 uM AZD8055 treatment between WT and AZD-insensitive 
Chlamydomonas cultures were compared showing continued 
growth of the AZD-insensitive strain following AZD8055 
treatment. ........................................................................................................................ 102 
Figure 4.6 Figure reproduced from ref [83]. Hierarchical clustering of 
differentially changing sites into 2 clusters (A). Visualization was 
performed in Perseus v1.6.0.0. Following data normalization and 
missing value imputation, intensity values were z-score normalized 
and grouped using k-means clustering with default parameters. 
Overall trends in site intensity were graphed and colored based on 
intensity (B). For each of the two clusters, motif analysis was 
performed (C) : motif analysis on clusters 1 and 2 from 
hierarchical clustering. Sequence logo visualizations were 
performed using pLOGO with serine or threonine residues fixed at 
position 0. Positions with significant residue presence are depicted 
as amino acid letters sized above the red line. For cluster 1, there 
was significant enrichment for a proline in the +1 position and 
arginine in the -3 position, RXXS/TP. For cluster 2, there was 
again significant enrichment for a proline in the +1 position and 
xix 
arginine in the -3 position in addition to an aspartic acid in the +3 
position, RXXS/TPXD. .................................................................................................. 103 
Figure 4.7 Figure reproduced from ref [83]. Commercial anti-phospho S6K 
antibody reactivity in Chlamydomonas with no signal (A). 
Comparison of RPS6 protein sequence between Arabidopsis and 
Chlamydomonas (B). a western blot in wild-type under different 
drug treatments for 0, 5, 15, 30, and 60 min with antibodies raised 
for Ser242 (C). ................................................................................................................ 104 
Figure 4.8 Figure reproduced from ref [83]. Bar charts of 10 modulated 
phosphosites on TOR pathway-associated proteins based on 
homology. Level of p-value statistical significance is denoted by p-
value ≤ 0.05 (*) and ≤ 0.01 (**) ..................................................................................... 105 
Figure 4.9 Figure reproduced from ref [83]. Bar chart of carotenoid content 
in WT Chlamydomonas after 8 hours of treatment with 
Rapamycin, Torin1, and AZD8055 compared to control ............................................... 106 
Figure 5.1 Quantitative coverage of the phosphoproteome of 
Chlamydomonas vip1-1 mutant following TOR inhibition. A pie 
chart showing the ratio of sites phosphorylated in this study with 
82.4% pSer, 16.2% pThr, and 1.4% pY (A). From the sites 
detected in this study, a bar chart with the amount of 
phosphorylation events detected per peptide with >90% of 
phosphopeptides detected singly phosphorylated (B). .................................................... 131 
Figure 5.2 Volcano plot of phosphosites modulated by TOR inhibition in a 
vip1-1 Chlamydomonas mutant. 149 sites significantly decreasing 
are shaded blue and 132 sites significantly increasing are shaded 
red. Differentially changing sites were determined using a two-
sample t-test with p-value ≤ 0.05 threshold and fold-change ± 2. .................................. 132 
Figure 5.3 Hierarchical clustering of differentially changing sites into 2 
clusters (A). Visualization was performed in Perseus v1.6.0.0. 
Following data normalization and missing value imputation, 
intensity values were z-score normalized and grouped using k-
means clustering with default parameters. Overall trends in site 
intensity were graphed and colored based on intensity (B). For 
each of the two clusters, motif analysis was performed (C): motif 
analysis on clusters 1 and 2 from hierarchical clustering. Sequence 
logo visualizations were performed using pLOGO with serine or 
threonine residues fixed at position 0. Positions with significant 
residue presence are depicted as amino acid letters sized above the 
red line. For cluster 1, there was significant enrichment for 
S/TXDEE motif with a significant amount of C-terminal acidic 
xx 
residues in the +2, +3, and +4 positions. For cluster 2, there was 
significant enrichment for a proline in the +1 position. .................................................. 133 
   
xxi 
LIST OF ABBREVIATIONS 
AMPK AMP-activated protein kinases  
AUC area under the curve 
CDKs cyclin-dependent protein kinases  
CID CTC-interacting domain  
CV coefficient of variation 
DDA data-dependent acquisition  
DIA data-independent acquisition  
DTT dithiothreitol  
EEF2 elongation factor 2  
EEF2K elongation factor 2 kinase 
FA formic acid 
FDR false discovery rates  
GO gene ontology 
HPLC high-pressure liquid chromatography  
IAM iodoacetamide   
IMAC Immobilized metal affinity chromatography 
InsPs inositol polyphosphate  
iTRAQ  Isobaric Tags for Relative and Absolute Quantification  
KO KEGG ontology  
LARP1 LA RNA-binding protein  
LFQ label-free quantification 
LOD limit of detection 
xxii 
LST8 lethal with sec-13 protein 8 
MAPK mitogen-activated protein kinase 
MCM minichromosome maintenance 
MeCN acetonitrile  
MGF mascot generic file 
MIBs multiplexed inhibitor beads  
MOAC metal oxide affinity chromatography  
MS/MS  tandem mass spectrometry 
MT mating type 
NEM N-Ethylmaleimide  
OD Optical density 
PAGE  polyacrylamine gel electrophoresis  
PBS phosphate-buffered saline  
PI3K phosphatidylinositol 3-kinase 
PPM parts per million 
PTMs Post-translational modifications  
Q-TOF quadrupole time-of-flight 
RAPTOR regulatory associate protein target of rapamycin  
SCX strong cation exchange  
SDS sodium dodecyl sulfate  
Ser Serine 
SILAC Stable Isotope Labeling by Amino Acids in Cell Culture  
SOPs standard operating procedures 
xxiii 
SWATH Sequential Windowed Acquisition of All Theoretical Fragment Ion Mass Spectra 
TAG triacylglycerol  
TAP Tris-Acetate-Phosphate  
TCEP Tris(2-carboxyethyl)phosphine hydrochloride 
TFA trifluoroacetic acid 
Thr Threonine 
TiO2 titanium dioxide 
TMT Tandem Mass Tags 
TOP Terminal Oligopyrimidine  
TOR Target of Rapamycin 
TORC1 TOR complex 1 
TORC2 TOR complex 2 
Tyr Tyrosine 
UPLC ultra-high pressure liquid chromatography  
1 
CHAPTER 1:  Chlamydomonas reinhardtii Phosphoproteomics 
1.1 Phosphoproteomics 
Post-translational modifications (PTMs) such as phosphorylation, acetylation and 
ubiquitination are crucial aspects of regulating protein expression. Occurring after protein 
products are translated, the addition or removal of PTM functional groups regulates protein 
folding and converts the primary sequence of proteins into functional protein products, or 
proteoforms1, with diverse structure and function within the cell. Proteoforms can exist with 
multiple PTMs that work in tandem regulating cellular signaling and contributing to the 
complexity of possible protein products involved in a cell. 
Protein phosphorylation is a prevalent PTM responsible for regulating a myriad of cellular 
processes from cell cycle to programmed cell death2-4. The addition or removal of a phosphate 
moiety onto the hydroxyl group of either serine (Ser), threonine (Thr), or tyrosine (Tyr) amino 
acid residues by a kinase or phosphatase is responsible for conformational changes on direct 
substrates which affect downstream signaling networks. The significant and ubiquitous role 
protein phosphorylation has within cellular processes such as cell survival, proliferation, 
metabolism, and cellular signaling emphasizes the need for an efficient and selective method for 
enrichment capable of identifying phosphorylation sites to understand the biological significance 
of the modification. The effects of perturbing phosphorylation events and subsequently studying 
them in vivo is of significance because it allows for identification of key proteins and, 
specifically, the phosphosites on those proteins that are involved in signaling pathways.  
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To assess the changes in phosphorylation events at the systems-level as a result of abiotic or 
biotic stress, a quantitative label-free platform with a reproducible phosphopeptide enrichment is 
necessary to address the substoichiometric levels of phosphorylation in cellular proteins. 
Currently, characterization of protein phosphorylation events remains an analytical challenge due 
to numerous contributions toward phosphopeptide losses such as reduced ionization efficiency 
over unphosphorylated peptides and losses during chromatography5. Phosphorylation enrichment 
strategies to combat these challenges have allowed for robust detection and quantitation of 
phosphorylation events. For phosphopeptide studies, affinity purification techniques such as 
immobilized metal affinity chromatography6 (IMAC) and titanium dioxide7 (TiO2) enrichment 
schemes are two of the most frequently used approaches. These techniques permit qualitative and 
quantitative evaluation on thousands of phosphorylation events in a single analysis however, 
careful sample preparation at the protein and peptide level are essential for success in both8. In 
IMAC and TiO2 enrichment strategies, binding of carboxyl groups to the IMAC or TiO2 material 
can result in co-purification of acidic peptides and phosphopeptides limiting specificity and 
requires method development such as pH modulation for IMAC9 and addition of organic acids to 
binding solvents in TiO2 based enrichments10. Both require extensive method optimization and 
reproducibility in sample preparation to gain a meaningful understanding of the 
phosphoproteome. When comparing the two affinity purification techniques, IMAC has been 
shown to be less selective than TiO27 but identifies more multiply phosphorylated peptides10. 
Additionally, TiO2 chromatography has been shown to be less sensitive to interfering compounds 
such as salts and detergents9, 11 than IMAC and all of these characteristics should be evaluated 
when determining the enrichment strategy best for the experimental design.  
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1.2 Label-Free Quantitation 
Over the past two decades, the use of “gel-free” or mass-spectrometry-based techniques for 
quantification of differential proteomics in biological systems has gained popularity. Offering a 
powerful analytical technique for studying large-scale protein expression and characterization 
over gel-based methods, LC-MS/MS proteomic platforms offer highly reproducible and accurate 
systems-level quantification. This allows for the investigation of the global effect a diseased state 
or cellular stress would have on the proteome by comparing healthy cells to diseased or stressed 
cells and identifying key proteins that are changing between conditions. This is known as 
differential proteomics. From these experiments, protein targets affected by the disease or stress 
are identified by their significant change to that in healthy cells. One of the quantitation 
approaches used to identify these protein targets is label-free quantitative proteomics.  
1.2.1 Label-Free Quantitative Proteomics 
When considering the quantitation method most suitable for a biological question, both 
labeled and label-free methods have benefits and limitations to consider before moving forward. 
LFQ proteomic strategies are an especially useful analytical approach for differential 
experiments because they can accommodate a wide range of experimental designs and are 
unlimited in experimental complexity as long as reproducible chromatography and mass 
accuracy can be achieved and maintained12-13. This is an advantage over stable isotope labeling 
approaches such as Stable Isotope Labeling by Amino Acids in Cell Culture (SILAC)14, Tandem 
Mass Tags (TMT)15, and Isobaric Tags for Relative and Absolute Quantification (iTRAQ)16, 
which are limited in experimental complexity and replicates to the number of labels available.  
A main advantage of labeling strategies is reduced acquisition time from pooling sample 
mixtures prior to acquisition and requiring a single LC-MS/MS run13. These multiplexing 
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capabilities allow for shorter acquisition time however labeling techniques, such as iTRAQ, have 
shown underestimations of ratios in quantitation, limited dynamic range, and instrument-specific 
requirements for use17. Multiple studies have compared labeling and label-free techniques in 
complex biological samples17-19, including a comparison in Chlamydomonas reinhardtii17, 
highlighting the benefits and limitations of each approach. To become a viable alternative to 
current labeling techniques, quantitative label-free proteomics must have highly reproducible 
sample processing and chromatography capable of accurately measuring changes in ion intensity 
amongst biological conditions or treatments across LC-MS/MS runs. Additionally, a 
comprehensive bioinformatics pipeline for accurate peak picking and processing -omics data into 
tangible quantitative information for biological inference is required20-21.  
This demand for high reproducibility both from chromatographic peaks across replicates and 
in the post-acquisition data analysis gave rise to a wide array of LFQ software suites available 
for peak picking, retention time alignment and statistical analysis. This includes commercial 
products such as Progenesis QI for proteomics (Nonlinear Dynamics), Scaffold22 and academic 
softwares such as MAXQUANT23 and Skyline24, among others13, 25. While the specific technical 
details are unique for each bioinformatic pipeline, the two most common methods for relative 
quantification using a label-free approach are peak intensity-based and spectral counting26. Peak 
intensity-based strategies rely on measuring and comparing MS signal intensity of peptide 
precursor ions belonging to a particular protein, (Figure 1.1) while spectral counting strategies 
count and compare the number of fragment spectra identifying peptides of a given proteins27. 
The fundamental steps of sample preparation (reduction, alkylation, digestion), separation and 
analysis by LC-MS/MS are common throughout. 
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For years, the predominant acquisition strategy for LFQ proteomics involves data-dependent 
acquisition (DDA) followed by searching of MS2 spectra against a database for protein inference. 
While this acquisition method is prevalent throughout current proteomic analyses, it can result in 
irreproducible precursor ion selection due to the stochastic nature of ion selection28, 
undersampling29, and a required minimal signal for ions to trigger MS2 analysis within a finite 
duty cycle30. Data-independent acquisition (DIA) strategies, which perform unbiased 
fragmentation of all peptide precursors to theoretically record all fragment ion signals above the 
instrument’s limit of detection (LOD)31, have gained in popularity in recent years. A hurdle to 
overcome is fragment ion identification since standard bottom-up (DDA) proteomic approaches 
such as searching an in silico digested library database are not possible and protein inference 
instead relies on preparing a spectral library for matching prior to performing an experiment32. 
While this technique requires additional front-end work to gain a comprehensive library of 
possible fragment ions for searching, the strategy can allow for a more complete look at the 
proteome.  
In addition to utilizing multiple acquisition strategies to improve proteome coverage and 
relative quantitation using an LFQ proteomic approach, experiments focused on subsets of the 
proteome can also require alterations to the LFQ pipeline discussed above. When focusing the 
analysis on PTMs, specifically phosphorylation on proteins, a reproducible enrichment strategy 
is required to remove background unphosphorylated species from interfering in the analysis. The 
study of protein phosphorylation events at the systems-level using this approach is called label-
free quantitative phosphoproteomics and is discussed further in the following section. 
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1.2.2 Label-Free Quantitative Phosphoproteomics 
Dynamic protein phosphorylation plays a central regulatory role in the living cell but 
studying these events remains an analytical challenge. Low phosphorylation stoichiometry and 
overall low abundance relative to unmodified proteins contribute to this and require an 
enrichment strategy prior to acquisition for reproducible detection and quantitation of 
phosphorylation events at the systems-level33-35. Enrichment can occur at the phosphoprotein 
level using pSer, pThr, pTyr antibodies and/or at the phosphopeptide level using mediums such 
as IMAC or metal oxide affinity chromatography (MOAC)34. For insight into the global 
phosphoproteome, peptide-based enrichment approaches in line with traditional LFQ sample 
processing have shown promise in maintaining high reproducibility among replicates allowing 
for label-free quantitation on phosphorylation sites that play significant roles in cellular 
pathways36. Similarly to differential proteomic experiments, the global effect a diseased state or 
cellular stress would have on the phosphoproteome can be determined by comparing healthy 
cells to diseased or stressed cells and identifying key phosphosites changing between conditions.  
While this uses many of the same software tools available for other LFQ experiments, the 
quantitative data in phosphoproteomic studies reflects both changes in phosphorylation status 
and change in expression of substrate proteins. Because of this, both factors must be considered 
when performing phosphosite quantification. While simultaneous quantification of protein 
expression and phosphorylation would allow true differential phosphorylation to be distinguished 
from protein expression, there are several technical challenges making this solution difficult to 
enact. Literature has shown a low overlap in quantitative coverage between unenriched whole-
cell proteins identified and phosphoproteins identified following enrichment with a significant 
portion of every phosphoproteome profile “invisible” without enrichment37. This is due to 
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limitations in instrument dynamic range and a bias toward high abundance proteins being 
selected for fragmentation, which is a driving force behind using a phosphopeptide enrichment 
strategy to remove unmodified proteins prior to analysis5 therefore making it possible in a single 
LC-MS/MS run to analyze the global protein expression or phosphorylation, but not both37. 
To address this, data normalization between global and phosphoproteome experiments to 
account for changes in protein expression when investigating changes in phosphorylation status 
are possible. This requires quantitative comparison of overlapping proteins in both whole-cell 
and phospho-enriched experiments to account for abundance differences not due to 
phosphorylation changes. But, normalization is only relevant for differential experiments that 
result in protein abundance levels changing during the time frame of the phosphoproteomic 
experiment. For experimental designs that investigate the phosphoproteome after short 
treatments such as 15 min. after target of rapamycin (TOR) inhibition38 to 24 hours following 
nitrogen stress39-40 in Chlamydomonas, no significant differences in protein abundances were 
identified. Therefore, phosphopeptide ratios in general were not considered affected by 
normalization to protein levels.  
1.3 Phosphoproteomics for Studying Cellular Signaling in Chlamydomonas reinhardtii 
The photosynthetic organism Chlamydomonas reinhardtii is an intensively-studied model for 
microalgal processes such as triacylglycerol (TAG) accumulation41-43 and cell cycle control44. 
With considerable efforts focused on genomic, transcriptomic and proteomic analyses42, 45-49, 
there have been significant advancements in understanding the molecular infrastructure and 
metabolic signaling in Chlamydomonas over the past decade since the genome was first 
sequenced45. From such analyses, interest in global studies on protein phosphorylation’s role in 
regulating cellular signaling arose with early studies detecting 83 phosphopeptides in the 
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Chlamydomonas eyespot50 and several hundred phosphoproteins in the flagella51-53. More 
recently, the phosphoproteome was extensively characterized with a conservative estimate of 
4,588 phosphoproteins corresponding to 15,862 unique phosphosites with numerous 
phosphoproteins in key biological pathways indicating the significance of protein 
phosphorylation and kinase-regulated signaling networks in Chlamydomonas54.  
Following these comprehensive studies, quantitative work in Chlamydomonas has been 
applied to investigate the effects of nutrient deprivation on the phosphoproteome. Nutrient 
deprivation has been shown to result in TAG and starch accumulation41-43 but fundamental 
research into algal metabolism regulation, specifically knowledge into Chlamydomonas 
signaling and regulatory processes to improve biofuel production, is needed. Recently, we have 
reported a quantitative phosphoproteomic strategy with coverage on 2,250 phosphopeptides32 
and similar reports have quantified 1,227 phosphopeptides where 470 phosphopeptides were 
significantly changing following nitrogen deprivation55.  
1.4 Target of Rapamycin Signaling in Chlamydomonas reinhardtii  
The Target of Rapamycin kinase is a conserved regulator of cell growth whose activity is 
modulated in response to nutrients, energy and stress56-60. TOR signaling coordinates a balance 
between protein synthesis and protein degradation as a response to the cell’s nutrient quality and 
quantity61. Because of the high potential behind microalgal biofuel production, significant 
attention has been focused on proteins regulating cell growth, such as the TOR kinase, in 
Chlamydomonas. As such, we have applied our LFQ phosphoproteomic work to probe the 
effects of TOR inhibition on the phosphoproteome quantifying 2,559 phosphopeptides with 219 
phosphopeptides significantly changing following TOR inhibition38. Homology among TOR 
targets in a diverse set of organisms suggests TOR-associated proteins are broadly conserved56; 
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and while the role of TOR in mammalian cell metabolism has been extensively investigated62, its 
role in photosynthetic organisms is less well established63-64. Since inhibition of the TOR kinase 
by rapamycin has shown TAG and lipid droplet formation similarly to other nutrient deprivation 
studies65, understanding its signaling and regulatory processes regulated by TOR is important. 
Key TORC1 complex proteins encoded by single-copy genes including TOR 
(Cre09.g400553.t1.1), regulatory associate protein target of rapamycin (RAPTOR) 
(Cre08.g371957.t1.1), and lethal with sec-13 protein 8 (LST8) (Cre17.g713900.t1.2) are 
conserved in Chlamydomonas66-67 but the substrates of TOR kinase and downstream signaling 
network have not been elucidated. In Chlamydomonas, TOR inhibition induces autophagy-like 
processes similar to those induced by nitrogen starvation59, 65, 68-69 and research into the 
regulatory processes is necessary to understand dynamic phosphorylation events involved in 
TAG accumulation and autophagy.  
1.5 Scope of Dissertation 
The focus of this dissertation is to improve the framework for studying protein 
phosphorylation quantitatively on a global scale in Chlamydomonas. For the work described 
herein, a peak intensity-based label-free quantitative approach has been optimized for studying 
the kinome and phosphoproteome in Chlamydomonas. First, I will introduce you to the standard 
operating procedures (SOPs) developed and optimized throughout the experimental chapters 
described herein (Chapter 2). SOPs have been established specifically for Chlamydomonas and 
detail optimized conditions from cell culture to biological inference via pathway analysis. 
Second, I will discuss the quantitative coverage obtained with this platform both from the 
kinome and the phosphoproteome (Chapter 3). This chapter focuses on employing the methods 
developed in Chapter 2 on studying the kinome and phosphoproteome in tandem in 
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Chlamydomonas with both DDA and DIA acquisition strategies (Figure 1.2). Next, I will build 
off the quantitative coverage that we have achieved in the phosphoproteome by using the 
quantitative phosphoproteomic workflow from Chapter 3 (Figure 1.3) to probe the effects of 
TOR inhibition in Chlamydomonas (Chapter 4). Following the investigation of TOR-modulated 
phosphosites in wild-type cells, I show the effects of studying this system using a rapamycin-
hypersensitive strain in Chapter 5 to glean more insight into the effects of TOR inhibition on the 
phosphoproteome. Lastly, I will highlight the expansion of this project through the investigation 
of other kinase-regulated cellular processes in Chlamydomonas in addition to other 
photosynthetic organisms such as Arabidopsis thaliana that would require minimal change to the 






Figure 1.1 Schematic of a label-free quantitative workflow showing n=5 replicates per condition. 
Chlamydomonas cells were cultured photoheterotrophically with subsequent protein extraction, 
digestion, and LC-MS/MS acquisition. Following acquisition, relative quantification using area 
under the curve (AUC) abundance at the MS1 level occurs between control and treatment 
samples to determine differentially changing proteins and protein identification is done through 






Figure 1.2 DDA and DIA acquisition workflows for AB Sciex TripleTOF 5600 instrument 
platform. For DDA, first 20 peptide precursors are selected for fragmentation every 2 second 
cycle based on optimized proteomic parameters70. For DIA, 20 MS/MS are selected for 
fragmentation based on windows of varying widths optimized to effectively cover the entire 
mass range while concurrently focusing on dense m/z regions with smaller Q1 windows and 









Figure 1.3 Standard bottom-up phosphoproteomic workflow including cell culturing, protein 
extraction, protein digestion, TiO2 phosphopeptide enrichment, LC-MS/MS acquisition, and 




1. Smith, L. M.; Kelleher, N. L.; Linial, M.; Goodlett, D.; Langridge-Smith, P.; Goo, Y. A.; 
Safford, G.; Bonilla, L.; Kruppa, G.; Zubarev, R., Proteoform: a single term describing 
protein complexity. Nature methods 2013, 10 (3), 186-187. 
2. Hunter, T., Protein kinases and phosphatases: the yin and yang of protein 
phosphorylation and signaling. Cell 1995, 80 (2), 225-236. 
3. Allen, J. F., Protein phosphorylation in regulation of photosynthesis. Biochimica et 
Biophysica Acta (BBA)-Bioenergetics 1992, 1098 (3), 275-335. 
4. Hubbard, M. J.; Cohen, P., On target with a new mechanism for the regulation of protein 
phosphorylation. Trends in biochemical sciences 1993, 18 (5), 172-177. 
5. Solari, F. A.; Dell'Aica, M.; Sickmann, A.; Zahedi, R. P., Why phosphoproteomics is still 
a challenge. Mol Biosyst 2015, 11 (6), 1487-1493. 
6. Neville, D. C.; Townsend, R. R.; Rozanas, C. R.; Verkman, A.; Price, E. M.; Gruis, D. 
B., Evidence for phosphorylation of serine 753 in CFTR using a novel metal‐ion affinity 
resin and matrix‐assisted laser desorption mass spectrometry. Protein Science 1997, 6 
(11), 2436-2445. 
7. Larsen, M. R.; Thingholm, T. E.; Jensen, O. N.; Roepstorff, P.; Jørgensen, T. J., Highly 
selective enrichment of phosphorylated peptides from peptide mixtures using titanium 
dioxide microcolumns. Molecular & cellular proteomics 2005, 4 (7), 873-886. 
8. Beltran, L.; Cutillas, P. R., Advances in phosphopeptide enrichment techniques for 
phosphoproteomics. Amino acids 2012, 43 (3), 1009-1024. 
9. Tsai, C.-F.; Wang, Y.-T.; Chen, Y.-R.; Lai, C.-Y.; Lin, P.-Y.; Pan, K.-T.; Chen, J.-Y.; 
Khoo, K.-H.; Chen, Y.-J., Immobilized metal affinity chromatography revisited: pH/acid 
control toward high selectivity in phosphoproteomics. Journal of proteome research 
2008, 7 (9), 4058-4069. 
10. Aryal, U. K.; Ross, A. R., Enrichment and analysis of phosphopeptides under different 
experimental conditions using titanium dioxide affinity chromatography and mass 
spectrometry. Rapid Communications in Mass Spectrometry 2010, 24 (2), 219-231. 
11. Ye, J.; Zhang, X.; Young, C.; Zhao, X.; Hao, Q.; Cheng, L.; Jensen, O. N., Optimized 
IMAC− IMAC protocol for phosphopeptide recovery from complex biological samples. 
Journal of proteome research 2010, 9 (7), 3561-3573. 
12. Neilson, K. A.; Ali, N. A.; Muralidharan, S.; Mirzaei, M.; Mariani, M.; Assadourian, G.; 
Lee, A.; Van Sluyter, S. C.; Haynes, P. A., Less label, more free: approaches in label‐free 
quantitative mass spectrometry. Proteomics 2011, 11 (4), 535-553. 
15 
13. Zhu, W.; Smith, J. W.; Huang, C.-M., Mass spectrometry-based label-free quantitative 
proteomics. BioMed Research International 2009, 2010. 
14. Ong, S.-E.; Blagoev, B.; Kratchmarova, I.; Kristensen, D. B.; Steen, H.; Pandey, A.; 
Mann, M., Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and 
accurate approach to expression proteomics. Molecular & cellular proteomics 2002, 1 
(5), 376-386. 
15. Thompson, A.; Schäfer, J.; Kuhn, K.; Kienle, S.; Schwarz, J.; Schmidt, G.; Neumann, T.; 
Hamon, C., Tandem mass tags: a novel quantification strategy for comparative analysis 
of complex protein mixtures by MS/MS. Analytical chemistry 2003, 75 (8), 1895-1904. 
16. Wiese, S.; Reidegeld, K. A.; Meyer, H. E.; Warscheid, B., Protein labeling by iTRAQ: a 
new tool for quantitative mass spectrometry in proteome research. Proteomics 2007, 7 
(3), 340-350. 
17. Wang, H.; Alvarez, S.; Hicks, L. M., Comprehensive comparison of iTRAQ and label-
free LC-based quantitative proteomics approaches using two Chlamydomonas reinhardtii 
strains of interest for biofuels engineering. Journal of proteome research 2011, 11 (1), 
487-501. 
18. Merl, J.; Ueffing, M.; Hauck, S. M.; von Toerne, C., Direct comparison of MS‐based 
label‐free and SILAC quantitative proteome profiling strategies in primary retinal Müller 
cells. Proteomics 2012, 12 (12), 1902-1911. 
19. Megger, D. A.; Bracht, T.; Meyer, H. E.; Sitek, B., Label-free quantification in clinical 
proteomics. Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics 2013, 1834 
(8), 1581-1590. 
20. Patel, V. J.; Thalassinos, K.; Slade, S. E.; Connolly, J. B.; Crombie, A.; Murrell, J. C.; 
Scrivens, J. H., A comparison of labeling and label-free mass spectrometry-based 
proteomics approaches. Journal of proteome research 2009, 8 (7), 3752-3759. 
21. Old, W. M.; Meyer-Arendt, K.; Aveline-Wolf, L.; Pierce, K. G.; Mendoza, A.; Sevinsky, 
J. R.; Resing, K. A.; Ahn, N. G., Comparison of label-free methods for quantifying 
human proteins by shotgun proteomics. Molecular & cellular proteomics 2005, 4 (10), 
1487-1502. 
22. Searle, B. C., Scaffold: a bioinformatic tool for validating MS/MS‐based proteomic 
studies. Proteomics 2010, 10 (6), 1265-1269. 
23. Cox, J.; Mann, M., MaxQuant enables high peptide identification rates, individualized 
ppb-range mass accuracies and proteome-wide protein quantification. Nature 
biotechnology 2008, 26 (12), 1367-1372. 
24. Schilling, B.; Rardin, M. J.; MacLean, B. X.; Zawadzka, A. M.; Frewen, B. E.; Cusack, 
M. P.; Sorensen, D. J.; Bereman, M. S.; Jing, E.; Wu, C. C., Platform-independent and 
label-free quantitation of proteomic data using MS1 extracted ion chromatograms in 
16 
Skyline application to protein acetylation and phosphorylation. Molecular & Cellular 
Proteomics 2012, 11 (5), 202-214. 
25. Nahnsen, S.; Bielow, C.; Reinert, K.; Kohlbacher, O., Tools for label-free peptide 
quantification. Mol Cell Proteomics 2013, 12 (3), 549-556. 
26. Bantscheff, M.; Schirle, M.; Sweetman, G.; Rick, J.; Kuster, B., Quantitative mass 
spectrometry in proteomics: a critical review. Analytical and bioanalytical chemistry 
2007, 389 (4), 1017-1031. 
27. Bantscheff, M.; Schirle, M.; Sweetman, G.; Rick, J.; Kuster, B., Quantitative mass 
spectrometry in proteomics: a critical review. Anal Bioanal Chem 2007, 389 (4), 1017-
1031. 
28. Liu, H.; Sadygov, R. G.; Yates, J. R., A model for random sampling and estimation of 
relative protein abundance in shotgun proteomics. Analytical chemistry 2004, 76 (14), 
4193-4201. 
29. Michalski, A.; Cox, J.; Mann, M., More than 100,000 detectable peptide species elute in 
single shotgun proteomics runs but the majority is inaccessible to data-dependent LC− 
MS/MS. Journal of proteome research 2011, 10 (4), 1785-1793. 
30. Oppermann, F. S.; Gnad, F.; Olsen, J. V.; Hornberger, R.; Greff, Z.; Kéri, G.; Mann, M.; 
Daub, H., Large-scale proteomics analysis of the human kinome. Molecular & Cellular 
Proteomics 2009, 8 (7), 1751-1764. 
31. Kuharev, J.; Navarro, P.; Distler, U.; Jahn, O.; Tenzer, S., In‐depth evaluation of software 
tools for data‐independent acquisition based label‐free quantification. Proteomics 2015, 
15 (18), 3140-3151. 
32. Werth, E. G.; McConnell, E. W.; Gilbert, T. S. K.; Couso Lianez, I.; Perez, C. A.; 
Manley, C. K.; Graves, L. M.; Umen, J. G.; Hicks, L. M., Probing the global kinome and 
phosphoproteome in Chlamydomonas reinhardtii via sequential enrichment and 
quantitative proteomics. The Plant Journal 2017, 89 (2), 416-426. 
33. Macek, B.; Mann, M.; Olsen, J. V., Global and site-specific quantitative 
phosphoproteomics: principles and applications. Annual review of pharmacology and 
toxicology 2009, 49, 199-221. 
34. Thingholm, T. E.; Jensen, O. N.; Larsen, M. R., Analytical strategies for 
phosphoproteomics. Proteomics 2009, 9 (6), 1451-1468. 
35. Kosako, H.; Nagano, K., Quantitative phosphoproteomics strategies for understanding 
protein kinase-mediated signal transduction pathways. Expert review of proteomics 2011, 
8 (1), 81-94. 
17 
36. Sharma, K.; D’Souza, R. C.; Tyanova, S.; Schaab, C.; Wiśniewski, J. R.; Cox, J.; Mann, 
M., Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and 
Ser/Thr-based signaling. Cell reports 2014, 8 (5), 1583-1594. 
37. Wu, R.; Dephoure, N.; Haas, W.; Huttlin, E. L.; Zhai, B.; Sowa, M. E.; Gygi, S. P., 
Correct interpretation of comprehensive phosphorylation dynamics requires 
normalization by protein expression changes. Molecular & cellular proteomics 2011, 10 
(8), M111. 009654. 
38. Werth, E. G.; McConnell, E. W.; Couso, I.; Perrine, Z.; Crespo, J. L.; Umen, J. G.; Hicks, 
L. M., Investigating the effect of Target of Rapamycin kinase inhibition on the 
Chlamydomonas reinhardtii phosphoproteome: from known homologs to new targets. 
Submitted. 2018. 
39. Valledor, L.; Furuhashi, T.; Recuenco-Muñoz, L.; Wienkoop, S.; Weckwerth, W., 
System-level network analysis of nitrogen starvation and recovery in Chlamydomonas 
reinhardtii reveals potential new targets for increased lipid accumulation. Biotechnology 
for biofuels 2014, 7 (1), 171. 
40. Cunningham Jr, F.; Gantt, E., Genes and enzymes of carotenoid biosynthesis in plants. 
Annual review of plant biology 1998, 49 (1), 557-583. 
41. Siaut, M.; Cuiné, S.; Cagnon, C.; Fessler, B.; Nguyen, M.; Carrier, P.; Beyly, A.; 
Beisson, F.; Triantaphylidès, C.; Li-Beisson, Y., Oil accumulation in the model green 
alga Chlamydomonas reinhardtii: characterization, variability between common 
laboratory strains and relationship with starch reserves. BMC biotechnology 2011, 11 (1), 
7. 
42. Park, J. J.; Wang, H.; Gargouri, M.; Deshpande, R. R.; Skepper, J. N.; Holguin, F. O.; 
Juergens, M. T.; Shachar‐Hill, Y.; Hicks, L. M.; Gang, D. R., The response of 
Chlamydomonas reinhardtii to nitrogen deprivation: a systems biology analysis. The 
Plant Journal 2015, 81 (4), 611-624. 
43. Merchant, S. S.; Kropat, J.; Liu, B.; Shaw, J.; Warakanont, J., TAG, you're it! 
Chlamydomonas as a reference organism for understanding algal triacylglycerol 
accumulation. Curr Opin Biotechnol 2012, 23 (3), 352-363. 
44. Cross, F. R.; Umen, J. G., The Chlamydomonas cell cycle. Plant J 2015, 82 (3), 370-392. 
45. Merchant, S. S.; Prochnik, S. E.; Vallon, O.; Harris, E. H.; Karpowicz, S. J.; Witman, G. 
B.; Terry, A.; Salamov, A.; Fritz-Laylin, L. K.; Maréchal-Drouard, L., The 
Chlamydomonas genome reveals the evolution of key animal and plant functions. Science 
2007, 318 (5848), 245-250. 
46. Zones, J. M.; Blaby, I. K.; Merchant, S. S.; Umen, J. G., High-Resolution Profiling of a 
Synchronized Diurnal Transcriptome from Chlamydomonas reinhardtii Reveals 
Continuous Cell and Metabolic Differentiation. Plant Cell 2015, 27 (10), 2743-2769. 
18 
47. Miller, R.; Wu, G.; Deshpande, R. R.; Vieler, A.; Gärtner, K.; Li, X.; Moellering, E. R.; 
Zauner, S.; Cornish, A.; Liu, B., Changes in transcript abundance in Chlamydomonas 
reinhardtii following nitrogen-deprivation predict diversion of metabolism. Plant 
physiology 2010, pp. 110.165159. 
48. Förster, B.; Mathesius, U.; Pogson, B. J., Comparative proteomics of high light stress in 
the model alga Chlamydomonas reinhardtii. Proteomics 2006, 6 (15), 4309-4320. 
49. Atteia, A.; Adrait, A.; Brugière, S.; Tardif, M.; Van Lis, R.; Deusch, O.; Dagan, T.; 
Kuhn, L.; Gontero, B.; Martin, W., A proteomic survey of Chlamydomonas reinhardtii 
mitochondria sheds new light on the metabolic plasticity of the organelle and on the 
nature of the α-proteobacterial mitochondrial ancestor. Molecular Biology and Evolution 
2009, 26 (7), 1533-1548. 
50. Wagner, V.; Ullmann, K.; Mollwo, A.; Kaminski, M.; Mittag, M.; Kreimer, G., The 
phosphoproteome of a Chlamydomonas reinhardtii eyespot fraction includes key proteins 
of the light signaling pathway. Plant physiology 2008, 146 (2), 772-788. 
51. Boesger, J.; Wagner, V.; Weisheit, W.; Mittag, M., Analysis of flagellar phosphoproteins 
from Chlamydomonas reinhardtii. Eukaryotic cell 2009, 8 (7), 922-932. 
52. Pan, J.; Naumann-Busch, B.; Wang, L.; Specht, M.; Scholz, M.; Trompelt, K.; Hippler, 
M., Protein phosphorylation is a key event of flagellar disassembly revealed by analysis 
of flagellar phosphoproteins during flagellar shortening in Chlamydomonas. Journal of 
proteome research 2011, 10 (8), 3830-3839. 
53. Wagner, V.; Geßner, G.; Heiland, I.; Kaminski, M.; Hawat, S.; Scheffler, K.; Mittag, M., 
Analysis of the phosphoproteome of Chlamydomonas reinhardtii provides new insights 
into various cellular pathways. Eukaryotic Cell 2006, 5 (3), 457-468. 
54. Wang, H.; Gau, B.; Slade, W. O.; Juergens, M.; Li, P.; Hicks, L. M., The global 
phosphoproteome of Chlamydomonas reinhardtii reveals complex organellar 
phosphorylation in the flagella and thylakoid membrane. Molecular & Cellular 
Proteomics 2014, 13 (9), 2337-2353. 
55. Roustan, V.; Bakhtiari, S.; Roustan, P.-J.; Weckwerth, W., Quantitative in vivo 
phosphoproteomics reveals reversible signaling processes during nitrogen starvation and 
recovery in the biofuel model organism Chlamydomonas reinhardtii. Biotechnology for 
biofuels 2017, 10 (1), 280. 
56. Loewith, R.; Hall, M. N., Target of rapamycin (TOR) in nutrient signaling and growth 
control. Genetics 2011, 189 (4), 1177-1201. 
57. Wullschleger, S.; Loewith, R.; Hall, M. N., TOR signaling in growth and metabolism. 
Cell 2006, 124 (3), 471-484. 
58. Dobrenel, T.; Caldana, C.; Hanson, J.; Robaglia, C.; Vincentz, M.; Veit, B.; Meyer, C., 
TOR Signaling and Nutrient Sensing. Annual review of plant biology 2016, 67, 261-285. 
19 
59. Pérez-Pérez, M. E.; Couso, I.; Crespo, J. L., The TOR Signaling Network in the Model 
Unicellular Green Alga Chlamydomonas reinhardtii. Biomolecules 2017, 7 (3), 54. 
60. González, A.; Hall, M. N., Nutrient sensing and TOR signaling in yeast and mammals. 
The EMBO journal 2017, e201696010. 
61. Raught, B.; Gingras, A. C.; Sonenberg, N., The target of rapamycin (TOR) proteins. Proc 
Natl Acad Sci U S A 2001, 98 (13), 7037-7044. 
62. Dibble, C. C.; Manning, B. D., Signal integration by mTORC1 coordinates nutrient input 
with biosynthetic output. Nature cell biology 2013, 15 (6), 555-564. 
63. Zhang, Y.; Persson, S.; Giavalisco, P., Differential regulation of carbon partitioning by 
the central growth regulator target of rapamycin (TOR). Molecular plant 2013, 6 (6), 
1731-1733. 
64. Xiong, Y.; Sheen, J., The role of target of rapamycin signaling networks in plant growth 
and metabolism. Plant physiology 2014, 164 (2), 499-512. 
65. Rodrigues, S. P.; Alvarez, S.; Werth, E. G.; Slade, W. O.; Gau, B.; Cahoon, E. B.; Hicks, 
L. M., Multiplexing strategy for simultaneous detection of redox-, phospho- and total 
proteome – understanding TOR regulating pathways in Chlamydomonas reinhardtii. 
Anal. Methods 2015, 7 (17), 7336-7344. 
66. van Dam, T. J.; Zwartkruis, F. J.; Bos, J. L.; Snel, B., Evolution of the TOR pathway. J 
Mol Evol 2011, 73 (3-4), 209-220. 
67. Diaz-Troya, S.; Florencio, F. J.; Crespo, J. L., Target of rapamycin and LST8 proteins 
associate with membranes from the endoplasmic reticulum in the unicellular green alga 
Chlamydomonas reinhardtii. Eukaryot Cell 2008, 7 (2), 212-222. 
68. Perez-Perez, M. E.; Florencio, F. J.; Crespo, J. L., Inhibition of target of rapamycin 
signaling and stress activate autophagy in Chlamydomonas reinhardtii. Plant Physiol 
2010, 152 (4), 1874-1888. 
69. Pérez-Pérez, M. E.; Couso, I.; Heredia-Martínez, L. G.; Crespo, J. L., Monitoring 
Autophagy in the Model Green Microalga Chlamydomonas reinhardtii. Cells 2017, 6 (4), 
36. 
70. Andrews, G. L.; Simons, B. L.; Young, J. B.; Hawkridge, A. M.; Muddiman, D. C., 
Performance characteristics of a new hybrid quadrupole time-of-flight tandem mass 
spectrometer (TripleTOF 5600). Analytical chemistry 2011, 83 (13), 5442-5446. 
20 
CHAPTER 2:  SOPs for Culturing, Extraction, Digestion, Enrichment, Data Analysis 
Techniques for Algal-based Phosphoproteomics 
2.1 Introduction 
Phosphoproteomic studies in plant and algal species are unique in a variety of ways when 
compared to mammalian-based studies from sample culturing to bioinformatic resources 
available for biological inference. While there are steps common throughout all bottom-up 
proteomic experiments, optimization specifically for algae at every step of the pipeline is 
required to achieve ideal results such as specialized culturing conditions and extraction 
techniques for effective lysis of cell-wall containing organisms. Because of this and other 
requirements, the following chapter describes the standard operating procedures optimized and 
utilized throughout the subsequent research chapters. 
2.2 Strain Selection and Algal Culturing 
Algal culturing can be performed under photoautotrophic conditions requiring light for 
growth or photoheteroautotrophically, which includes a carbon source in the media and allows 
for growth in the absence of light. For cell synchronization to occur in Chlamydomonas, cells 
grown photoautotrophically require minimal media and a consistent light period such as diurnal 
cycles (12 h light, 12 h dark) driving photosynthetic cell growth and the cell division cycle1. For 
the experiments described throughout this dissertation, photoheteroautotrophic growth was 
employed using Tris-Acetate-Phosphate (TAP) solid and liquid media2 from protocols made 
available through the Chlamydomonas Resource Center (https://www.chlamycollection.org). 
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Photohetereoautotrophic growth that does not involve cell synchronization was employed due to 
the dense cell cultures required for the large amount of cellular starting material needed for this 
phosphoproteomic workflow, a requirement not feasible with reproducible growth in light driven 
photoautotrophic cultures.  
The strains used in the experimental chapters are all cell-walled strains with much of the 
method development work done in the wild-type strain CC-2895 6145c mt-. While it requires an 
optimized extraction method for effective cell lysis, using a cell-walled wild-type strain for 
differential phosphoproteomic studies was chosen to not extraneously stress the cell prior to 
investigating the effect of exogenous stresses on the phosphoproteome, which is a concern if 
using a cell wall-less mutant. For work on the rapamycin-hypersensitive mutant, vip1-1, the cell-
walled strain CC-1690 mt+ was used as the parental strain to generate vip1-1 (Chapter 5). 
After strain selection, algal culturing conditions require uniform growth across replicates. To 
measure log-phase growth and ensure harvesting at early-log phase, growth conditions were 
assessed using a Beckman Coulter cell counter with corresponding optical density (OD750) 
measurements to evaluate during each experiment using UV-Vis. Cells were harvested at 
approximately 5x107 cells/mL (OD750 ~ 0.4). For differential phosphoproteomic experiments 
discussed in Chapters 4 and 5, replicates of drug treatments were harvested to avoid variability 
amongst drug treatments through performing drug incubations for each replicate together. For 
example, in chapter 4, replicate 1 for Torin1, AZD8055, Rapamycin, and control drug treatments 
were harvested together and the process was continued until the fifth replicate for each treatment. 
The following protocol outlines the cell culturing and harvesting process used throughout the 
subsequent research chapters. 
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Cell Culturing, Day 1: 
1. Prepare 350 mL starting liquid culture from strains grown on solid TAP media. Use a 1 L 
flask for 350 mL of culture to provide sufficient room for consistent mixing.  
a. Perform mixing at 120 RPM with 100 μmol m–2 s–1 white light at room 
temperature. 
2. Grow overnight; typical doubling time is approximately 6 hr. 
Day 2: 
3. Measure cell count using Beckman Coulter cell counter, perform dilutions into new 
liquid TAP media cultures splitting cells into the number of flasks required for each 
replicate of the final experiment. Cells will be harvested at approximately 5x107 cells/mL 
therefore dilute cultures of approximately 3.0 x106 cells/mL should be prepared 24 hours 
prior to harvesting.  
a. To reduce batch effects between replicates, dilutions for each set of replicates 
should be prepared so they are staggered growth. For example, if it requires 
approximately 1 hr to perform drug treatment and harvesting for each replicate, 
stagger dilutions of each replicate by one hour so each will grow to approximately 
5x107 cells/mL at the appropriate time. 
4. Grow overnight  
5. While cells are growing, prepare stock solutions of chemical inhibitors used. For 
Chapters 4 and 5, this requires a final concentration for AZD8055, Torin1, and 
Rapamycin of 700 µM, 500 µM, and 500 µM, respectively. 
a. Prepare 1 mM stock solutions in DMSO and store at -20°C to use the next day. 
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Day 3: 
6. For each replicate, perform drug incubation to actively growing cultures at approximately 
5x107 cells/mL concentration.  
7. Following drug incubation, quench cell cultures in a final concentration of 40% 
methanol. Prepare pre-chilled 80% methanol and pour equal volumes of cell culture prior 
to centrifugation for a final concentration of 40% methanol. This requires 350 mL 80% 
methanol for each replicate.  
8. Centrifuge each culture for 5 min at 6,000 x g at 4°C 
9. Decant supernatant with special attention to not disturb dark green cell pellet in 
centrifuge bottle. 
10. Resuspend pellet in 10 mL of fresh TAP media, transfer solution to 15-mL conical 
centrifuge tube. 
11. Centrifuge each culture for 2 min at 3,200 x g, maximum speed for Eppendorf 5810 
centrifuge, at 4°C 
12. Decant supernatant with special attention to not disturb dark green cell pellet in conical 
centrifuge tube. 
13. Place conical centrifuge tube containing cell pellet in liquid nitrogen, once fully frozen 
store at -80°C until performing plant-based protein extraction. 
2.3 Plant-based Extraction Techniques 
Similar to other protein extractions, the objective of this step is to lyse the cells and gain 
access to proteins for downstream analysis. Because Chlamydomonas cells contain a cell-wall, 
efficient protein extraction requires both physical and reagent-based methods for cell lysis such 
as the use of a sonication step and the addition of detergents. For this, both native and denaturing 
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protein extractions have been adapted for efficient protein extraction in Chlamydomonas and are 
described below.  
2.3.1 Native Extraction 
Some enrichment techniques require native protein conformations to properly function. This 
consideration limits the detergents available for use during protein extraction and can require 
additional steps to effectively lyse cells, especially those that contain a cell wall. For the kinome 
enrichment employed in Chapter 3, the multiplexed inhibitor beads (MIBs) designed to 
preferentially bind to kinases over other proteins in the cell lysate required native kinase 
conformation for effective binding thus a native protein extraction was adapted from Daub et. 
al.3 for algal cells. This protocol uses cell lysis via adaptive focused acoustics as an alternative to 
traditional sonication methods to reduce protein degradation and aggregation during cell 
disruption by avoiding sample overheating4. This is necessary to assist in lysing cells in a native 
environment absent from detergents. Compared to denaturing extraction procedures, this method 
yielded approximately 7.8 mg of protein per gram of wet cell pellet5, only slightly reduced from 
the 8.0-9.5 mg g-1 extracted under denaturing conditions6-7. 
Native Protein Extraction: 
1. Algal culturing is performed as described above in section 2.2 with minor changes to 
accommodate a native protein extraction. Specifically, cells are not quenched in methanol 
and protein extraction is performed directly following centrifugation instead of storage at 
-80°C. 
2. Following algal culturing, cells are resuspended in non-denaturing lysis buffer and kept 
on ice. Cells are resuspended in 4 mL for every 1 gram of cell pellet. 
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a. Non-denaturing lysis buffer contains: 50 mM HEPES, pH 7.5, 0.5% Triton X-
100, 150 mM NaCl, 1mM EDTA, 1mM EGTA, 10 mM NaF, 2.5 mM NaVO4, 
and EDTA-free cOmplete protease inhibitor cocktail (Roche) and phosphatase 
inhibitor cocktails 2 and 3 (Sigma). 
3. Cells in lysis buffer are then subjected to acoustic sonication for 3 min at 200 
cycles/burst, 100 W power, and 13% duty cycle using an E220 focused ultra-sonicator 
(Covaris, Woburn, MA, USA).  
4. Samples are transferred from glass Covaris tubes to Eppendorf centrifuge tubes. While 
transferring, the remaining samples are kept on ice. 
5. Cell lysates are centrifuged at 16,000 x g for 10 min and the supernatant is collected. 
6. While on ice, a small amount of each replicate is used for protein quantification using 
CB-X Protein Assay using manufacturer guidelines (G-Biosciences). 
7. Following protein quantification, each replicate is normalized to the same concentration 
of 5.5mg/3mL for subsequent kinome and phosphoproteome enrichments (Section 2.5) 
using fresh lysis buffer, requiring at least 5 mg of lysate for kinome enrichment. 
2.3.2 Denaturing Extraction 
For peptide-based enrichment techniques that did not require a native protein lysate, such as 
the enrichments employed in Chapters 4 and 5, a Tris-based protein extraction with ionic, and 
denaturing, detergents was utilized to reproducibly extract a large subset of the proteome in 
Chlamydomonas. While the native protein extraction was optimized to yield similar amounts of 
mg g-1,5 the addition of denaturing detergents to more effectively lyse cells was used when native 
conformation was not necessary.  
Denaturing protein extraction: 
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1. Algal culturing is performed as described in Section 2.2 
2. Following algal culturing, cells are resuspended in lysis buffer and kept on ice. Cells are 
resuspended in 4 mL for every 1 gram of cell pellet. 
a. Lysis buffer contains: 100 mM Tris, pH 8.0, 1% SDS, 1x cOmplete protease 
inhibitor and phosSTOP phosphatase inhibitor cocktails (Roche). 
3. Cells in lysis buffer are then subjected to acoustic sonication in a 4°C water bath for 3 
min at 200 cycles/burst, 100 W power, and 12% duty cycle using an E220 focused ultra-
sonicator (Covaris, Woburn, MA, USA).  
4. Samples are transferred from glass Covaris tubes to Eppendorf centrifuge tubes. While 
transferring, the remaining samples are kept on ice. 
5. Cell lysates are centrifuged at 16,000 x g for 10 min and the supernatant is collected. 
6. Back extraction from remaining pellet is performed by adding fresh lysis buffer and 
vortexing. 
7. The samples are centrifuge at 16,000 x g for 10 min and the supernatant is collected and 
recombined with the first extraction. 
8. Proteins are precipitated using 5 volumes of cold 100 mM ammonium acetate in 
methanol. 
9. Samples are incubated for 3hr at -80°C. 
10. After centrifugation for 5 min at 2,000 x g, the supernatant is decanted without disturbing 
the protein pellet. 
11. Two washes are performed with fresh 100 mM ammonium acetate in methanol and a 
final wash with 70% ethanol, each followed with another centrifugation as described in 
step 10. 
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a. Protein pellets are vortexed with wash solution before spinning down. 
12. Pellets are allowed to dry for approximately 5 min in hood followed by resolubilization in 
minimal resuspension buffer. Each 350 mL culture of starting material is resuspended in 
1-2 mL of resuspension buffer for each replicate. 
a. Resuspension buffer contains: 8M urea in 100 mM Tris 
13. Resuspended protein is incubated at room temperature for 1 hr. 
14. A small amount of each replicate is aliquoted for protein quantification using CB-X 
Protein Assay using manufacturer guidelines (G-Biosciences). 
15. Each replicate is normalized to the same concentration using fresh resuspension buffer 
before moving forward. 
16. Resuspended protein lysates are stored at -80°C until continuing to protein-level 
enrichment or reduction, alkylation, and digestion. 
2.4 Kinome Enrichment 
To effectively enrich for the kinome of Chlamydomonas over other proteins in the cell lysate, 
a kinome enrichment strategy known as multiplexed inhibitor beads, MIBs, was performed prior 
to digestion on protein lysate samples that underwent native extraction. The MIBs columns were 
adapted for algal samples from a workflow previously described8 and are composed of a 6 bead 
mix containing the following inhibitors: CTX0294885, VI16832, Purvalanol B, Shokat, PP58 
and UNC21474 in the ratio of 1.5:1 (CTX0294885, VI16832): (Purvalanol B, Shokat, PP58 and 
UNC21474). This protocol was utilized in Chapter 3 to quantitatively characterize the kinome in 
tandem with the phosphoproteome using an LFQ proteomics-based approach. 
Kinome enrichment:  
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1. Following native extraction, 5.5 mg/ 3 mL samples of protein lysate are loaded onto 
MIBs column. 
2. 350 µL of bead slurry are used per replicate. 
3. The MIBs mixture is vortexed to homogenize slurry and 350 µL are pipetted onto each 
column. 
4. Prior to loading sample, the MIBs column is washed with 2 mL of “high salt” buffer. 
a. High salt buffer contains: 50 mM HEPES, pH = 7.5, 1 M NaCl, 0.5% Triton X-
100, 1 mM EDTA, 1 mM EGTA. 
5. 3 mL of protein lysate is pipetted onto the MIBs columns. The flow-through is reloaded 
one time. 
6. The column is washed with 5 mL “high salt” buffer followed by 5 mL of “low salt” 
buffer. 
a. Low salt buffer contains: 50 mM HEPES, pH = 7.5, 50 mM NaCl, 0.5% Triton X-
100, 1 mM EDTA, 1 mM EGTA. 
7. The column is wash with 500 µL of low salt buffer containing 0.1% SDS. 
8. The column is incubated with 500 µL of MIBs elution buffer at 95°C for 15 min. 
a. MIBs elution buffer contains: 0.5% SDS, 1% β-mercaptoethanol, 0.1% Tris, pH = 
6.8 
9. The elution is collected following incubation 
10. The elution (steps 8 and 9) is repeated one time. 
11. Following protein-level enrichment, protein precipitation is performed (Section 2.3.2, 
step 5) followed by reduction, alkylation, and digestion as discussed in the following 
section. 
29 
2.5 Digestion and C18 Clean-Up Techniques 
While reduction, alkylation, and protein digestion are common steps throughout all bottom-
up proteomic experiments, numerous reducing and alkylating agents in addition to experimental 
parameters during protein digestion have been tested to determine the best conditions. In 
Chlamydomonas, reducing agents such as dithiothreitol (DTT)7 and Tris(2-
carboxyethyl)phosphine hydrochloride (TCEP)9-10 have been used to study protein thiols and the 
effectiveness of alkylation between iodoacetamide  (IAM) and N-Ethylmaleimide (NEM) has 
been studied7. Additionally, to limit overheating of phosphopeptides leading to sample 
degradation, digestion was performed at 25°C instead of the traditional 37°C overnight. The 
following protocol was used to perform the reduction, alkylation, and digestion followed by 
desalting using a C-18 column. 
Reduction, Alkylation, and Digestion: 
1. Samples stored at -80°C are allowed to thaw to room temperature. 
2. Samples are reduced using 10 mM dithiothreitol for 30 min at room temperature. 
a. Prepare 1 mL of 500 mM DTT solution and add 20 µL for each 1 mL of protein 
lysate. 
3. Alkylation is done using 40 mM iodoacetamide for 45 min in darkness at room 
temperature. 
a. Prepare 2 mL of 500 mM IAM solution and add 80 uL for each 1 mL of protein 
lysate. 
4. Following alkylation, samples are diluted 5-fold in 100 mM Tris so the concentration of 
urea is <2M, which is a requirement for effective protein digestion. 
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5. Overnight digestion is performed using Trypsin Gold (Promega) at a protease:protein 
ratio of 1:50 for 16 hr. at 25°C. For phosphopeptide enrichment experiments, this 
requires 40 µg of Trypsin Gold for every 2 mg of protein lysate. 
6. Following the 16 hr incubation, digestion is quenched using a stock of 5% TFA to 
pH<3.0 
7. Samples are frozen at -80°C following digestion until C18 Clean Up using 50 mg SepPak 
(Waters) cartridges. 
C-18 Clean Up: 
8. Desalting is performed following protein digestion using commercially available 50 mg 
SepPak (Waters) cartridges on a vacuum manifold. To prepare, samples are thawed on 
ice and centrifuged for 5 min at 5,000 x g to pellet. Undigested protein is removed from 
peptide mixture to avoid clogging C-18 cleanup columns. 
9. Prior to loading samples onto the column, columns are wet using 1 mL of acetonitrile 
working with up to five columns at a time. Experiments requiring 20 samples such as in 
Chapter 4, are done in four sets of five. 
10. A small amount of vacuum is used to maintain a constant flow of approximately 1 drop 
per second throughout the entire workflow until elution which is done without vacuum. 
11. Columns are equilibrated using 2 mL of 1% TFA in water. 
12. Peptide samples are passed through the column recovering flow through 
13. Flow through is reapplied across the columns 
14. Salts are removed by flowing 2 mL of 1% TFA in water following the flow through. 
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15. To elute desalted peptide mixture from column, 1.5 mL of 60% acetonitrile, 0.1% TFA in 
water is used. Elution is performed at ambient pressure with no additional vacuum 
applied. 
a. The desalted peptides are recovered using a 2 mL Eppendorf centrifuge tube. 
b. Once the 1.5 mL of 60% acetonitrile, 0.1% TFA in water have passed through the 
columns, the remaining amount is recovered by applying vacuum for 
approximately 5 sec. 
16. Following peptide elution, samples are frozen at -80°C and vacuum centrifuged to 
dryness prior to phosphopeptide enrichment 
a. For samples that will not undergo peptide-level enrichment, they are ready for 
LC-MS/MS analysis following vacuum centrifugation to dryness (Section 2.7) 
2.6 Phosphoproteomic Techniques 
Reproducibility in sample preparation and processing is crucial for LFQ proteomics. When 
introducing an enrichment strategy and additional sample handling steps to the pipeline, 
variability is inherently increased. To reduce the variability introduced with the phosphopeptide 
enrichment step, the ideal protein:resin ratio was determined specifically for the Chlamydomonas 
cellular matrix (Figure 2.1). The following protocol uses commercially available 3 mg. TiO2 
phosphopeptide enrichment columns (GL Sciences) and was adapted from the protocol provided 
by the Duke Proteomics Core Facility (http://www.genome.duke.edu/cores/proteomics/) for 
Chlamydomonas. 2 mg. of peptide lysate starting material was used for each replicate in the LFQ 
phosphopeptide work described in Chapters 3-5.  
Phosphopeptide Enrichment: 
1. Columns are pre-eluted using 100 µL of elution buffer for each sample replicate. 
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a. Elution buffer contains: 20% acetonitrile, 5% aqueous ammonia. 
2. Columns are centrifuged at room temperature at 1000 x g for 2 min. 
3. Conditioning is done by adding 100 µL of 80% acetonitrile, 1% TFA in water to each 
column. 
4. Columns are centrifuged at room temperature at 1000 x g for 2 min. 
5. Steps 3 and 4 are repeated one time. 
6. Columns are conditioned using 100 µL of 80% acetonitrile, 1% TFA, 30 mg/mL phthalic 
acid. 
7. Columns are centrifuged at room temperature at 1000 x g for 2 min. 
8. Steps 6 and 7 are repeated twice. 
9. Samples that were previously dried down following C18 clean-up (Section 2.4, step 16) 
are resuspended in 150 µL of 80% acetonitrile, 1% TFA, 30 mg/mL phthalic acid. 
10. Following resuspension, samples are centrifuged at 10,000 x g for 5 min prior to loading 
onto the column to make sure there is no solid material that could clog the column. 
11. 150 µL of peptide sample is added to each enrichment column. 
12. The columns are centrifuged at room temperature at 1000 x g for 5 min recovering the 
flow through. 
13. Flow through is reapplied following steps 11 and 12 twice. 
14. Following peptide lysate binding, the columns are washed using 100 µL of 80% 
acetonitrile, 1% TFA in water, 30 mg/mL phthalic acid. 
15. The columns are centrifuged at room temperature at 1000 x g for 2 min. 
16. Steps 14 and 15 are repeated one time. 
17. The columns are washed again using 100 µL of 80% acetonitrile, 1% TFA in water. 
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18. The columns are centrifuged at room temperature at 1000 x g for 2 min. 
19. Steps 17 and 18 are repeated twice.  
20. Phosphopeptide-enriched samples are eluted by adding 100 µL of elution buffer. 
21. The columns are centrifuged at room temperature at 1000 x g for 5 min. 
22. Steps 20 and 21 are repeated for a total of 200 µL of elution. 
23. The elution is then frozen and vacuum centrifuged to dryness prior to ZipTip sample 
clean-up and subsequent LC-MS/MS acquisition. 
2.7 LC-MS/MS Analysis 
Following sample preparation techniques used throughout the LFQ proteomic and 
phosphoproteomic pipelines described above, reproducible LC-MS/MS sample preparation and 
acquisition is additionally required. To prepare samples for LC-MS/MS, samples are dried to 
completeness via vacuum centrifugation prior to resuspension in 3% MeCN, 0.1% TFA in water 
for phosphopeptide samples and resuspended in 3% MeCN, 0.1% formic acid (FA) in water for 
kinome and non-enriched samples. The LC-MS/MS system used throughout this dissertation is a 
NanoACQUITY coupled to a TripleTOF 5600 (AB Sciex) that is optimized for one microgram 
of lysate on column per sample. For general workflows, dried samples are prepared in 1µg/ 5µL 
concentrations with 5 µL injection volumes. For phosphopeptide-enriched samples, dried 
elutions following phosphopeptide enrichment are resuspended in 20 µL with 5 µL injection 
volumes for each replicate.  
For peptide separation, a 90-min linear gradient from 95% H2O/5% MeCN /0.1% FA to 65% 
H2O/35% MeCN /0.1% FA was used. Each sample was loaded onto a trap column (NanoAcquity 
UPLC 2G-W/M Trap 5 μm Symmetry C18, 180 μm × 20 mm) at a flow rate of 5 μL min–1 for 5 
min. Peptides were separated using a C18 column (NanoAcquity UPLC 1.8 μm HSS T3, 75 μm 
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× 250 mm) at a flow rate of 300 nL min–1. For both MS acquisition strategies described below, 
the TripleTOF 5600 Q-TOF was operated in positive ionization nanoelectrospray and high-
sensitivity mode for data acquisition as previously described7. Data-dependent acquisition was 
employed for all phosphoproteomic work described in the following research chapters and the 
data-independent acquisition workflow described below was employed for the kinome analysis 
in Chapter 3. 
2.7.1 DDA and SWATH (DIA) Acquisition Parameters 
Based on previous performance studies for the TripleTOF 5600 system11 and our laboratory’s 
assessment of our NanoACQUITY coupled to TripleTOF 5600 platform7, DDA runs selected the 
first 20 features above 150 counts having a +2 to +5 charge state for fragmentation for each two 
second cycle. For DIA runs via SWATH (Sequential Windowed Acquisition of All Theoretical 
Fragment Ion Mass Spectra), fragmentation was instead performed across the entire mass range 
for each two second cycle. This was done using 20 sequential windows across the mass range 
with varying widths optimized to effectively cover the entire mass range while concurrently 
focusing on dense m/z regions with smaller Q1 windows and less dense m/z regions with larger 
Q1 windows (Figure 2.2). Sequential window widths optimized for the DIA kinome analysis can 
be found in Table 2.1. 
2.8 Label-Free Quantitative Data Processing and Analysis Techniques 
Following data acquisition, steps to align experimental runs, infer protein identifications, and 
provide quantitative information are necessary to infer biological significance. For DDA 
workflows, this was done using Progenesis QI for Proteomics (Nonlinear Dynamics) as 
discovery analysis software, Mascot Daemon (Matrix Science) for protein identification, and 
Python and Perseus for data filtering. For the SWATH workflow, this was done using PeakView 
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(AB Sciex) for quantitative review of MS/MS spectra and alignment to the ion library, which 
used Mascot Daemon database searching to generate the ion library identifications. The data 
processing steps for each acquisition type are outlined in the following sections. 
2.8.1 DDA Data Processing and Analysis 
DDA Data analysis workflow: 
1. Acquired spectra files (*.wiff) are imported into Progenesis QI for Proteomics (v2.0, 
Nonlinear Dynamics). 
2. Automatic processing is done, allowing a reference spectra to be assigned. 
3. To minimize run-to-run differences, each file is aligned to reference spectra and the 
alignment is manually validated requiring ≥ 80% score for each *.wiff against the 
reference spectra.  
a. For alignments with <80% score, manual alignment vectors are included before 
redoing the automatic alignment. 
4. Following alignment validation and review, the automatic processing is continued, setting 
up the experimental design specifying control and treatment runs. 
5. A combined peak list (*.mgf) is then generated under the “identify peptides” tab for all 
runs.  
6. The file is exported for peptide sequence determination and protein inference by Mascot 
(v2.5.1, Matrix Science) using parameters described in Figure 2.3. 
7. Following database searching, Mascot Percolator algorithm is employed, requiring ≤ 1% 
peptide FDR. 
8. Resulting matches are exported as *.xml file. Matches are also exported as *.csv file with 
query level raw peptide match data included. 
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9. *.xml file is uploaded into Progenesis QI for Proteomics to match peaks from the raw 
spectra. 
10. Following this, peptide measurements as *.csv are exported for analysis of 
phosphoproteomic experiments and protein measurements are exported as *.csv for 
analysis of phosphoproteomics and kinome experiments. Prior to exporting protein 
measurements for phosphoproteomic experiments, the identifications are refined so 
protein scores of less than 13 are removed. Filtering steps to parse results were written as 
custom scripts in the Python programming language. Figure 2.4 displays an example 
output following Python filtering to be used for filtering and data visualization. 
a. For phosphoproteomic work, data filtering steps employed are shown in Figure 
2.5 with the first three steps performed in Python and removal of rows with >50% 
zeros in each condition performed in Perseus. 
b. For kinome LFQ work, analysis was performed on protein measurements after 
filtering for proteins with ≥2 unique peptides used for identification in Excel. 
11. Data normalization and visualization is performed as described in Section 2.10. 
2.8.2 SWATH Data Processing and Analysis 
Prior to LFQ analysis of SWATH files, an ion library composed of DDA runs to compare 
SWATH spectra against is required. For the SWATH ion library, 15 strong cation exchange 
(SCX) fractions in addition to kinome DDA runs were analyzed to compose a library of 4,198 
protein identifications, which were used as the source for protein identifications for SWATH 
prior to LFQ analysis. The process of ion library generation in addition to SWATH file 
processing after ion library generation are described in this section.  
Ion Library Generation for SWATH: 
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1. Raw *.wiff files from fractionated DDA runs and additional DDA runs that will compose 
the ion library are imported into ProteinPilot (AB Sciex, v.5.0) under the LC “Identify 
Proteins” tab. 
2. Using Paragon processing, digestion and Cys alkylation type are specified as trypsin and 
iodoacetamide, respectively. 
3. Thorough ID search with a biological modification ID focus and the database of interest 
are specified before searching. 
4. Following searching, *.group file generated for ion library for SWATH data analysis is 
exported. 
SWATH Data Analysis Workflow: 
5. Following ion library generation, *.group file is imported into PeakView (AB Sciex, 
v.2.1) by selecting ion library from quantitation tab. 
6. When prompted, a maximum number of proteins to import is specified that is above the 
amount of identifications specified in ProteinPilot for the ion library of interest. 
7. Shared peptides are not imported and “unlabeled” sample type is selected. 
8. Once ion library is loaded, raw *.wiff sample files are added to PeakView. 
9. Retention time calibration is performed using 1-2 peptides every 10 minutes throughout 
gradient from 30-90 min. 
10. SWATH data is processed using settings specified in Table 2.2. 
11. The processed experiment is exported to an Excel workbook file. 
12. In Excel, a confidence cutoff score is filtered to be >1.3 (95% confidence). 
13. Data normalization and visualization is performed as described in Section 2.9. 
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2.9 Data Visualization and Biological Inference Techniques 
To find significance in the quantitative data provided in the above workflow, strategies for 
statistical analysis, data visualization and biological inference such as pathway annotation are 
required. To perform this, multiple software and online tools are available. For this work, 
statistical analysis is performed using Perseus12-13 and annotation data for Chlamydomonas is 
provided by Phytozome14, the Plant Comparative Genomics portal of the Department of 
Energy’s Joint Genome Institute (https://phytozome.jgi.doe.gov). Online tools such as KEGG 
pathway analysis15-16 and DAVID functional annotation17-18 allow for further understanding of 
pathways of interest from statistically significant proteins with annotation in the 
Chlamydomonas genome. Together, these resources provide downstream biological analysis 
from the quantitative data to better understand effects on cellular signaling from complex 
proteomic and phosphoproteomic datasets. 
Statistical Analysis Workflow: 
1. The quantitative dataset *.csv file is converted to a *.txt file in Excel to import to 
Perseus v1.6.0.0. 
2. The *.txt file is imported specifying normalized abundance data for each replicate in the 
experiment as “Main” type columns. 
3. Additional columns are specified as numerical, text, or categorical based on column 
characteristics. For phosphopeptide work, the Identifier column is imported and for 
kinome and unenriched work, the protein accession column is imported as a “text” 
column. 
4. Following importing of the data matrix, the experimental design is specified for 
statistical testing by adding a categorical annotation row. 
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a. Each replicate of a condition should have the same name in the categorical row. 
5. The data are Log2 transformed to normalize prior to testing. 
6. The appropriate test is performed based on the experimental design. Comparisons are 
specified using categorical rows. 
a. For example, if comparing two conditions, two-sample Student’s T-test are 
performed. For comparison across multiple conditions, ANOVA testing is used. 
7. Following testing, the final matrix is exported as *.txt file. 
8. In Excel, *.txt file is filtered for the appropriate fold change. This is performed by 
comparing averages of each condition with a threshold for significance. For chapters 4 
and 5, a fold change FC>2 and p-value<0.05 were used. 
9. Sites or proteins significantly changing based on statistical testing are highlighted. 
10. With matrix parsed for significantly changing rows, *.txt file is reimported into Perseus 
v.1.6.0.0 for data visualization and cluster analysis. 
11. Abundance values are standardized by performing a Z-score. 
12. Hierarchical clustering is performed following default parameters to compare site or 
protein trends across conditions. 
13. Following Perseus analysis, the final matrix is exported with cluster assignment. Figure 
2.6 shows an example block diagram to perform this analysis. 
14. KEGG or DAVID pathway analysis is performed from Phytozome annotations for sites 




Table 2.1 Sequential window m/z values across Q1 mass range from 350.0-1250.0 m/z for 
SWATH acquisition employed during kinome analysis in Chapter 3.  
Window m/z range Window m/z range 
1 350.0-358.0 11 665.0-698.2 
2 357.0-411.9 12 697.2-731.8 
3 410.9-445.5 13 730.8-767.5 
4 444.5-474.9 14 766.5-805.3 
5 473.9-507.1 15 804.3-848.7 
6 506.1-541.4 16 847.7-893.5 
7 540.4-574.4 17 892.5-943.9 
8 573.4-605.1 18 942.9-1007.6 
9 604.1-635.2 19 1006.6-1102.1 
10 634.2-666.0 20 1101.1-1249.9 
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Table 2.2 Overview of processing settings for SWATH data processing. 
Number of Peptides per Protein: 6 
Number of Transitions per Protein 6 
Peptide Confidence Threshold % 95 
False Discovery Rate Threshold % 1.0 
XIC Extraction Window (min) 10 
XIC width (ppm) 20 





Figure 2.1 Figure reproduced from [5]. Overview of coverage of phosphopeptides identified and 







Figure 2.2 Variable windows used for SWATH acquisition. Window sizes are based on 
generating a peak list from DDA LC-MS/MS run representative of SWATH samples. Smaller 
Q1 windows are used for regions of the mass range where many peptide precursors are 





Figure 2.3 Overview of database searching requirements employed in LFQ proteomic 
experiments. Searches of MS/MS data used a trypsin protease specificity with the possibility of 
two missed cleavages, peptide/fragment mass tolerances of 20ppm/0.1 Da, and variable 
modifications of acetylation at the protein N-terminus, carbamidomethylation at cysteine, 
oxidation at methionine, and deamidation at asparagine or glutamine. Variable modifications of 
phosphorylation at serine or threonine and phosphorylation at tyrosine were appended to this list 
when working with phosphorylation enriched datasets.  
45 
 
Figure 2.4 Example Python output following custom scripts written implemented to parse results. 
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Figure 2.5 Overview of filtering steps in phosphoproteomic experiments required following 










1. Cross, F. R.; Umen, J. G., The Chlamydomonas cell cycle. Plant J 2015, 82 (3), 370-392. 
2. Gorman, D. S.; Levine, R., Cytochrome f and plastocyanin: their sequence in the 
photosynthetic electron transport chain of Chlamydomonas reinhardi. Proceedings of the 
National Academy of Sciences 1965, 54 (6), 1665-1669. 
3. Daub, H.; Olsen, J. V.; Bairlein, M.; Gnad, F.; Oppermann, F. S.; Korner, R.; Greff, Z.; 
Keri, G.; Stemmann, O.; Mann, M., Kinase-selective enrichment enables quantitative 
phosphoproteomics of the kinome across the cell cycle. Mol Cell 2008, 31 (3), 438-448. 
4. Dhabaria, A.; Cifani, P.; Reed, C.; Steen, H.; Kentsis, A., A High-Efficiency Cellular 
Extraction System for Biological Proteomics. J Proteome Res 2015, 14 (8), 3403-3408. 
5. Werth, E. G.; McConnell, E. W.; Gilbert, T. S. K.; Couso Lianez, I.; Perez, C. A.; 
Manley, C. K.; Graves, L. M.; Umen, J. G.; Hicks, L. M., Probing the global kinome and 
phosphoproteome in Chlamydomonas reinhardtii via sequential enrichment and 
quantitative proteomics. The Plant Journal 2017, 89 (2), 416-426. 
6. Maldonado, A. M.; Echevarría-Zomeño, S.; Jean-Baptiste, S.; Hernández, M.; Jorrín-
Novo, J. V., Evaluation of three different protocols of protein extraction for Arabidopsis 
thaliana leaf proteome analysis by two-dimensional electrophoresis. Journal of 
Proteomics 2008, 71 (4), 461-472. 
7. Slade, W. O.; Werth, E. G.; McConnell, E. W.; Alvarez, S.; Hicks, L. M., Quantifying 
reversible oxidation of protein thiols in photosynthetic organisms. J Am Soc Mass 
Spectrom 2015, 26 (4), 631-640. 
8. Duncan, J. S.; Whittle, M. C.; Nakamura, K.; Abell, A. N.; Midland, A. A.; Zawistowski, 
J. S.; Johnson, N. L.; Granger, D. A.; Jordan, N. V.; Darr, D. B.; Usary, J.; Kuan, P. F.; 
Smalley, D. M.; Major, B.; He, X.; Hoadley, K. A.; Zhou, B.; Sharpless, N. E.; Perou, C. 
M.; Kim, W. Y.; Gomez, S. M.; Chen, X.; Jin, J.; Frye, S. V.; Earp, H. S.; Graves, L. M.; 
Johnson, G. L., Dynamic reprogramming of the kinome in response to targeted MEK 
inhibition in triple-negative breast cancer. Cell 2012, 149 (2), 307-321. 
9. Bräutigam, A.; Schaumlöffel, D.; Krauss, G.-J.; Wesenberg, D., Analytical approach for 
characterization of cadmium-induced thiol peptides—a case study using Chlamydomonas 
reinhardtii. Analytical and bioanalytical chemistry 2009, 395 (6), 1737-1747. 
10. Lee, D. Y.; Park, J.-J.; Barupal, D. K.; Fiehn, O., System response of metabolic networks 
in Chlamydomonas reinhardtii to total available ammonium. Molecular & Cellular 
Proteomics 2012, 11 (10), 973-988. 
11. Andrews, G. L.; Simons, B. L.; Young, J. B.; Hawkridge, A. M.; Muddiman, D. C., 
Performance characteristics of a new hybrid quadrupole time-of-flight tandem mass 
spectrometer (TripleTOF 5600). Analytical chemistry 2011, 83 (13), 5442-5446. 
49 
12. Tyanova, S.; Temu, T.; Sinitcyn, P.; Carlson, A.; Hein, M. Y.; Geiger, T.; Mann, M.; 
Cox, J., The Perseus computational platform for comprehensive analysis of (prote) omics 
data. Nature methods 2016, 13 (9), 731-740. 
13. Cox, J.; Mann, M., 1D and 2D annotation enrichment: a statistical method integrating 
quantitative proteomics with complementary high-throughput data. BMC bioinformatics 
2012, 13 (16), S12. 
14. Goodstein, D. M.; Shu, S.; Howson, R.; Neupane, R.; Hayes, R. D.; Fazo, J.; Mitros, T.; 
Dirks, W.; Hellsten, U.; Putnam, N., Phytozome: a comparative platform for green plant 
genomics. Nucleic acids research 2011, 40 (D1), D1178-D1186. 
15. Kanehisa, M.; Goto, S., KEGG: kyoto encyclopedia of genes and genomes. Nucleic acids 
research 2000, 28 (1), 27-30. 
16. Kanehisa, M.; Sato, Y.; Kawashima, M.; Furumichi, M.; Tanabe, M., KEGG as a 
reference resource for gene and protein annotation. Nucleic acids research 2015, 44 (D1), 
D457-D462. 
17. Huang, D. W.; Sherman, B. T.; Lempicki, R. A., Bioinformatics enrichment tools: paths 
toward the comprehensive functional analysis of large gene lists. Nucleic acids research 
2008, 37 (1), 1-13. 
18. Huang, D. W.; Sherman, B. T.; Lempicki, R. A., Systematic and integrative analysis of 




CHAPTER 3:  Probing the Global Kinome and Phosphoproteome in Chlamydomonas 
reinhardtii via Sequential Enrichment and Quantitative Proteomics 
*Reprinted with permission, from Werth, E.G., McConnell, E.M., Gilbert, T. S. K, Lianez, I. C., 
Perez, C. A., Manley, C. K., Graves, L. M., Umen, J. G., Hicks, L. M. Probing the global kinome 
and phosphoproteome in Chlamydomonas reinhardtii via sequential enrichment and quantitative 
proteomics. Plant Journal 2017, 89, 416-426. doi: 10.1111/tpj.13384 
 
3.1 Introduction 
Expression and activity modulation of kinases is essential for organismal fitness and survival. 
Kinases regulate cellular signaling by site-specific phosphorylation of target proteins, thereby 
altering activity, subcellular localization, or complex formation1. Approaches for measuring 
kinase abundances have historically relied on highly specific antibody-based immunoassays2, 
thus restricting coverage and throughput to a small subset of target kinases. Research aimed at 
dissecting the roles of kinases on a global "-omics” scale has grown within the past decade with 
the potential to become more comprehensive for discovery-based, untargeted kinome analyses. 
Utilization of immobilized kinase inhibitors [e.g., multiplexed inhibitor beads (MIBs)3 or 
kinobeads4] preferentially capture low abundance protein kinases by targeting the ATP-binding 
domain of intact native kinases. This approach has enabled protein-level kinome analysis2, the 
utility of which has been demonstrated in numerous studies in mammalian systems5-8. Herein, we 
employ a MIBs-based kinome enrichment in tandem with a phosphoproteome analysis from the 
same starting material. Development of this sequential enrichment strategy in a model eukaryotic 
photosynthetic organism, Chlamydomonas reinhardtii (Chlamydomonas), enabled simultaneous   
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coverage and quantification of its kinome and phosphoproteome using mass spectrometry-based 
quantitative label-free proteomics. 
Chlamydomonas is an intensively-studied and well-developed model for investigating 
diverse biological processes including photosynthesis, chloroplast biogenesis, cell growth and 
motility9-11. The Chlamydomonas kinome contains an estimated 355 protein kinases12 and forms 
a highly dynamic network of signaling pathways as illustrated by studies of the flagellar 
phosphoproteome13 and proteomic analysis into the effects changes in kinase expression have on 
photosynthesis14. While global kinome enrichment has not yet been reported in Chlamydomonas, 
recent efforts by our laboratory to profile the global phosphoproteome identified 4,588 
phosphoproteins and 15,862 unique phosphosites in this model organism15.  
Herein, a strategy is described for in-tandem kinome and phosphoproteome analysis from a 
single sample that provides quantitative information and increased coverage of expressed kinases 
and localized phosphosites on phosphoproteins potentially involved in kinase signaling 
pathways. We first optimized a native protein extraction for cell wall-containing 
Chlamydomonas strain CC-2895 (6145c mt-). Then, a MIBs global kinome enrichment strategy 
was used to enrich for intact kinases and ATP-binding proteins from the background via 
preferential binding to a mixture of moderate- to broadly-selective immobilized pan-kinase 
inhibitors. Quantitative reproducibility and overall coverage was compared between both data-
dependent mass spectrometric acquisition (DDA) and data-independent mass spectrometric 
acquisition (DIA) via Sequential Windowed Acquisition of All Theoretical Fragment Ion Mass 
Spectra (SWATH) for the kinome-enriched samples. Proteolysis of unbound protein lysate from 
MIBs followed by TiO2-based phosphopeptide enrichment and DDA enabled quantification of 
site-specific phosphorylation from the same samples. This workflow generates extensive 
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complementary datasets that may help increase understanding of kinase signaling pathways and 
regulated phosphorylation events in a quantitative manner.  
3.2 Materials and Methods 
3.2.1 Cell Growth and Native Extraction 
Three biological replicates of C. reinhardtii strain CC-2895 6145c mt- (Chlamydomonas 
Resource Center) were grown at 22 ˚C in 350 mL Tris-acetate-phosphate (TAP) media16 under 
continuous light (50 µE m-2 s-1) on an Innova 2300 (New Brunswick Scientific, Enfield, CT, 
USA) shaker at 130 rpm. Cultures were harvested at early-log phase (OD750 0.4 – 0.5) by 
centrifuging at 4,000g for 5 min and discarding the supernatant.  Each replicate was resuspended 
in 50 mM HEPES, pH 7.5 buffer containing 0.5% Triton X-100 in the presence of EDTA-free 
cOmplete protease inhibitor cocktail (Roche) and phosphatase inhibitor cocktails 2 and 3 
(Sigma) as previously described 3. Samples were lysed by sonicating for 3 min at 200 
cycles/burst, 100 W power, and 12% duty cycle using an E220 focused ultra-sonicator (Covaris, 
Woburn, MA, USA). Extracts were clarified via centrifugation (16,000g, 10 min) and adjusted to 
a final concentration of 1 M NaCl. Samples were normalized to 5.5 mg of protein per 3 mL of 
lysis buffer following determination of protein concentration using the CB-X protein assay (G-
Biosciences, St. Louis, MO, USA). 
3.2.2 Kinome Enrichment 
Following native extraction, 5.5 mg of protein from each Chlamydomonas biological 
replicate was introduced on a MIBs column to isolate protein kinases and ATP-binding proteins 
from the lysate as previously described3. MIBs columns were composed of a 6 bead mix 
containing the following inhibitors: CTX0294885, VI16832, Purvalanol B, Shokat, PP58 and 
UNC21474 in the ratio of 1.5:1 (CTX0294885, VI16832): (Purvalanol B, Shokat, PP58 and 
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UNC21474). The flow through was reloaded once to the column before being collected and 
stored at -80°C for downstream applications employed in conjunction with enrichment due to the 
large amount of total protein remaining (~5.3 mg). Non-specifically bound proteins were 
removed using 5 mL each of wash buffer (50 mM HEPES, pH 7.5, 0.5% Triton X-100, 1 mM 
EDTA, 1 mM EGTA and 0.1% SDS) containing high-salt (1 M NaCl) or low-salt (150 mM 
NaCl). MIBs bound proteins were eluted from the column using 500 μL of 100 mM Tris-HCl, 
pH 6.8, 0.5% SDS, and 1% β-mercaptoethanol heated to 95°C for 15 min, twice.  
3.2.3 Protein Digestion and Reduction 
Enriched proteins were purified using a chloroform/methanol precipitation and resuspended 
in 50 mM HEPES, pH 8. Samples were reduced using 10 mM dithiothreitol and subsequently 
alkylated with 40 mM iodoacetamide prior to overnight digestion. For kinome-enriched and 
whole-cell (unenriched) samples, digestion was performed at 37 °C with Trypsin Gold 
(Promega) at a ratio of 1:100 protease:protein. For phosphoproteome analysis, digestion of MIBs 
flow through was performed at 25 °C at a ratio of 1:50 protease:protein. 
3.2.4 Solid-Phase Extraction 
After digestion, samples were acidified to 0.2% trifluoroacetic acid (TFA) following solid-
phase extraction. For enriched and unenriched samples, desalting was performed using Pierce 
spin columns and C18 50 mg Sep-Pak cartridges (Waters) were used for phosphorylation-
enriched samples.  SPE columns were prepared by washing with acetonitrile (MeCN) followed 
by 80% MeCN/20% H2O/0.1% TFA and 0.1% TFA. Digested protein lysates were applied to the 
columns and reloaded 2 times before being washed with 0.1% TFA and eluted using 80% 
MeCN/20% H2O/0.1% TFA. 
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3.2.5 Phosphopeptide Enrichment  
Following protein digestion and solid-phase extraction, 2 mg aliquots of flow through from 
MIBs enrichment were subjected to phosphorylation enrichment using 3 mg Titansphere Phos-
TiO2 Kit spin columns (GL Sciences). Replicates were dried by vacuum centrifugation and 
resuspended in 200 μL of 80% MeCN, 1% TFA and containing 25 mg/mL phthalic acid. 
Following each step in the enrichment, centrifugation at 1,000g for 2 min was performed. After 
pre-eluting the TiO2 tips in 20% MeCN, 5% ammonium hydroxide, columns were conditioned 
with 80% MeCN, 1% TFA and peptide samples were loaded 3 times. Washes were performed 4 
times using 80% MeCN, 1% TFA to remove non-specifically bound peptides. Phosphopeptides 
were eluted with 20% MeCN, 5% ammonium hydroxide and concentrated using vacuum 
centrifugation prior to LC-MS/MS analysis.  
3.2.6 DDA and SWATH MS Acquisition 
For all samples, peptides were resuspended in 95% H20/5% MeCN/0.1% TFA before 
separation via a 100 min linear gradient from 95% H20/5% MeCN/0.1% formic acid (FA) to 
65% H20/35% MeCN/0.1% FA via a NanoAcquity UPLC (Waters, Milford, MA, USA). Each 
sample was loaded onto a trap column (NanoAcquity UPLC 2G-W/M Trap 5 μm Symmetry 
C18, 180 μm × 20 mm) at a flow rate of 5 μL min–1 for 5 min. Peptides were separated using a 
C18 column (NanoAcquity UPLC 1.8 μm HSS T3, 75 μm × 250 mm) at a flow rate of 300 nL 
min–1. A TripleTOF 5600 (AB Sciex, Concord, Canada) mass spectrometer was operated in 
positive ionization and high sensitivity mode for data acquisition as previously described17, with 
the first 20 features above 150 counts threshold having a charge state of +2 to +5 selected for 
fragmentation during every 2 s cycle for DDA runs. SWATH samples were acquired using a 
variable acquisition window SWATH approach generated from previous MIBs-enriched or 
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whole cell lysate DDA runs with the 20 m/z windows used for both kinome enriched and no 
enrichment datasets. In addition to supplementary tables for MS datasets, the mass spectrometry 
proteomics data have been deposited to the ProteomeXchange Consortium 
(http://www.proteomexchange.org) via the PRIDE partner repository18 with the dataset identifier 
PXD004681 and 10.6019/PXD004681. 
3.2.7 DDA Data Processing 
Acquired spectra (*.wiff) files were imported into Progenesis QI for proteomics (v2.0, 
Nonlinear Dynamics). A reference spectra was automatically assigned and total ion 
chromatograms were then aligned to minimize run-to-run differences in peak retention time. 
Alignment was validated (≥ 80% score) and a combined peak list (*.mgf) for all runs was 
exported for peptide sequence determination and protein inference by Mascot (v2.5.1, Matrix 
Science). Database searching was performed using the C. reinhardtii Phytozome v11 database 
(http://www.phytozome.net/; accessed May, 2015) appended with the NCBI chloroplast and 
mitochondria databases (19,603 entries). Sequences for common laboratory contaminants 
(http://www.thegpm.org/cRAP/; 116 entries) were appended to the database. Searches of MS/MS 
data used a trypsin protease specificity with the possibility of two missed cleavages, 
peptide/fragment mass tolerances of 10ppm/0.08 Da, and variable modifications of acetylation at 
the protein N-terminus, carbamidomethylation at cysteine, oxidation at methionine, and 
deamidation at asparagine or glutamine. Variable modifications of phosphorylation at serine or 
threonine and phosphorylation at tyrosine were appended to this list when working with 
phosphorylation enriched datasets. Significant peptide identifications above the identity or 
homology threshold were adjusted to ≤ 1% peptide FDR using the Mascot Percolator algorithm 
19 and resulting matches were exported (*.xml) for further analysis. Peptide identifications in the 
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result file were uploaded to Progenesis QI for proteomics and matched to peaks from the raw 
spectra. Peptide measurements were then exported (*.csv) and custom scripts written in the 
Python programming language were implemented to parse results. Briefly, only peptides with 
Mascot ion score ≥ 13 and abundance > 0 across all samples, requiring detection in every 
biological replicate, were considered. Homologous proteins with shared peptides were then 
grouped together to satisfy the principle of parsimony. After grouping, the script performed site 
localization of variable modifications using an implementation of the Mascot Delta Score20. 
Confident site localization was considered if the difference between the best and second best 
Mascot ion score was ≥ 10 for alternative modification sites on an otherwise identical peptide-
spectrum match. 
3.2.8 Ion Library Generation 
Raw (*.wiff) files from 8 MIBs-enriched DDA runs in addition to 15 SCX fraction DDA 
runs were combined and processed using ProteinPilot (Sciex, v5.0). Trypsin and iodoacetamide 
were specified for digestion and cysteine alkylation, respectively. A thorough ID search effort 
with a biological modification ID focus were specified and searched against the C. reinhardtii 
Phytozome v11 database concatenated with NCBI chloroplast and mitochondria entries as 
mentioned above. Following search, the resulting file (*.group) was imported into PeakView 
(v.2.1, AB Sciex) for SWATH data analysis. 
3.2.9 SWATH Data Processing 
Raw (*.swath) files were imported into PeakView for quantitative review of MS/MS spectra 
and alignment to ion library allowing for 6 peptides per protein and 6 transitions per peptide. 
Peptide confidence threshold was set to 95% with an FDR threshold of < 1%. XIC extraction 
window was opened to 10 minutes with 20 ppm mass tolerance. Following retention time 
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calibration in the PeakView software and processing, an Excel workbook file was exported and 
filtered for a confidence cutoff score > 1.3 (95% confidence). Logarithm base 2 transformation 
and data normalization by the central tendency approach were performed using the R package 
Inferno21 with subsequent data analysis in the Python and R programming languages. 
3.3 Results and Discussion 
3.3.1 Native Protein Extraction of Chlamydomonas 
The MIBs kinome enrichment strategy utilizes the affinity of kinases for ATP analogs and 
therefore requires non-denaturing protein extraction techniques. Cell lysis via adaptive focused 
acoustics is an alternative to traditional sonication methods that reduces protein degradation and 
aggregation during cell disruption by avoiding sample overheating22, and this method has 
previously been found effective for disrupting Chlamydomonas cells23. We optimized and 
implemented an acoustic-wave sonication method for native protein extraction from 
Chlamydomonas with the goal of maximizing yield to accommodate the requirement for high 
protein amounts in kinome and phosphoproteome enrichment steps used downstream. 
Our method (detailed in the Materials and Methods section) yielded an average of 7.8 mg of 
protein per g of wet cell pellet from each replicate that was only slightly reduced compared to a 
denaturing Tris-buffered phenol extraction routinely used for protein extractions from 
photosynthetic organisms that yields 8.0-9.5 mg/g17, 24. Coverage was also similar when 
comparing global profiles of whole cell lysates: 2,093 proteins were inferred from 9,607 unique 
peptides for native extraction and 2,063 proteins were inferred from 10,533 unique peptides for 
Tris-buffered phenol extraction based on standard DDA LC-MS/MS acquisition performed as 
previously described17. Importantly, the optimized native extraction provided sufficient material 
(5.5 mg protein extracted from 0.7 g wet pellet) for subsequent kinome and phosphopeptide 
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enrichments. As outlined in Figure 3.1, lysates from three biological replicates containing 5.5 mg 
each of native protein were subjected to a MIBs-based method to enrich for ATP-binding 
proteins (Figure 3.1B)25. Eluates were proteolyzed and processed via quantitative label-free 
proteomics as described below. 
3.3.2 Kinome DDA and SWATH Data Acquisition  
Both data-dependent acquisition (DDA) and data-independent acquisition (DIA) via SWATH 
were performed to compare depth of coverage of the kinome as well as quantitative accuracy of 
each acquisition approach. Untargeted methods relying on DDA are ubiquitous in bottom-up 
proteomics, but pose a challenge for identifying low abundance proteins because they require a 
minimum signal for specific ions to trigger a tandem MS (MS2) analysis within a finite duty 
cycle25. SWATH acquisition can improve detection of low abundance proteins because it is not 
limited by such parameters. Instead, SWATH acquisition allows for fragmentation of all 
transmitted ions simultaneously by iteratively stepping the quadrupole (Q1) through 20 separate 
windows across the mass range (350-1250 m/z) and passing all ions through to the collision cell. 
This DIA strategy is further enhanced by using narrower Q1 windows in dense regions of the 
mass range and wider Q1 windows in sparse regions. 
Implementation of a SWATH platform requires initial DDA runs with fractionation for 
exhaustive coverage to generate a spectral library for peptide matching and protein identification 
(Figure 3.2).  The resulting ion library comprised of 15 strong-cation exchange (SCX) fractions 
and 8 MIBs runs contains 4,198 proteins (64,124 distinct peptides) with a confidence cutoff 
score > 1.3 (95% confidence in ProteinPilot), serving as the basis for SWATH spectral 
matching/identification. These 4,198 proteins represent 21% (4,198/19,603) of the predicted C. 
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reinhardtii proteome and includes 235/355 protein kinases12 and 404/553 additional ATP-
binding proteins classified by gene ontology. 
Data from total lysates and MIBs-enriched samples showed improved coverage using 
SWATH acquisition over DDA alone, with lower between-replicate median variability in the 
kinome-enriched and total lysate samples from SWATH acquisition (Figure 3.3). Proteins 
identified through SWATH acquisition (Table S1) increased MIBs enriched data coverage by 
597 proteins (37%) relative to DDA (Figure 3.3A, Table S2) including 36 more kinases. Three 
biological replicates were used to compare quantitative reproducibility for both SWATH and 
DDA methods. For the kinome-enriched samples, 90% of the 1,391 quantified proteins from 
SWATH acquisition had a coefficient of variation (CV) below 10%, and 90% of the 974 proteins 
via the DDA workflow had a CV below 11% (Figure 3.3C).  The overall trend of increased 
coverage while maintaining low variability with SWATH is also evident with whole cell lysate 
samples (Figure 3.3B, C) where 253 (16%) additional proteins were identified using SWATH 
(Figure 3.3D) versus DDA alone. Compared to DDA acquisition, SWATH-MS maintains high 
reproducibility while providing additional coverage and is therefore preferential for label-free 
differential studies of MIBs enriched proteins. A breakdown of the chemical characteristics of 
the peptides identified in the MIB-enrichment dataset can be found in Figure 3.4. 
3.3.3 Phosphopeptide Enrichment 
Tandem investigation of the phosphoproteome and kinome from the same starting biological 
material simplifies analysis and may help generate or constrain hypotheses concerning kinase-
substrate relationships. Following lysate loading onto MIBs columns, the flow through that 
contained >95% of the starting protein was processed for phosphopeptides using a titanium 
dioxide-based enrichment (Figure 3.1C)26. 
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Variability between replicates for phosphopeptide enrichment was minimized by optimizing 
the protein-to-resin ratio and by use of a chemical additive that was selected from several tested 
candidates to minimize non-specific binding to the resin. A range of peptide loading levels from 
0.5-2.5 mg was tested for enrichment on pre-packed 3 mg TiO2 tip-columns and 2 mg was 
chosen for further experiments based on maximum reproducible phosphopeptide coverage. 
Numerous chemical additives have proven successful for decreasing non-specific binding during 
phosphopeptide enrichment, and were assessed here by their effect on recovery of non-
phosphorylated peptides identified in post-enrichment samples. Among the additives tested [e.g., 
glycerol, glycolic acid, and lactic acid27-28], phthalic acid yielded the greatest reduction in non-
specific binding with a phosphopeptide enrichment efficiency of approximately 67% (~33% of 
the dataset was not phosphorylated) and a 10% increase in phosphopeptide coverage over the 
second best additive, glycolic acid.  
Following enrichment for three biological replicates and DDA acquisition, retention time 
alignment, normalization of intensity across otherwise identical replicates and log transformation 
were performed. Ninety percent of the 2,304 phosphopeptides had < 11% CV (Figure 3.5C) with 
1,314 unique phosphosites localized among the 1,052 proteins (Table S5, highlighted in yellow). 
Among these 1,077 proteins were 243 identified from the kinome enrichment experiment (Figure 
3.5A) containing 484 phosphosites. Approximately 86.6% of the phosphosites detected were 
pSer, 12.8% pThr and 0.6% pTyr (Figure 3.5B) with >80% of the phosphopeptides singly 
phosphorylated (Figure 3.5D), similar to the distribution reported previously for 
Chlamydomonas15. A breakdown of chemical characteristics of the peptides identified in the 
phosphopeptide-enrichment dataset can be found in Figure 3.6. 
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3.3.4 Kinome and Phosphoproteome Coverage Using MIBs and TiO2 Enrichment 
Our enrichment method identified 115 protein kinases, >50% (62/115) of which were not 
detected without kinome enrichment (Figure 3.7A; Table S3). Gene ontology (GO) classification 
of proteins only identified following kinome enrichment (Table S4) revealed significant 
enrichment for the terms protein phosphorylation, ATP-binding, and MAP kinase (Figure 3.7B) 
validating the effectiveness of a MIBs approach for kinome analysis in Chlamydomonas. Among 
the kinases identified with MIBs enrichment and not from the total proteome, 57 serine/threonine 
protein kinases were identified whose homologs in other species are associated with signaling 
cascades which influence cell growth, survival, and differentiation.  Of the 115 kinases identified 
using MIBs, 36 were themselves phosphoproteins (Table S5, bolded) with a total of 71 
phosphosites quantified from the TiO2 enrichment experiment (Table 1).  Nine of these 
phosphosites (Table 1, asterisk) could not be confidently identified in  our prior global 
phosphoproteomics study15. Maintaining high reproducibility between replicates despite the 
MIBs enrichment not being exhaustive allows for capture during TiO2 enrichment of MIBs flow 
through - with 30 of the 36 kinases detected in the phosphopeptide dataset also appearing as high 
confidence proteins in the MIBs dataset (<11% CV). The phosphoproteomics dataset is also 
helpful in providing additional coverage on phosphoproteins/substrates not revealed in the 
kinome-enriched dataset. Figure 3.5A highlights the overlap between proteins identified in the 
kinome and phosphoproteome datasets, of which 834 phosphoproteins inferred from 1,584 
phosphopeptides were identified and quantified only from the phosphoproteome dataset. Protein 
kinases found from MIBs or phosphopeptide enrichment include Chlamydomonas homologs of 
mitogen-activated protein (MAP) kinases 4 and 5 (Cre01.g010000.t1.2, Cre12.g509000.t1.1, 
Cre12.g530000.t1.2, Cre13.g607300.t1.2) and MEKK protein kinase (Cre01.g016570.t1.1) in the 
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MIBs data set, along with MAP kinase related proteins Cre13.g563733.t2.1 (MAPK kinase 6) 
and Cre10.g461150.t1.2 (MAPK/ERK kinase kinase 1) from the phosphoproteome dataset.  
This combination of localizing phosphosites on kinases as well as coverage on downstream 
targets has the potential to provide quantitative information into dynamic protein 
phosphorylation events occurring in Chlamydomonas. For example, Table 3.2 shows the 
quantitative coverage provided by the kinome and phosphoproteome enrichments on 13 proteins 
with KEGG ontology (KO) terms29-30 mapping to the cell cycle. These proteins, three of which 
are Chlamydomonas cell-cycle regulatory genes with available Chlamydomonas mutants31, 
include cyclin-dependent kinases (Cre10.g465900.t1.2, Cre08.g372550.t1.1), a Chlamydomonas 
homolog of GSK3B (Cre12.g511850.t1.2) and phosphosite coverage on minichromosome 
maintenance (MCM2/3/5) family proteins (Cre07.g316850.t1.2 [pSer S119], 
Cre06.g295700.t1.1[pSer 545]) in addition to phosphosite localization on pSer25 of E2F 
transcription factor (Cre01.g052300.t1.1). Without this tandem enrichment approach, only 5 of 
the 13 proteins mapping to the cell cycle were identified without the benefit of site specificity.  
Kinases uniquely found in the kinome enrichment involved with cellular energy status 
include SNF1 kinase homolog 10 (Cre04.g211600.t1.1), 3'-phosphoinositide-dependent protein 
kinase 1 (Cre11.g467568.t1.1), and 5'-AMP-activated protein kinase beta-2 subunit protein 
(Cre10.g457500.t1.1). Previous work has shown energy dependent protein kinases, specifically 
SNF1 and phosphatidylinositol 3-kinase (PI3K), as important regulatory factors upon triggering 
of autophagy with SNF1 kinase, a key factor in glucose sensing in yeast, completely blocking 
autophagy induced by nitrogen starvation following gene deletion in Chlamydomonas32-33. Along 
with these, AMP-activated protein kinases (AMPKs) have been shown as important upstream 
positive regulators of autophagy in mammalian cells34. A relationship of positive regulation 
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between protein kinase expression levels and autophagy was evident in the Arabidopsis thaliana 
ATG1/13 kinase complex following nutrient limitation indicating ATG1/13 as both a regulator 
and a target of autophagy35, with possible relevance to stress adaptation in Chlamydomonas upon 
similar stresses. Because autophagy is such a crucial cellular response to stress, obtaining 
quantitative coverage of energy dependent protein kinases that might control autophagy and their 
possible downstream targets may facilitate experiments to elucidate autophagy related signaling 
mechanisms. For example, through the induction of stress in Chlamydomonas and the use of 
differential proteomic studies of the kinome and phosphoproteome, future studies using this 
tandem enrichment have the potential to target specific pathways and investigate global kinome 
and phosphoproteome changes in a quantitative fashion. While this method is capable of 
extensive coverage into the kinome, this approach is only an initial screen for proteins of interest 
and would require subsequent studies to further validate kinase activity and conformational 
changes occurring upon various physiological conditions.  
3.4 Conclusion/Summary 
Herein, a dual enrichment strategy first targeting intact protein kinases via capture on MIBs 
with subsequent proteolytic digestion of unbound proteins and peptide-based phosphorylation 
enrichment from the same sample is presented. MIBs enrichment permits a >50% increase in 
coverage of the kinome compared with unenriched samples, and increases the potential to 
investigate protein kinases and their predicted substrates in the same experiment. With high 
quantitative reproducibility among replicates and increased coverage of the kinome, studies 
aimed at investigating changes in kinase expression levels under different conditions could 
reveal kinases and ATP-binding proteins involved in specific signaling pathways. Further, 
tandem probing of the phosphoproteome allows for simultaneous discovery of differential 
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phosphorylation of substrate proteins in the same experiment. Ultimately, this approach can link 





Table 3.1 Phosphosite coverage on MIBs-identified kinases. * previously undetected. Based on 
phosphopeptide enrichment on the MIBs flow through, 71 phosphosites were localized from 36 
protein kinases identified in the kinome enrichment dataset and 9 sites were not previously 
detected. 
Kinase Accession Description Phosphosites 
Cre01.g031300.t1.1 calcium dependent protein kinase 1 T1245 
Cre02.g076900.t1.1 serine/threonine protein kinase 2 S71 
Cre02.g113600.t1.2 ataurora3 T137, S432*, S434* 
Cre02.g120250.t1.1 STT7 homolog STN7 S533, S740 
Cre02.g147900.t1.1 Pyruvate kinase family protein S463, S584, T587*, S597 
Cre03.g168150.t1.2 VH1-interacting kinase S15 
Cre03.g199000.t1.2 phototropin 2 S577 
Cre05.g232750.t1.2 NIMA-related kinase 5 T300 
Cre06.g262900.t1.2 phosphofructokinase 5 S77, S81 
Cre06.g280950.t1.2 Pyruvate kinase family protein S463, S466, S490, S494, 
S497, S676 
Cre06.g292700.t1.2 Protein kinase superfamily protein S167 
Cre06.g302800.t1.2 with no lysine (K) kinase 3 S283 
Cre07.g317300.t1.1 Protein kinase superfamily protein S524 
Cre07.g328900.t1.2 calcium-dependent protein kinase 17 S472*, S481  
Cre07.g337300.t1.1 Protein kinase superfamily protein S70, S76, S82, S274, S507*, 
T508, S509, S532, S712 
Cre08.g382800.t1.2 calcium-dependent protein kinase 17 S645, S647 
Cre08.g385850.t1.2 cyclin dependent kinase group C2 T206 
Cre10.g428650.t1.2 geminivirus rep interacting kinase 2 T631 
Cre10.g457500.t1.1  5\'-AMP-activated protein kinase beta-2 subunit protein S25 
Cre10.g457700.t1.2 calmodulin-domain protein kinase cdpk isoform 2 S324 
Cre12.g485600.t1.2 Protein kinase superfamily protein S222*, S526* 
Cre12.g499500.t1.1 Protein kinase superfamily protein S173, S177 
Cre12.g508900.t1.2 MAP kinase 4 T202, Y204 
Cre12.g511850.t1.2 shaggy-like kinase 13 Y323 
Cre12.g527000.t1.2 calcium-dependent protein kinase 34 S612, S615 
Cre12.g551250.t1.2 Protein kinase superfamily protein S835 
Cre13.g566450.t1.2 Protein kinase superfamily protein with 
octicosapeptide/Phox/Bem1p domain 
S104*, S266, S274, T405 
Cre13.g571700.t1.1 calmodulin-domain protein kinase cdpk isoform 2 T365*, S448, S474 
Cre13.g575300.t1.1 Protein kinase family protein with ARM repeat domain S800 
Cre13.g584100.t1.1 PB1 domain-containing protein tyrosine kinase S661 
Cre13.g591400.t1.1 pantothenate kinase 2 S577, S1070 
Cre13.g607300.t1.2 MAP kinase 5 S403 
Cre16.g661100.t1.2 Protein kinase superfamily protein T156, Y158 
Cre16.g664850.t1.1 Protein kinase superfamily protein with 
octicosapeptide/Phox/Bem1p domain 
S772 
Cre16.g665364.t1.1 phosphoenolpyruvate carboxylase-related kinase 1 S92, T121 
Cre17.g734250.t1.1 PB1 domain-containing protein tyrosine kinase S848, S1003 
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Table 3.2 Identified proteins in the cell cycle signaling pathway in Chlamydomonas. * indicates 
Chlamydomonas cell-cycle regulatory genes with available Chlamydomonas mutants based on 
(Cross and Umen 2015). Bolded accessions indicate proteins unique to the kinome enrichment 
and italicized rows indicate proteins unique to phosphopeptide enrichment. 
Protein Protein Description KEGG/ec KO 
Cre07.g341700.t1.1 putative protein kinase 1 2.7.12.2 K08866 
Cre08.g372550.t1.1* cyclin-dependent kinase B1;2 2.7.11.22 K07760 
Cre10.g465900.t1.2* cell division control 2 2.7.11.22, 
2.7.11.23 
K02206 
Cre07.g316850.t1.2--S119 Minichromosome maintenance (MCM2/3/5) 
family protein 
3.6.4.12 K02212 
Cre12.g543450.t1.2--S2 RING-box 1  K03868 
Cre01.g052300.t1.1--S25* E2F transcription factor 1  K06620 
Cre06.g295700.t1.1--S545 Minichromosome maintenance (MCM2/3/5) 
family protein 
3.6.4.12 K02541 
Cre09.g387393.t1.1--S426 histone deacetylase 1 3.5.1.98 K06067 
Cre12.g511850.t1.2--Y323 shaggy-like kinase 13 2.7.11.1 K03083 
Cre06.g257500.t1.2 general regulatory factor 7  K06630 
Cre12.g515850.t1.2 proliferating cellular nuclear antigen 1  K04802 












Figure 3.1 Figure reproduced from ref [36]. Overview of kinome and phosphoproteome 
workflow. (A) Schematic highlighting the focused ultrasonication performed during native 
protein extraction before MIBs kinome enrichment. (B) Following protein extraction, 5.5 mg of 
cell lysate is incubated with Sepharose beads covalently bound to a mixture of moderate and 
pan-kinase inhibitors. Proteins that are not bound to the MIBs beads (flow through) are saved for 
subsequent phosphopeptide enrichment. After washes, intact kinases and additional ATP-binding 
proteins are eluted from the columns and subjected to DDA and SWATH-MS analysis. (C) For 
the proteins collected in the flow through of the MIBs enrichment, phosphopeptide enrichment 






Figure 3.2 Figure reproduced from [36]. SWATH ion library generation. Schematic depicting ion 
library generation for SWATH data spectral matching and protein identification. An ion library 
was generated from a combination of 15 fractions derived from digested whole cell lysate 
separated by SCX and acquired via DDA. Additionally, 8 DDA runs of MIBs-enriched samples 
were included to assure exhaustive coverage of proteins in the ion library. After acquisition of all 
DDA runs, database searching was performed using ProteinPilot v5.0 and the result file (*.group 





Figure 3.3 Figure reproduced from [36]. Comparison of data independent (SWATH) and data 
dependent acquisition (DDA) methods for kinome identification. Venn diagram showing overlap 
of proteins identified between SWATH and DDA acquisition strategies for kinome enrichment 
(A) and no kinome enrichment (B) datasets. (C) Box-whisker plot showing distribution of CV 
values for 90% of proteins identified using DDA and SWATH acquisition strategies with and 
without enrichment. (D) Breakdown of coverage for both SWATH and DDA MS acquisition for 




Figure 3.4 Figure reproduced from [36]. Chemical characteristics of the peptides identified in the 
MIBs dataset including (A) Amino acid length, (B) Molecular Weight, (C) pI, (D) amount of 





Figure 3.5 Figure reproduced from [36]. Comparison of proteins identified in MIBs and 
phosphopeptide enrichments. (A) Venn diagram comparing the overlap and unique proteins 
identified from kinome enrichment versus phosphopeptide enrichment. 243 proteins were found 
in both data sets, with 1307 identified solely in MIBs and 834 via phosphopeptide enrichment. (B) 
Of the phosphorylation sites confidently localized, 86.6% were pSer, 12.8% were pThr, and 0.6% 
were pTyr. (C) Box-whisker plot showing distribution of %CV of each protein for DDA from TiO2 





Figure 3.6 Figure reproduced from ref [36]. Chemical characteristics of the peptides identified in 
the phosphopeptide dataset including (A) Amino acid length, (B) Molecular Weight, (C) pI, (D) 






Figure 3.7 Figure reproduced from [36]. Comparison of proteins identified and enriched GO terms 
from MIBs. (A) Venn diagram comparing the overlap and unique proteins identified with and 
without enrichment in addition to a table highlighting protein groups of interest in the 229 proteins 
unique to MIBs enrichment. (B) Bar graph highlighting the GO terms enriched following 
enrichment of Gene Ontology terms for biological processes, molecular functions, and cellular 
processes using default parameters in Blast2GO (http://www.Blast2GO.com/b2ghome, BioBam, 
Valencia, Spain) using the Fisher method with multiple testing correction based on Benjamani 






1. Daub, H.; Olsen, J. V.; Bairlein, M.; Gnad, F.; Oppermann, F. S.; Korner, R.; Greff, Z.; 
Keri, G.; Stemmann, O.; Mann, M., Kinase-selective enrichment enables quantitative 
phosphoproteomics of the kinome across the cell cycle. Mol Cell 2008, 31 (3), 438-448. 
2. Xiao, Y.; Wang, Y., Global discovery of protein kinases and other nucleotide-binding 
proteins by mass spectrometry. Mass Spectrom Rev 2014, 35 (5), 601-619. 
3. Duncan, J. S.; Whittle, M. C.; Nakamura, K.; Abell, A. N.; Midland, A. A.; Zawistowski, 
J. S.; Johnson, N. L.; Granger, D. A.; Jordan, N. V.; Darr, D. B.; Usary, J.; Kuan, P. F.; 
Smalley, D. M.; Major, B.; He, X.; Hoadley, K. A.; Zhou, B.; Sharpless, N. E.; Perou, C. 
M.; Kim, W. Y.; Gomez, S. M.; Chen, X.; Jin, J.; Frye, S. V.; Earp, H. S.; Graves, L. M.; 
Johnson, G. L., Dynamic reprogramming of the kinome in response to targeted MEK 
inhibition in triple-negative breast cancer. Cell 2012, 149 (2), 307-321. 
4. Bantscheff, M.; Eberhard, D.; Abraham, Y.; Bastuck, S.; Boesche, M.; Hobson, S.; 
Mathieson, T.; Perrin, J.; Raida, M.; Rau, C.; Reader, V.; Sweetman, G.; Bauer, A.; 
Bouwmeester, T.; Hopf, C.; Kruse, U.; Neubauer, G.; Ramsden, N.; Rick, J.; Kuster, B.; 
Drewes, G., Quantitative chemical proteomics reveals mechanisms of action of clinical 
ABL kinase inhibitors. Nat Biotechnol 2007, 25 (9), 1035-1044. 
5. Cooper, M. J.; Cox, N. J.; Zimmerman, E. I.; Dewar, B. J.; Duncan, J. S.; Whittle, M. C.; 
Nguyen, T. A.; Jones, L. S.; Ghose Roy, S.; Smalley, D. M.; Kuan, P. F.; Richards, K. L.; 
Christopherson, R. I.; Jin, J.; Frye, S. V.; Johnson, G. L.; Baldwin, A. S.; Graves, L. M., 
Application of multiplexed kinase inhibitor beads to study kinome adaptations in drug-
resistant leukemia. PLoS One 2013, 8 (6), e66755. 
6. Graves, L. M.; Duncan, J. S.; Whittle, M. C.; Johnson, G. L., The dynamic nature of the 
kinome. Biochem J 2013, 450 (1), 1-8. 
7. Stuhlmiller, T. J.; Miller, S. M.; Zawistowski, J. S.; Nakamura, K.; Beltran, A. S.; 
Duncan, J. S.; Angus, S. P.; Collins, K. A.; Granger, D. A.; Reuther, R. A.; Graves, L. 
M.; Gomez, S. M.; Kuan, P. F.; Parker, J. S.; Chen, X.; Sciaky, N.; Carey, L. A.; Earp, H. 
S.; Jin, J.; Johnson, G. L., Inhibition of Lapatinib-Induced Kinome Reprogramming in 
ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains. Cell Rep 
2015, 11 (3), 390-404. 
8. Johnson, G. L.; Stuhlmiller, T. J.; Angus, S. P.; Zawistowski, J. S.; Graves, L. M., 
Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition 
of the BRAF-MEK-ERK pathway in cancer. Clin Cancer Res 2014, 20 (10), 2516-2522. 
9. Zones, J. M.; Blaby, I. K.; Merchant, S. S.; Umen, J. G., High-Resolution Profiling of a 
Synchronized Diurnal Transcriptome from Chlamydomonas reinhardtii Reveals 
Continuous Cell and Metabolic Differentiation. Plant Cell 2015, 27 (10), 2743-2769. 
75 
10. Crespo, J. L.; Diaz-Troya, S.; Florencio, F. J., Inhibition of target of rapamycin signaling 
by rapamycin in the unicellular green alga Chlamydomonas reinhardtii. Plant Physiol 
2005, 139 (4), 1736-1749. 
11. Merchant, S. S.; Prochnik, S. E.; Vallon, O.; Harris, E. H.; Karpowicz, S. J.; Witman, G. 
B.; Terry, A.; Salamov, A.; Fritz-Laylin, L. K.; Maréchal-Drouard, L., The 
Chlamydomonas genome reveals the evolution of key animal and plant functions. Science 
2007, 318 (5848), 245-250. 
12. Wheeler, G. L.; Miranda-Saavedra, D.; Barton, G. J., Genome analysis of the unicellular 
green alga Chlamydomonas reinhardtii Indicates an ancient evolutionary origin for key 
pattern recognition and cell-signaling protein families. Genetics 2008, 179 (1), 193-197. 
13. Boesger, J.; Wagner, V.; Weisheit, W.; Mittag, M., Analysis of flagellar phosphoproteins 
from Chlamydomonas reinhardtii. Eukaryot Cell 2009, 8 (7), 922-932. 
14. Lee, C.; Rhee, J.-K.; Kim, D.; Choi, Y.-E., Proteomic study reveals photosynthesis as 
downstream of both MAP kinase and cAMP signaling pathways in Chlamydomonas 
reinhardtii. Photosynthetica 2015, 53 (4), 625-629. 
15. Wang, H.; Gau, B.; Slade, W. O.; Juergens, M.; Li, P.; Hicks, L. M., The global 
phosphoproteome of Chlamydomonas reinhardtii reveals complex organellar 
phosphorylation in the flagella and thylakoid membrane. Molecular & Cellular 
Proteomics 2014, 13 (9), 2337-2353. 
16. Harris, E. H.; Stern, D. B.; Witman, G. B., The chlamydomonas sourcebook. Cambridge 
Univ Press: 2009; Vol. 1. 
17. Slade, W. O.; Werth, E. G.; McConnell, E. W.; Alvarez, S.; Hicks, L. M., Quantifying 
reversible oxidation of protein thiols in photosynthetic organisms. J Am Soc Mass 
Spectrom 2015, 26 (4), 631-640. 
18. Vizcaíno, J. A.; Côté, R. G.; Csordas, A.; Dianes, J. A.; Fabregat, A.; Foster, J. M.; Griss, 
J.; Alpi, E.; Birim, M.; Contell, J., The PRoteomics IDEntifications (PRIDE) database 
and associated tools: status in 2013. Nucleic acids research 2013, 41 (D1), D1063-
D1069. 
19. Käll, L.; Canterbury, J. D.; Weston, J.; Noble, W. S.; MacCoss, M. J., Semi-supervised 
learning for peptide identification from shotgun proteomics datasets. Nature methods 
2007, 4 (11), 923-925. 
20. Savitski, M. M.; Lemeer, S.; Boesche, M.; Lang, M.; Mathieson, T.; Bantscheff, M.; 
Kuster, B., Confident phosphorylation site localization using the Mascot Delta Score. 
Molecular & Cellular Proteomics 2011, 10 (2), M110. 003830. 
21. Polpitiya, A. D.; Qian, W. J.; Jaitly, N.; Petyuk, V. A.; Adkins, J. N.; Camp, D. G., 2nd; 
Anderson, G. A.; Smith, R. D., DAnTE: a statistical tool for quantitative analysis of -
omics data. Bioinformatics 2008, 24 (13), 1556-1558. 
76 
22. Dhabaria, A.; Cifani, P.; Reed, C.; Steen, H.; Kentsis, A., A High-Efficiency Cellular 
Extraction System for Biological Proteomics. J Proteome Res 2015, 14 (8), 3403-3408. 
23. Bigelow, T. A.; Xu, J.; Stessman, D. J.; Yao, L.; Spalding, M. H.; Wang, T., Lysis of 
Chlamydomonas reinhardtii by high-intensity focused ultrasound as a function of 
exposure time. Ultrason Sonochem 2014, 21 (3), 1258-1264. 
24. Maldonado, A. M.; Echevarría-Zomeño, S.; Jean-Baptiste, S.; Hernández, M.; Jorrín-
Novo, J. V., Evaluation of three different protocols of protein extraction for Arabidopsis 
thaliana leaf proteome analysis by two-dimensional electrophoresis. Journal of 
Proteomics 2008, 71 (4), 461-472. 
25. Oppermann, F. S.; Gnad, F.; Olsen, J. V.; Hornberger, R.; Greff, Z.; Kéri, G.; Mann, M.; 
Daub, H., Large-scale proteomics analysis of the human kinome. Molecular & Cellular 
Proteomics 2009, 8 (7), 1751-1764. 
26. Thingholm, T. E.; Jorgensen, T. J.; Jensen, O. N.; Larsen, M. R., Highly selective 
enrichment of phosphorylated peptides using titanium dioxide. Nat Protoc 2006, 1 (4), 
1929-1935. 
27. Sugiyama, N.; Masuda, T.; Shinoda, K.; Nakamura, A.; Tomita, M.; Ishihama, Y., 
Phosphopeptide enrichment by aliphatic hydroxy acid-modified metal oxide 
chromatography for nano-LC-MS/MS in proteomics applications. Molecular & Cellular 
Proteomics 2007, 6 (6), 1103-1109. 
28. Jensen, S. S.; Larsen, M. R., Evaluation of the impact of some experimental procedures 
on different phosphopeptide enrichment techniques. Rapid Communications in Mass 
Spectrometry 2007, 21 (22), 3635-3645. 
29. Kanehisa, M.; Goto, S., KEGG: kyoto encyclopedia of genes and genomes. Nucleic acids 
research 2000, 28 (1), 27-30. 
30. Kanehisa, M.; Sato, Y.; Kawashima, M.; Furumichi, M.; Tanabe, M., KEGG as a 
reference resource for gene and protein annotation. Nucleic acids research 2015, 
gkv1070. 
31. Cross, F. R.; Umen, J. G., The Chlamydomonas cell cycle. Plant J 2015, 82 (3), 370-392. 
32. Perez-Perez, M. E.; Florencio, F. J.; Crespo, J. L., Inhibition of target of rapamycin 
signaling and stress activate autophagy in Chlamydomonas reinhardtii. Plant Physiol 
2010, 152 (4), 1874-1888. 
33. Wang, Z.; Wilson, W. A.; Fujino, M. A.; Roach, P. J., Antagonistic controls of autophagy 
and glycogen accumulation by Snf1p, the yeast homolog of AMP-activated protein 
kinase, and the cyclin-dependent kinase Pho85p. Molecular and cellular biology 2001, 21 
(17), 5742-5752. 
77 
34. Pérez-Pérez, M. E.; Lemaire, S. D.; Crespo, J. L., Reactive oxygen species and autophagy 
in plants and algae. Plant physiology 2012, 160 (1), 156-164. 
35. Suttangkakul, A.; Li, F.; Chung, T.; Vierstra, R. D., The ATG1/ATG13 protein kinase 
complex is both a regulator and a target of autophagic recycling in Arabidopsis. The 
Plant Cell 2011, 23 (10), 3761-3779. 
36. Werth, E. G.; McConnell, E. W.; Gilbert, T. S. K.; Couso Lianez, I.; Perez, C. A.; 
Manley, C. K.; Graves, L. M.; Umen, J. G.; Hicks, L. M., Probing the global kinome and 
phosphoproteome in Chlamydomonas reinhardtii via sequential enrichment and 
quantitative proteomics. The Plant Journal 2017, 89 (2), 416-426. 
78 
CHAPTER 4:  Investigating the Effect of Target of Rapamycin Kinase Inhibition on the 
Chlamydomonas reinhardtii Phosphoproteome: From Known Homologs to New Targets. 
*Manuscript submitted for publication. Authors: Werth, E.G., McConnell, E.M., Couso, I., 
Perrine, Z., Crespo, J. L., Umen, J. G., Hicks, L. M. Investigating the effect of Target of 
Rapamycin kinase inhibition on the Chlamydomonas reinhardtii phosphoproteome: from known 
homologs to new targets. 2018 
 
4.1 Introduction 
The Target of Rapamycin (TOR) protein kinase is a conserved eukaryotic growth regulator 
whose activity is modulated in response to stress, nutrients and energy supply1-5. In metazoans 
and fungi, TOR is found in two compositionally and functionally distinct multiprotein complexes 
(TORC1) and (TORC2) that control rates of biosynthetic growth and cytoskeletal dynamics 
respectively2, 6. In the green lineage (algae and land plants), only homologs of TORC1 proteins 
have been identified3, 7-8. TORC1 kinase activity is modulated by nutrients and stress, and serves 
to control protein biosynthesis and other metabolic processes in response to environmental 
conditions6. Selective chemical inhibitors of TOR kinase including rapamycin, AZD8055, and 
Torin1 have been instrumental in dissecting the TOR signaling pathway9-12. Rapamycin (Rap) 
inhibits TORC1 activity through an allosteric mechanism requiring formation of a FKBP12-Rap 
complex13-15.  Recent studies support the notion that several functions of TOR kinase are not 
inhibited by rapamycin11. Instead, novel drugs like Torin1 and AZD8055 have been reported to 
more completely inhibit TOR kinase by acting as ATP-competitors10-11. Torin1 has slower off-
binding kinetics than other mTOR inhibitors in mammalian cell lines, possibly due to   
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conformational change induction in the kinase that is energetically more difficult to recover from 
leading to a more pronounced and longer inhibition of the TORC1 pathway16. AZD8055 is an 
ATP-competitive inhibitor of mTOR and all PI3K class I isoforms noted to inhibit the mTORC1 
and mTORC2 substrate phosphorylation17. These drugs were used to inhibit TOR activity in 
plants where rapamycin treatment is not highly effective18-19.  
The role of TOR in mammalian and fungal cell metabolism has been extensively 
investigated20-21, while its role in photosynthetic eukaryotes is less well established3, 22-23. TOR 
has been shown to control growth, metabolism and life span in the model plant Arabidopsis 
thaliana (Arabidopsis)24-27 where the TOR gene is essential28. The model green alga 
Chlamydomonas reinhardtii (Chlamydomonas) has key TORC1 complex proteins encoded by 
single-copy genes including TOR (Cre09.g400553.t1.1), regulatory associate protein target of 
rapamycin (RAPTOR) (Cre08.g371957.t1.1), and lethal with sec-13 protein 8 (LST8) 
(Cre17.g713900.t1.2) 7-8. Treatment of Chlamydomonas cultures with rapamycin has been shown 
to slow but not completely arrest cell growth29, activate autophagy 30, and induce lipid droplet 
formation31-32. Recent work reported a connection between TOR kinase and inositol 
polyphosphate signaling that governs carbon metabolism and lipid accumulation33. 
Chlamydomonas cells are sensitive to Torin1  and AZD8055 that are potent inhibitors of cell 
growth at saturating doses33 and induce triacylglycerol accumulation34. However, the TOR 
pathway in Chlamydomonas has yet to be extensively characterized and, to date, only a limited 
number of candidate TOR kinase substrates have been identified.  
We characterized the phosphoproteome of Chlamydomonas that produced a conservative 
estimate of 4,588 phosphoproteins / 15,862 unique phosphosites35 through a qualitative strategy 
involving extensive fractionation and complementary enrichment strategies, and have now 
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developed label-free quantification (LFQ) to allow simultaneous quantification of 2,547 
Chlamydomonas phosphosites36. Herein we characterized the effects of TOR inhibition on the 
Chlamydomonas phosphoproteome. Cultures treated with saturating doses of different TOR 
inhibitors (rapamycin, AZD8055 and Torin1) revealed hundreds of affected phosphosites with a 
significant overlap observed between those seen with different inhibitors. Phosphosites from an 
AZD-resistant mutant were compared with wild type after AZD treatment revealing very few 
potential off target effects.  Hierarchical clustering was used to classify sites and motif analysis 
was used to assess consensus motifs in clusters.   
4.2 Materials and Methods 
4.2.1 Cell Culturing and Drug Treatment 
Strain CC-1690 wild-type mt+ (Sager 21 gr) (Sager, 1955) was used for the wild-type 
Chlamydomonas analysis across all chemical inhibitors. For the control AZD-insensitive strain 
experiments, strain was obtained from the Umen laboratory (Donald Danforth Plant Science 
Center). All cultures were maintained on TAP (Tris acetate phosphate) agar plates and grown in 
350-mL TAP liquid cultures at 25ºC as previously described33. Experiments were done using 
five replicate cultures grown to exponential phase (1-2x106 cells/mL) for each drug condition 
and control and quenched with 40% methanol prior to harvesting by centrifuging at 4000 g for 5 
min and discarding supernatant. To limit batch effects, replicate “n” of each drug and control 
were harvested together (Figure 4.1) prior to downstream processing. Cell pellets were then flash 
frozen using liquid nitrogen and stored at -80ºC until use. For AZD8055-, Torin 1-, and 
rapamycin- treated (LC Laboratories) cultures, drug was added to a final concentration of 500 
nM for rapamycin and Torin 1, and 700 nM for AZD8055 from 1mM stocks in DMSO for 15 
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min prior to harvesting. For control replicates, just drug vehicle (DMSO) without a chemical 
inhibitor was added to each replicate culture for 15 min prior to harvesting. 
4.2.2 Protein Extraction 
Cell pellets were resuspended in lysis buffer containing 100 mM Tris, pH 8.0 with 1x 
concentrations of cOmplete protease inhibitor and phosSTOP phosphatase inhibitor cocktails 
(Roche, Indianapolis, IN, USA). Cells were lysed via sonication using an E220 focused 
ultrasonicator (Covaris, Woburn, MA, USA) for 120 s at 200 cycles/burst, 100 W power and 
13% duty cycle. Following ultrasonication, the supernatant was collected from cellular debris by 
centrifugation for 10 min at 15,000 g at 4ºC and proteins were precipitated using 5 volumes of 
cold 100 mM ammonium acetate in methanol. Following 3 hr incubation at -80ºC, protein was 
pelleted by centrifugation for 5 min at 2,000 g followed by two washes with fresh 100 mM 
ammonium acetate in methanol and a final wash with 70% ethanol. Cell pellets were 
resuspended in 8M urea and protein concentration was determined using the CB-X assay (G-
Biosciences, St. Louis, MO, USA). 
4.2.3 Protein Digestion and Reduction. 
Samples were reduced using 10 mM dithiothreitol for 30 min at RT and subsequently 
alkylated with 40 mM iodoacetamide for 45 min in darkness at RT prior to overnight digestion. 
Samples were diluted 5-fold in 100 mM Tris following alkylation and digestion was performed 
at 25°C for 16 h with Trypsin Gold (Promega) at a protease:protein ratio of 1:50. 
4.2.4 Solid-Phase Extraction. 
After digestion, samples were acidified to pH<3.0 with trifluoroacetic acid (TFA). Pelleted, 
undigested protein was cleared from the supernatant by centrifugation for 5 min at 5,000 g prior 
to solid-phase extraction. Desalting was performed using C18 50 mg Sep-Pak cartridges 
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(Waters). Columns were prepared by washing with acetonitrile (MeCN) followed by 80% 
MeCN/20%H2O/0.1% TFA and 0.1% TFA. Digested protein lysates were applied to the columns 
and reloaded twice before being washed with 0.1% TFA and eluted using 80% MeCN/20% 
H2O/0.1% TFA. 
4.2.5 Phosphopeptide Enrichment and Clean-Up. 
Following protein digestion and solid-phase extraction, replicates were dried down using 
vacuum centrifugation and phosphopeptide enrichment was performed on 2-mg aliquots of each 
sample using 3 mg Titansphere Phos-TiO2 kit spin columns (GL Sciences) as previously 
described36. After enrichment, samples were dried down and desalted again using ZipTips 
(Millipore) as per manufacturers protocol prior to LC-MS/MS acquisition. 
4.2.6 LC-MS/MS Acquisition and Data Processing. 
Following ZipTip clean-up, peptides were dried down and resuspended in 20 µL of 0.1% 
TFA, 5% MeCN before separation via a 90-min linear gradient from 95% H2O/5% MeCN/0.1% 
formic acid (FA) to 65% H2O/35% MeCN/0.1% FA via a NanoAcquity UPLC (Waters). Each 
sample was loaded onto a trap column (NanoAcquity UPLC 2G-W/M Trap 5 μm Symmetry 
C18, 180 μm × 20 mm) at a flow rate of 5 μL min–1 for 5 min. Peptides were separated using a 
C18 column (NanoAcquity UPLC 1.8 μm HSS T3, 75 μm × 250 mm) at a flow rate of 300 nL 
min–1. A TripleTOF 5600 (AB Sciex) Q-TOF was operated in positive-ionization 
nanoelectrospray and high-sensitivity mode for data acquisition as previously described37. In 
addition to the Supporting Information tables for MS datasets, the mass spectrometry proteomics 
data have been deposited to the ProteomeXChange Consortium via PRIDE partner repository38 
identifier PXD007221. Acquired spectra (*.wiff) files were imported into Progenesis QI for 
proteomics (v2.0, Nonlinear Dynamics) as previously described36 with peptide sequence 
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determination and protein inference done by Mascot (v.2.5.1; Matrix Science) using the C. 
reinhardtii Phytozome v.11 database (www.phytozome.net/; accessed May 2015) appended with 
the NCBI chloroplast and mitochondrial databases (19,603 entries) and sequences for common 
laboratory contaminants (http://thegpm.org/cRAP/; 116 entries). For database searching, trypsin 
protease specificity with up to two missed cleavages, peptide/fragment mass tolerances of 20 
ppm/0.1 Da, a fixed modification of carbamidomethylation at cysteine, and variable 
modifications of acetylation at the protein N-terminus, oxidation at methionine, deamidation at 
asparagine or glutamine, phosphorylation at serine or threonine and phosphorylation at tyrosine 
were used. Peptide false discovery rates (FDR) were adjusted to ≤1% using the Mascot 
Percolator algorithm39 and only peptides with a Mascot ion score over 13 were considered.  
Custom scripts written in Python were implemented to parse results following data 
normalization and quantification in Progenesis QI for proteomics. Shared peptides between 
proteins were grouped together to satisfy the principle of parsimony and represented in Table S1 
by the protein accession with the highest amount of unique peptides, otherwise the largest 
confidence score assigned by Progenesis QI for proteomics. Additionally, the script appended 
site localization of variable modifications using an implementation of the Mascot Delta Score40 
to the peptide measurements (*.csv) export from Progenesis QI for proteomics with confident 
site localization considered a Mascot Delta score >90%. Following scoring, only peptides with 
phosphorylation at serine, threonine, or tyrosine were considered for further processing and 
analysis. 
4.2.7 Downstream Bioinformatics Analysis. 
Missing value imputation was performed on logarithmized normalized abundances in Perseus 
v1.6.0.041-42 requiring at least three of the five replicates in all drug conditions and control to be 
84 
nonzero to continue through the workflow. For t-test analyses, replicates were grouped and the 
statistical tests were performed with fold change threshold of ±2 and p≤0.05 significance 
threshold. KEGG pathway annotation43, Gene Ontology (GO)44 term annotation, hierarchical 
clustering, and motif analysis were performed following statistical testing to glean biological 
insight on modulated sites found in the study. For hierarchical clustering, visualization was 
performed in Perseus v1.6.0.0. Following data normalization and missing value imputation, 
intensity values were z-score normalized and grouped using k-means clustering with default 
parameters. For motif analysis, sequence logo visualizations were performed using pLOGO with 
serine or threonine residues fixed at position 0. Positions with significant residue presence are 
depicted as amino acid letters sized above the red line45. 
4.2.8 Carotenoid Analysis. 
Chlamydomonas cells were collected by centrifugation (4000 g for 5 min) and resuspended 
in 80% acetone. Samples were heat up for 5 min in a water bath at 90ºC and then centrifuge at 
10000g 10min. The supernatant evaporated under N2, and then resuspended in 80%acetone. The 
separation and chromatographic analysis of pigments was performed in a HPLC using a Waters 
Spherisorb ODS2 column (4.6 · 250 mm, 5 lm particle size). The chromatographic method 
described by Baroli et al., 200346. Pigments were eluted at a flow rate of 1.0 mL min-1 with a 
linear gradient from 100% solvent A (acetonitrile:methanol:0.1mM Tris-HCl pH 8.0 [84:2:14]) 
to 100% solvent B (methanol:ethyl acetate [68:32]) for 20 min, followed by 7 min of solvent B, 
then 1 min with a linear gradient from 100% solvent B to 100% solvent A, and finally 6 min with 
solvent A. The carotenoids were detected at 440 nm using a Waters 2996 photodiode-array 
detector. The different carotenoids were identified using standards from Sigma (USA) and DHI 
(Germany). This analysis was normalized by dry cell weight. 
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4.2.9 Dry Weight Determination 
Dry weight was determined by filtering an exact volume of microalgae culture (30 ml) on 
pre-targeted glass-fiber filters (1µm pore size). The filter was washed with a solution of 
ammonium formate (0.5 M) to remove salts and dried at 100 ◦C for 24 h. The dried filters were 
weighed in an analytical balance and the dry weight calculated by difference. 
4.2.10 SDS-PAGE and Western Blotting 
Chlamydomonas cells from liquid cultures were collected by centrifugation (4000 g for 5 
min), washed in 50 mM Tris-HCl (pH 7.5), 10 mM NaF, 10 mM NaN3, 10 mM p-
nitrophenylphosphate, 10 mM sodium pyrophosphate, and 10 mM b-glycerophosphate), and 
resuspended in a minimal volume of the same solution supplemented with Protease Inhibitor 
Cocktail (Sigma). Cells were lysed by two cycles of slow freezing to –80 °C followed by 
thawing at room temperature. The soluble cell extract was separated from the insoluble fraction 
by centrifugation (15 000 g for 20 min) in a microcentrifuge at 4 °C.  For immunoblot analyses, 
total protein extracts (20 μg) were subjected to 12% SDS–PAGE and then transferred to PVDF 
membranes (Millipore). Αnti-P-RPS6(Ser242) and Αnti-RPS6 primary antibodies were 
generated as described in Dobrenel et al., 201647  and produced by Proteogenix, (France). 
Phospho-p70 S6 kinase (Thr(P)-389) polyclonal antibody (Cell Signaling, 9205) was used as 
described in Xiong et al., 201248. Primary antibodies were diluted 1:2000 and 1:1000 
respectively. Secondary anti-rabbit (Sigma) antibodies were diluted 1:5000 and 1:10 000, 
respectively, in phosphate-buffered saline (PBS) containing 0.1% (v/v) Tween-20 (Applichem) 
and 5% (w/v) milk powder. The Luminata Crescendo Millipore immunoblotting detection 
system (Millipore) was used to detect the proteins. Proteins were quantified with the Coomassie 
dye binding method (BioRad).  
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4.3 Results and Discussion 
4.3.1 Parameter Selection for TORC1-Specific Inhibition 
Previous studies in Chlamydomonas have shown rapamycin drug saturation ranging from 
500 nM-1µM29. For this study, 500 nM rapamycin was selected and saturating doses for Torin1 
and AZD8055 in wild-type Chlamydomonas strain CC-1690 were determined using serial 
dilutions with previously published target concentrations33. Growth inhibition saturated at 500 
nM for Torin1 and 700 nM for AZD8055 (Figure 4.2). 
While reports have shown phosphorylation changes as early as 2 minutes after rapamycin 
treatment 49, a 15-minute time point was chosen based on the high number of changes seen in 
mammalian cell lines at this time point49-51 and to ensure reproducibility in treatment and 
harvesting across 20 samples (control, AZD8055-, Torin1-, and rapamycin-treated with n=5) 
from the early logarithmic phase of growth. Growth for each replicate was staggered, and to limit 
batch-effects replicates were harvested in sets, each containing a control sample and the three 
different drug-tested samples (Figure 1) prior to downstream processing.  
Prior rapamycin phosphoproteomic experiments in mammalian studies have shown that 
phosphopeptide ratios in general were not affected by normalization to protein levels at a 15 min 
time point51. To confirm this in Chlamydomonas reinhardtii, a whole-cell proteomics experiment 
(n=4) was performed to test the overlap between quantitative coverage on whole-cell and 
phospho-enriched results after 15 min of rapamycin inhibition. These results showed that protein 
abundance levels in general are not affected with only 18 of the 1,539 proteins quantified 
significantly changing (Supplemental Table S4) with no significant differences in protein 
abundances between control and treatment (Figure 4.3). While 4 of the 18 proteins changing at 
the protein level were identified in the phosphoproteomics study detailed below, they were not 
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detected as phospho-modulated following chemical inhibition and thus not proteins of interest in 
this study. Thus, we have confidence that the statistically significant phosphorylation sites 
detected are from changes in the phosphorylation status and not an artefact of protein expression 
or turnover. 
4.3.2 Quantitative Coverage of the TOR-Inhibited Phosphoproteome 
Label- free quantitative phosphoproteomics was used to compare normalized abundance 
values of control samples (n=5) versus samples treated with each of the chemical inhibitors 
(n=5) using an area under the curve (AUC) MS1 intensity-based quantitation method. For this 
approach, the change in chromatographic peak area between control and chemically-inhibited 
replicates for each phosphopeptide was the basis for determining relative phosphopeptide 
abundance. Tip-based TiO2 phosphopeptide enrichment that previously showed high 
reproducibility between samples36 was used for sample preparation. As part of the LFQ pipeline, 
quantitative data was filtered for only peptides containing a phosphorylation site on Ser, Thr, or 
Tyr after peak picking and peptide sequence determination. At least 3 of the 5 replicates for each 
condition were required to have nonzero abundances to remain in the final dataset presented in 
Table S1 and missing value imputation was performed on log-transformed normalized 
abundances41-42. Highly variable sites remaining in the dataset were then removed by filtering out 
those with a coefficient of variation of >25% in >2 experimental conditions. The resulting 
dataset contained 2,547 unique phosphosites from 1,432 different proteins (Table S1) in 
untreated control samples. To determine sites of interest following chemical inhibition with 
Torin1, AZD8055, or rapamycin, two sample Student’s T-tests were performed between samples 
from each chemical inhibitor compared and control samples. From this, 258 phosphosites from 
219 phosphopeptides showed at least a two-fold change and a p-value ≤ 0.05 (Figure 4.4A, Table 
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S2). High confidence phosphorylation site assignments (90% site-localization based on Mascot 
Delta scoring40) were achieved for 48% of the dataset (1,123 of the 2,363 phosphopeptides) 
listed in Table S1. AZD8055 treatment resulted in 97 phosphopeptides modulated in the wild-
type strain (Figure 4.4A). A matched control experiment using an AZD-insensitive strain which 
grow similar to wild-type (Figure 4.5) showed only 13 low abundance phosphosites differentially 
changing (Table S3, Figure 4.4B). Of the 13, no overlap was found with the 258 modulated 
phosphosites in the main dataset. 
Torin1 treatment caused the largest number of significant changes with 103 up- and 57 
down-modulated phosphosites. AZD8055 treatment caused 75 up- and 19 down-modulated 
phosphosites, while rapamycin treatment caused 40 up- and 35 down-modulated phosphosites. 
Overlap analysis of the differential sites for each drug revealed 88% (57/66) of all the down-
modulated sites were in the Torin1 subset, while 42% (24/57) of the Torin1 down-modulated 
sites were not detected with AZD or rapamycin. Up-regulated sites were also compared for each 
condition and to determine if the conditions had significant overlap between down- and up- 
modulated sites, a hypergeometric test was performed with p-values of 3.76x10-25 and 2.87 x10-
34, respectively, showing significant overlap. 
4.3.3 Cluster Analysis and Phosphosite Motif Identification 
Kinase specificity can be dictated by amino acid residues immediately surrounding 
phosphorylation sites on substrates52. Mammalian TOR has been shown to mainly (but not 
exclusively) phosphorylate (S/T)P motifs and motifs with hydrophobic residues surrounding the 
phosphorylation site making it a relatively promiscuous kinase whose substrate choices may also 
be influenced by additional interactions outside the phosphosite region53. Hierarchical clustering 
of Chlamydomonas modulated phosphosites generated 2 distinct clusters (Figure 4.6A,B), and 
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motif analysis45 was performed on decreasing (cluster 1) and increasing (cluster 2) clusters . 
Cluster 1 phosphosites, which contained 94% of sites that significantly decrease in 
phosphorylation upon TOR inhibition, had significant enrichment for a proline in the +1 position 
and arginine in the -3 position with respect to the phosphorylation site (position 0) that showed 
strong enrichment for serine over threonine (Figure 4.6C). Cluster 2 phosphosites also had 
significant enrichment for a proline in the +1 position and arginine in the -3 position in addition 
to enrichment for an aspartic acid at the +3 position. Thus, CrTOR may have a preference for 
phosphorylation of (S/T)P motifs on substrates, similar to mTOR53 and other diverse proline-
directed kinases including cyclin-dependent protein kinases (CDKs) and mitogen-activated 
protein kinases (MAPKs)54. Additionally, a phosphoproteomic study using mammalian cell line 
MCF7 identified the RXXS/TP motif identified in clusters 1 and 2 as a rapamycin-sensitive 
motif49. Other studies have also found RXRXXS/T and RXXS/T motifs50-51 enriched among 
rapamycin-sensitive phosphosites that are recognized by mTOR-regulated kinases Akt, S6K1 
and SGK155. Cluster 2 additionally has an acidic motif also found in casein kinase- II 
substrates56. 
4.3.4 Phosphosites in TORC1 Complex Proteins 
Numerous phosphosites in mammalian homologs of TORC1 complex proteins are regulated 
by the TOR pathway and/or are phosphorylated autocatalytically57. This includes sites on Raptor 
and mTOR homologs. Therefore, phosphosites found on CrTORC1 complex proteins could be 
affected by TOR inhibition. TORC1 complex proteins conserved in Chlamydomonas include 
TOR (Cre09.g400553.t1.1), Raptor (Cre08.g371957.t1.1), and LST8 (Cre17.g713900.t1.2)8, 30, 33, 
58. While there is a known LST8 homolog in Chlamydomonas, it is not known to be 
phosphorylated35. Phosphosites on Raptor (Ser782/783:NL) (Not Localized:NL) and TOR 
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(Ser2598) were detected in this study, however no statistically significant modulation in their 
abundance was detected. BLASTP alignment of human Raptor (Uniprot Q8N122) with CrRaptor 
revealed high sequence overlap on the N-terminal region of the protein (residues 9-627 with 57% 
identity), however known TORC1-sensitive phosphosites in the human Raptor homolog (i.e. 
Ser719, Ser721, Ser722, Ser859, and Ser86357, 59) were not conserved in CrRaptor. Similarly, 
human mTOR (Uniprot P42345) phosphosites Ser2159/Thr2164 that are within the kinase 
domain promoting mTORC1-associated mTOR Ser2481 autophosphorylation60 are not 
conserved in CrTOR. The limited sequence conservation among CrTORC1 phosphosites with 
mammalian TOR phosphosites precludes any predictions about functions of CrTORC1 protein 
phosphorylation. Other phosphosites on CrTORC1 complex proteins that were detected in 
previous work on the global phosphoproteome in Chlamydomonas35 might be significant for 
regulation but they were not observed in our data. Future experiments with additional 
fractionation to increase the dynamic range of quantitative coverage could allow for deeper 
coverage and more comprehensive detection of phosphosites. 
4.3.5 Sites Modulated by TORC1 Inhibition – Known and Putative Substrates. 
In animal cells TORC1-inhibition blocks phosphorylation of multiple substrates including S6 
kinases and eukaryotic translation initiation factors, leading to a reduction in translation initiation 
rates for a subset of mRNAs61-63. Phosphorylation of Ser371 and Thr389 in human p70S6K1 
(Uniprot P23443-2) are reduced by treatment of cells with TOR inhibitors64-65. While we 
identified one potential site (site was not localized) (Thr771/Ser773/Thr777:NL) on a 
Chlamydomonas homolog of ribosomal protein S6 kinase (S6K; Cre13.g579200.t1.2), its 
phosphorylation state was not significantly altered by TOR inhibitors (Table 1). No coverage 
was obtained on predicted conserved sites Ser915 and Thr932, which align to human p70S6K1 
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Ser371 and Thr389, respectively, although these sites have been detected previously in 
Chlamydomonas35. Moreover, while commercial anti-phospho S6K antibodies have been shown 
to detect phospho-S6K in plants48, 66 they have not detected a signal in Chlamydomonas in our 
hands (Figure 4.7A) and in another study 33, thus limiting our ability to independently validate 
Chlamydomonas TOR substrate phosphopeptides. On the other hand, Chlamydomonas 
ribosomal protein S6 (RPS6, Cre09.g400650.t1.2), a predicted target of S6K, showed a 2.1-fold 
decrease in phosphorylation on Thr127 following Torin1 treatment (Figure 4.8, Table 1). While 
this site is potentially TORC1-regulated, antibodies specific for this phosphosite needed for 
validation are not available. In Arabidopsis, a phosphosite on the C-terminal extremity peptide of 
RPS6, Ser240,  had decreased phosphorylation following TOR inactivation47. While this exact 
site is not conserved in Chlamydomonas, the phosphoserine next to it, Ser241 in Arabidopsis 
(aligning to Ser242 in Chlamydomonas) has been detected in prior work35; however it was not 
detected in this study (Figure 4.7B). To determine if Ser242 in Chlamydomonas is TORC1-
regulated, a western blot of proteins fractionated from wild-type cells under different drug 
treatments for 0, 5, 15, 30, and 60 min was performed with antibodies raised for phosphorylated 
and non-phosphorylated Ser242 (Figure 4.7C), the latter used as a control for monitoring protein 
level. Interestingly, this site does not seem to change drastically with Torin1, AZD8055, or 
rapamycin treatment contrary to results on the C-terminal phosphosite in Arabidopsis.  
4.3.6 Sites Modulated by TORC1 Inhibition – Known TOR Pathway Association. 
Of the 258 phosphosites detected as significantly modulated in this study, 10 are in homologs 
of proteins associated with the TOR signaling pathway (Figure 4.8, Table 1). In addition to four 
sites of decreasing phosphorylation, six proteins related to the TOR pathway had an increase in 
protein phosphorylation following chemical inhibition. While initially an unexpected 
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observation, similar increases were previously reported for some phosphosites in a 
phosphoproteomic study of TOR inhibition in mouse liver50. In our study, sites with increasing 
phosphorylation after TOR inhibition include elongation factor 2 (EEF2, Cre12.g516200.t1.2) 
whose animal homologs showed reduced activity upon phosphorylation. In human cells, 
phosphorylation of  EEF2 Thr57 by elongation factor 2 kinase (EEF2K, Cre17.g721850.t1.2) 
inactivates EEF2 activity, an essential factor for protein synthesis 67. This site is conserved in 
Chlamydomonas EEF2 (Thr57/Thr59:NL) where we detect a 4.75-fold increase in 
phosphorylation with AZD8055 treatment with a predicted effect of reduced translation initiation 
rates. From these data we predict that CrTOR signaling may inhibit EEF2 kinase activity, and 
that this inhibition is relieved in the presence of TOR inhibitors. 
LA RNA-binding protein (LARP1, Cre10.g441200.t1.2) had two phosphosites that both 
underwent large decreases in phosphorylation upon treatment with the three chemical inhibitors. 
Ser817 was decreased 0.06AZD8055, 0.05Torin1, and 0.13RAP and Ser 737/738:NL was decreased 
0.08AZD8055 and 0.01Torin 1 but no change in rapamycin (0.99RAP) (Figure 4.8). In mammals, 
LARP1 phosphorylation also requires mTORC155, 68-69 with studies in human cell lines 
establishing LARP1 as a target of mTORC1 and S6K with non-phosphorylated LARP1 
interacting with both 5’ and 3’ UTRs of RP mRNAs and inhibiting their translation70. Additional 
reports have shown LARP1 as a direct substrate of mTORC1 in mammalian cells with mTORC1 
controlling Terminal Oligopyrimidine (TOP) mRNA translation via LARP170-71. The dramatic 
modulation of LARP1 phosphorylation detected in our study indicates that LARP1 may have a 
parallel role in Chlamydomonas. The human LARP1 phosphosites are not conserved with those 
we found in Chlamydomonas. However, based on the NCBI conserved domain searching72, the 
DM15 domain required for the interaction of LARP1 with mTORC1 in human cell lines is 
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conserved in Chlamydomonas LARP1, and the phospho-Ser817 detected in our study is adjacent 
to the DM15 domain (877-915) in Chlamydomonas, a region in mammalian LARP1shown to be 
required for interaction with mTORC170.  
4.3.7 Additional Proteins with Phosphosites Altered by TORC1 Inhibition 
The majority of differential phosphosites we identified were not previously linked to TOR 
signaling, including in Chlamydomonas. These include sites on a translation-related protein 
(Cre17.g696250.t1.1) and RNA-binding proteins (Cre10.g441200.t1.2, Cre10.g466450.t1.1, 
Cre16.g659150.t1.1, Cre16.g662702.t1.1 Cre17.g729150.t1.2). One of the most down-modulated 
proteins annotated as CTC-interacting domain 4 (CID4, Cre01.g063997.t1.1), has been shown to 
have an important function in regulation of translation and mRNA stability in eukaryotes73-74. 
CID4 had 2 sites, Ser441 (FC=0.2AZD8055, FC=0.14TORIN1) and Ser439/Ser441/Ser446:NL 
(FC=0.03AZD8055, FC=0.05TORIN1) with a large decrease in phosphorylation upon inhibitor 
treatment. While little is known about the relationship between this protein and TORC1 
signaling, the CTC domain, more recently referred to as the MLLE domain75, is also found in 
evolutionarily conserved Poly (A)-binding proteins (PABPs). The large decrease in CID4 
phosphorylation seen upon inhibition of the CrTORC1 pathway in our study implies a potential 
role for TORC1 mediated control of translation through CID4.  
Another differential phosphosite of interest following TORC1 inhibition that was not 
previously linked to TOR regulation is a site on lycopene beta/epsilon cyclase protein 
(Cre04.g221550.t1.2--Thr800/Ser802:NL). This phosphosite is significantly increased upon 
Torin1 treatment (FC=4.02) and the total protein level remained constant upon rapamycin 
treatment (Supplementary Table S4, FC=0.88). Lycopene beta/epsilon cyclases are required for 
carotenoid biosynthesis, carrying out cyclation of lycopene to yield α- and β- carotenes76-78 
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which have been shown to be high-value compounds participating in light harvesting and in the 
protection of the photosynthetic apparatus against photo-oxidation damage79. To further 
investigate the effect of TORC1 inhibition on carotenoid biosynthesis based on this 
phosphoproteomic finding, carotenoid levels in AZD-, Torin1- and rapamycin-treated cells were 
assessed after eight hours of treatment with three biological and two technical replicates (Figure 
4.9, Table 2). After eight hours of treatment, there was a significant increase in various 
carotenoids measured in TOR-inhibited samples including β-carotene, which is directly 
downstream of cyclase activity (Figure 4.9, Table 2). While the effects on carotenoid 
biosynthesis and secondary metabolism following TORC1 inhibition required eight hours to 
become detectable, this is the first evidence that carotenoid production is modulated by TOR 
signaling. Additionally, altered cyclase protein levels are not likely responsible for this finding 
since previous studies showed no change in lycopene beta/epsilon cyclase protein level after up 
to 24 hours of nitrogen stress80-81, a condition that is metabolically similar to TOR inhibition30, 82.  
Numerous phosphosites from proteins without Phytozome database descriptions were also 
found to be down-regulated upon CrTORC1 inhibition, including some sites with large decreases 
(>five-fold). For all unannotated proteins, we searched for pfam, Panther, KOG, KEGG, KO, and 
GO pathway terms and domain conservation using Phytozome and NCBI annotations (Table S4). 
Numerous proteins had conserved domains including structural maintenance of chromosomes 
(Accession: cl25732), autophagy protein (Accession: cl27196), transmembrane proteins 
(Accession: cl24526), and small acidic protein (Accession: pfam15477). While the large changes 
upon chemical inhibition are potentially interesting, especially the five proteins containing sites 
with at least a five-fold decrease in phosphorylation (Cre03.g152150.t1.2, Cre06.g263250.t1.1, 
Cre11.g469150.t1.2, Cre05.g236650.t1.1, Cre13.g582800.t1.2), future targeted work would be 
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required to infer biological significance to this observation. To aid in this, the fifty-eight 
modulated sites without Phytozome database annotation were also homology searched for best 
BLAST hit IDs in Volvox, Gonium, and Arabidopsis to find homologs among green lineage 
(Table S5) and Table S2 displays all of the experimentally derived sites modulated by AZD8055, 
Torin1, and/or rapamycin and will serve as a guide in follow-up studies.  
4.4 Conclusion/Summary 
In summary, we obtained a candidate list of phosphosites modulated following TORC1 
inhibition. We achieved extensive coverage of the TOR-modulated phosphoproteome in 
Chlamydomonas using a quantitative label-free approach. Our approach was validated by the 
overlap of phosphosites altered using different TOR inhibitors and by our identification of 
Chlamydomonas homologs of TOR signaling-related proteins such as RPS6 and LARP1 that had 
decreased phosphorylation upon TORC1 inhibition. Follow-up experiments guided by our 
phosphoproteomic findings in lycopene beta/epsilon cyclase showed that carotenoid levels are 
affected by TORC1 inhibition, the first evidence that carotenoid production is under TOR 
control. Conserved TOR substrate motifs were also identified such as RXXS/TP and RXXS/TP. 
Our study provides a new resource for investigating the phosphorylation networks governed by 




Table 4.1 TOR targets identified with fold change values for drug condition versus control. Fold 
change values shaded red indicate a statistically significant increase in phosphopeptide 
abundance for specified drug treatment versus control. Fold change values shaded blue indicate a 
statistically significant decrease in phosphopeptide abudance for specified drug treatment versus 




Table 4.2 Carotenoid content in WT Chlamydomonas after 8 hours of treatment with 






Figure 4.1 Figure reproduced from ref [83]. Drug treatment and cell harvesting workflow in 
Chlamydomonas cells. Replicate “n” (1-5) of each drug condition and control were harvested 
together prior to downstream processing. To minimize inter-condition batch effects, “n” replicate 





Figure 4.2 Figure reproduced from ref [83]. Titration experiment for AZD8055 and Torin1 to 





Figure 4.3 Figure reproduced from ref [83]. Pearson correlation coefficient between replicates of 
control and rapamycin-treated cells following protein-level analysis. Logarithmized protein 
abundances across 4 replicates for control and 15 min. rapamycin-treated cells showing high 
correlation regardless of treatment with no significant differences in protein abundances between 





Figure 4.4 Figure reproduced from ref [83]. Sites modulated by chemical inhibition. Results of 
differential analysis between each chemical inhibitor drug treatment compared to control for both 
wild-type (A) and AZD-insensitive (B) Chlamydomonas strains. For comparison of overlap 
between the drug conditions in the WT dataset, a Pearson’s correlation was performed 
comparing all condition types. From this, the highest correlation among conditions was between 










Figure 4.5 Figure reproduced from ref [83]. Spot test for comparison of growth between WT and 
AZD-insensitive Chlamydomonas cultures after 3 and 5 days of growth. WT and AZD-
insensitive strains were grown on solid TAP media and cultures were diluted 1/5 and 1/25. 
Additionally, after 5 days of growth, spot tests for 0.5 uM- 2 uM AZD8055 treatment between 
WT and AZD-insensitive Chlamydomonas cultures were compared showing continued growth of 






Figure 4.6 Figure reproduced from ref [83]. Hierarchical clustering of differentially changing sites 
into 2 clusters (A). Visualization was performed in Perseus v1.6.0.0. Following data 
normalization and missing value imputation, intensity values were z-score normalized and 
grouped using k-means clustering with default parameters. Overall trends in site intensity were 
graphed and colored based on intensity (B). For each of the two clusters, motif analysis was 
performed (C) : motif analysis on clusters 1 and 2 from hierarchical clustering. Sequence logo 
visualizations were performed using pLOGO with serine or threonine residues fixed at position 
0. Positions with significant residue presence are depicted as amino acid letters sized above the 
red line. For cluster 1, there was significant enrichment for a proline in the +1 position and 
arginine in the -3 position, RXXS/TP. For cluster 2, there was again significant enrichment for a 





Figure 4.7 Figure reproduced from ref [83]. Commercial anti-phospho S6K antibody reactivity in 
Chlamydomonas with no signal (A). Comparison of RPS6 protein sequence between Arabidopsis 
and Chlamydomonas (B). a western blot in wild-type under different drug treatments for 0, 5, 15, 







Figure 4.8 Figure reproduced from ref [83]. Bar charts of 10 modulated phosphosites on TOR 
pathway-associated proteins based on homology. Level of p-value statistical significance is 




Figure 4.9 Figure reproduced from ref [83]. Bar chart of carotenoid content in WT 
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CHAPTER 5:  Pathway Inhibition of Rapamycin-Hypersensitive Vip-1 Mutant 
Chlamydomonas Strain Revealed via Phosphoproteomics 
*Manuscript to be submitted for publication. Authors: Werth, E.G., Couso, I., Umen, J. G., 
Hicks, L. M. Pathway Inhibition of Rapamycin-Hypersensitive Vip-1 Mutant Chlamydomonas 
Strain Revealed via Phosphoproteomics.  
 
5.1 Introduction 
Characterizing cellular regulation of carbon metabolism and triacylglycerol (TAG) 
accumulation in algae is required to harness its potential as a biofuel feedstock1-6. Elucidation of 
intracellular carbon regulatory networks and the interplay between them will provide better 
strategies for improving yields and storage of fixed carbon. Many interconnected signaling 
networks are tied to lipid and TAG accumulation in algae including target of rapamycin (TOR)1, 
7-8 and inositol polyphosphate (InsPs) signaling9-10. Recently, a connection between the TOR 
kinase pathway and inositol polyphosphate signaling has been reported in Chlamydomonas11, an 
interaction previously only suggested in yeast and animals12-13. 
TOR kinase signaling is a master regulator of cellular processes from cell cycle to autophagy 
and modulates activity in response to nutrients and stress to control protein biosynthesis and 
other metabolic processes14-19. Highly studied in metazoans and fungi15, 20, TOR is found in two 
compositionally and functionally distinct multiprotein complexes, TORC1 and TORC215, 19, but 
only homologs of TORC1 are found in the green lineage14, 21-22. In the model green alga 
Chlamydomonas reinhardtii (Chlamydomonas), key TORC1 complex proteins such as TOR 
(Cre09.g400553.t1.1), regulatory associate protein target of rapamycin (RAPTOR) 
(Cre08.g371957.t1.1), and lethal with sec-13 protein 8 (LST8) (Cre17.g713900.t1.2) are   
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conserved21, 23. Selective chemical inhibition of TOR kinase, has been shown to induce TAG 
accumulation8 and phosphoproteomics revealed 258 significantly modulated phosphosites on 
both TOR signaling-related proteins and numerous sites not previously known to be TOR-
regulated, including a role in carotenoid biosynthesis24.  
Inositol pyrophosphates are signaling molecules critically important in eukaryotes that play a 
role in stress response25-28 and function in diverse cellular processes such as energy sensing, 
telomere maintenance, homeostasis, and storage9, 29. In yeast and animal systems, two distinct 
families of enzymes are capable of producing pyrophosphorylated inositols, IP6K/KCS19 and 
VIP30-32. VIP proteins belong to a class of enzymes known as diphosphate kinases in animals33 
that are conserved in plants9, 32 and capable of synthesizing polyphosphate inositols. Plants have 
been shown to have large amounts of InsP6, the precursor to signaling molecules containing 
diphosphate or triphosphate chains attached to the inositol ring34-35. Molecules synthesized by 
InsP6, such as InsP7 and InsP8, contain high energy pyrophosphate bonds that may store energy in 
the cell36 however due to their low amounts and high turnover rates, it has been suggested that 
they serve as more than simply energy storage molecules37-38.  
A direct link between the Chlamydomonas TOR and InsP pathways was revealed by 
characterization of a mutant, vip1-1, that conferred hypersensitivity to the TOR inhibitor 
rapamycin. This loss-of-function mutation in the VIP1 gene was identified in an insertional 
mutagenesis screen for rapamycin-hypersensitive Chlamydomonas11. Vip1-1 is predicted to 
encode a conserved inositol hexakisphosphate kinase from the VIP family that 
pyrophosphorylates phytic acid, InsP6. This mutant has defects in InsP7 and InsP8 accumulation 
with InsP7 and InsP8 levels at 20 to 30% of wild-type levels but InsP6 levels maintaining 
approximately 70% wild-type levels11.  
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The discovery of interplay between the TOR and InsP signaling systems allows for the 
opportunity to investigate the effects of TOR inhibition on the phosphoproteome of a rapamycin-
hypersensitive mutant, vip1-1. Rapamycin-treated cultures revealed similarities with the sites 
modulated in the wild-type study (Chapter 4) and contained a subset of phosphosites not 
previously identified as TOR regulated. Cluster and motif analysis was used to identify 
significant trends among the phosphosites changing. 
5.2 Materials and Methods 
5.2.1 Cell Culturing and Rapamycin Treatment. 
Strain CC-1690 mt+ (Sager 21 gr) (Sager, 1955) was used as the parental strain to generate 
vip1-1 for the rapamycin-hypersensitive strain. Insertional mutagenesis39 with a hygromycin 
resistance gene, aph7”40 was used to generate mutants and transformation was performed as 
previously described11. Rapamycin-hypersensitive mutants were identified by comparing growth 
on TAP (Tris Acetate Phosphate) agar plates to TAP + 500 nM rapamycin plates.  
For phosphoproteomic studies, all cultures were maintained on TAP agar plates and grown in 
350-mL TAP liquid cultures at 25ºC as previously described11. Experiments were done using 
five replicate cultures grown to exponential phase (1-2x106 cells/mL) for control and rapamycin-
treated samples and quenched with 40% methanol prior to harvesting by centrifuging at 4000 g 
for 5 min and discarding supernatant as previously described24. Cell pellets were then flash 
frozen using liquid nitrogen and stored at -80ºC until use. For rapamycin-treated cultures, drug 
was added to a final concentration of 500 nM for rapamycin (LC Laboratories) from 1mM stocks 
in DMSO for 15 min prior to harvesting. For control replicates, drug vehicle (DMSO) without 
rapamycin was added to each replicate culture for 15 min prior to harvesting. 
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5.2.2 Protein Extraction. 
Cell pellets were resuspended in lysis buffer containing 100 mM Tris, pH 8.0 with 1x 
concentrations of cOmplete protease inhibitor and phosSTOP phosphatase inhibitor cocktails 
(Roche, Indianapolis, IN, USA). Cells were lysed via sonication using an E220 focused 
ultrasonicator (Covaris, Woburn, MA, USA) for 120 s at 200 cycles/burst, 100 W power and 
13% duty cycle. Following ultrasonication, the supernatant was collected from cellular debris by 
centrifugation for 10 min at 15,000 g at 4ºC and proteins were precipitated using 5 volumes of 
cold 100 mM ammonium acetate in methanol. Following 3 hr incubation at -80ºC, protein was 
pelleted by centrifugation for 5 min at 2,000 g followed by two washes with fresh 100 mM 
ammonium acetate in methanol and a final wash with 70% ethanol. Cell pellets were 
resuspended in 8M urea and protein concentration was determined using the CB-X assay (G-
Biosciences, St. Louis, MO, USA). 
5.2.3 Protein Digestion and Reduction. 
Each 2 mg protein sample replicate at approximately 1mg/mL concentration was reduced 
using 10 mM dithiothreitol for 30 min at RT and subsequently alkylated with 40 mM 
iodoacetamide for 45 min in darkness at RT. Following reduction and alkylation, samples were 
diluted 5-fold in 100 mM Tris to reduce urea concentration to 1.6M for effective trypsin 
digestion performed at 25°C for 16 h with Trypsin Gold (Promega) at a protease:protein ratio of 
1:50. 
5.2.4 Solid-Phase Extraction. 
After digestion, samples were acidified to pH<3.0 with trifluoroacetic acid (TFA). Pelleted, 
undigested protein was cleared from the supernatant by centrifugation for 5 min at 5,000 g prior 
to solid-phase extraction. Desalting was performed using C18 50 mg Sep-Pak cartridges 
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(Waters). Columns were prepared by washing with acetonitrile (MeCN) followed by 80% 
MeCN/20%H2O/0.1% TFA and 0.1% TFA. Digested protein lysates were applied to the columns 
and reloaded twice before being washed with 0.1% TFA and eluted using 80% MeCN/20% 
H2O/0.1% TFA. 
5.2.5 Phosphopeptide Enrichment and Clean-Up. 
Following protein digestion and solid-phase extraction, replicates were dried down using 
vacuum centrifugation and phosphopeptide enrichment was performed on 2 mg aliquots of each 
sample using 3 mg Titansphere Phos-TiO2 kit spin columns (GL Sciences) as previously 
described24, 41. After enrichment, samples were dried down and resuspended in 15 µL of 1% 
formic acid and 2% MeCN prior to desalting using ZipTips (Millipore). Briefly, ZipTip sample 
clean-up involved equilibrating tip-based columns 3x with 10 µL of 100% MeCN followed by 
3x with 10 µL of 0.1% formic acid. Peptides were then loaded on the ZipTip by passing the 
lysate through 10x. After loading peptides onto the column, ZipTips were washed 6x with 10 µL 
of 0.1% formic acid and eluted using 5 µL of 60% MeCN/0.1% formic acid repeatedly pipetting 
the ZipTip up and down 10x. 
5.2.6 LC-MS/MS Acquisition and Data Processing 
Following ZipTip clean-up, peptides were dried down and resuspended in 20 µL of 0.1% 
TFA, 5% MeCN with 25% of total sample loaded onto the column for LC-MS/MS analysis. 
Separation using a C18 column (NanoAcquity UPLC 1.8 μm HSS T3, 75 μm × 250 mm) was 
performed via a 90-min linear gradient from 95% H2O/5% MeCN/0.1% formic acid (FA) to 65% 
H2O/35% MeCN/0.1% FA via a NanoAcquity UPLC (Waters). Each sample was loaded onto a 
trap column (NanoAcquity UPLC 2G-W/M Trap 5 μm Symmetry C18, 180 μm × 20 mm) at a 
flow rate of 5 μL min–1 for 5 min. Peptides were separated using a C18 column (NanoAcquity 
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UPLC 1.8 μm HSS T3, 75 μm × 250 mm) at a flow rate of 300 nL min–1. A TripleTOF 5600 
(AB Sciex) Q-TOF was operated in positive-ionization nanoelectrospray and high-sensitivity 
mode for data acquisition as previously described42. The MS survey spectrum was accumulated 
from a mass range of 350 to 1250 m/z in 250 ms. For MS/MS experiments, the first 20 features 
above 150 counts threshold and having a charge state of +2 to +5 were fragmented using rolling 
collision energy ±5%, with 87.5 ms spectra accumulation/experiment. 
Acquired spectra (*.wiff) files were imported into Progenesis QI for proteomics (v2.0, 
Nonlinear Dynamics) as previously described41 with peptide sequence determination and protein 
inference done by Mascot (v.2.5.1; Matrix Science) using the C. reinhardtii Phytozome v.11 
database (www.phytozome.net/; accessed May 2015) appended with the NCBI chloroplast and 
mitochondrial databases (19,603 entries) and sequences for common laboratory contaminants 
(http://thegpm.org/cRAP/; 116 entries). For database searching, trypsin protease specificity with 
up to two missed cleavages, peptide/fragment mass tolerances of 20 ppm/0.1 Da, a fixed 
modification of carbamidomethylation at cysteine, and variable modifications of acetylation at 
the protein N-terminus, oxidation at methionine, deamidation at asparagine or glutamine, 
phosphorylation at serine or threonine and phosphorylation at tyrosine were used. Peptide false 
discovery rates (FDR) were adjusted to ≤1% using the Mascot Percolator algorithm43 and only 
peptides with a Mascot ion score over 13 were considered.  
Custom scripts written in Python were implemented to parse results following data 
normalization and quantification in Progenesis QI for proteomics as previously described24, 41. 
Shared peptides between proteins were grouped together to satisfy the principle of parsimony 
and represented in Table S1 by the protein accession with the highest amount of unique peptides, 
otherwise the largest confidence score assigned by Progenesis QI for proteomics. Additionally, 
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the script appended site localization of variable modifications using an implementation of the 
Mascot Delta Score44 to the peptide measurements (*.csv) export from Progenesis QI for 
proteomics with confident site localization considered a Mascot Delta score >90%. Following 
scoring, only peptides with phosphorylation at serine, threonine, or tyrosine were considered for 
further processing and analysis. Additionally, a coefficient of variation filter to remove highly 
variable sites that were remaining was performed removing sites with >25% coefficient of 
variation in both control and rapamycin-treated subsets prior to statistical testing. 
Supporting Information tables and raw mass spectrometry data have been deposited to the 
ProteomeXChange Consortium via PRIDE partner repository45 identifier PXD009163.  
5.2.7 Downstream Bioinformatic Analysis. 
Missing value imputation was performed on logarithmized normalized abundances in Perseus 
v1.6.0.046-47 requiring at least three of the five replicates in rapamycin-treated and control to be 
nonzero to continue through the workflow. Missing values were replaced by random numbers 
drawn from a normal distribution on log-transformed normalized abundances46, 48. This was 
performed using default parameters in the statistical software Perseus v1.6.0.0 optimized to 
mimic the circumstance that typically missing values represent low abundance measurements49. 
For two sample Student’s T-test analyses, replicates were grouped and the statistical tests were 
performed with fold change ±2 and p≤0.05 significance threshold to compare control and 
rapamycin-treated replicates. KEGG pathway annotation50, Gene Ontology (GO)51 term 
annotation, hierarchical clustering, and motif analysis were performed following statistical 
testing to glean biological insight on modulated sites found in the study. For hierarchical 
clustering, visualization was performed in Perseus v1.6.0.0. Following data normalization and 
missing value imputation, intensity values were z-score normalized and grouped using k-means 
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clustering with default parameters for hierarchical clustering. For motif analysis, sites ±7 around 
the phosphosites in each cluster were visualized using pLOGO. Positions with significant residue 
presence are depicted as amino acid letters sized above the red line52. 
5.3 Results and Discussion 
5.3.1 Experimental Design 
Vip1-1 mutant cells were treated with a saturating dose of rapamycin (500 µM)7, 11 for 15 
minutes to study early phosphorylation changes. The concentration for rapamycin treatment was 
based on the concentration used to characterize the vip1-1 mutant line previously11 and the 15-
minute time point was based on the time point used in TOR inhibition phosphoproteomic studies 
in Chlamydomonas24 and other organisms53-55.  
5.3.2 Quantitative Coverage of the TOR-Inhibited Phosphoproteome in vip1-1 Mutant 
Five replicates of vip1-1 mutant cells treated with rapamycin were compared to five control 
replicates treated with drug vehicle (DMSO) to study the TOR-inhibited phosphoproteome using 
a label-free quantitative approach. Quantitative coverage on 2,699 phosphosites inferred to 1,442 
phosphoproteins (Table S1) was obtained. The majority of sites were found on serine with 82.4% 
(pS), 16.2% of sites phosphorylated on threonine (pT), and 1.4% phosphorylated on tyrosine 
(pY) (Figure 5.1A).  The majority, 90.8%, of phosphopeptides quantified, were singly 
phosphorylated with 8.2% doubly phosphorylated, and 1% multiply phosphorylated (Figure 
5.1B), similar to what has been found in previous investigations24, 41, 56. 
Inhibition of TOR in the Vip1-1 rapamycin-hypersensitive mutant revealed 316 phosphosites 
from 281 phosphopeptides significantly changing with at least a two-fold change and a p-value ≤ 
0.05 (Figure 5.2, Table S2). These sites are comprised of previously identified phosphosites that 
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are known to be TOR-regulated and highlighted in Table 5.1 in addition to novel sites that are 
significantly changing in the vip1-1 mutant but not previously in wild-type studies24.  
5.3.3 Cluster Analysis and Phosphosite Motif Identification. 
To identify significant trends among the phosphosites changing following TOR inhibition, 
hierarchical k-means clustering was performed resulting in 2 clusters for increasing and 
decreasing sites (Figure 5.3 A,B). Each cluster was examined for significant motifs surrounding 
phosphosites (Figure 5.3 C) since amino acid residues immediately surrounding phosphorylation 
sites on substrates can dictate kinase specificity57. Cluster 1, which is composed of sites 
increasing in abundance following rapamycin treatment, had significant enrichment for an 
aspartic acid residue in the +2 position and glutamic acids in the +3 and +4 positions with respect 
to the phosphorylation site (position 0). These sites indicate an overall acidic motif on the C-
terminal side of the phosphorylation sites. An acidic motif comprised of an enrichment for an 
aspartic acid in the +3 position was identified in the sites increasing in the wild-type study24 but 
additional sites in the +2 and +4 positions were only identified in the vip1-1 strain. This 
enhanced acidic motif may be connected to inositol polyphosphate signaling in Chlamydomonas, 
as acidic residues C-terminal to phosphoserines in yeast have been shown to be critical for 
inositol pyrophosphate signaling and is presumed to be required for binding to magnesium58. In 
cluster 2, which is composed of sites decreasing in abundance following rapamycin treatment, 
there was significant enrichment for a proline in the +1 position indicating substrates for proline-
directed kinases. This common motif was also identified in decreasing sites in the wild-type. 
However, common rapamycin-sensitive motifs such as RXRXXS/T and RXXS/T seen in wild-
type and previous mammalian cell line studies55 were not identified in either cluster 1 or 2 in 
vip1-1.  
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5.3.4 Phosphosites Modulated by TORC1 Inhibition in vip1-1 Strain– Known and Putative 
Substrates 
To begin to understand TOR signaling in vip1-1, proteins that are known TOR targets or 
associated with the pathway, based on homology to other systems21 and from previous TOR 
studies in Chlamydomonas7, 24, 59-60, were evaluated (Table 5.1). Sites on two proteins conserved 
in the CrTORC1 complex, TOR and RAPTOR, were identified in this study. Two phosphosites 
on CrTOR (Cre09.g400553.t1.1), S770/773:NL and S2598, were identified in addition to one 
phosphosite on RAPTOR (Cre08.g371957.t1.1), S782/S783:NL. Site S770/773:NL on CrTOR 
significantly decreased 2.86-fold in abundance following rapamycin treatment. Overall, 28 sites 
on 14 proteins were identified (Table 5.1) and 18 of the 28 sites (64%) were also identified in the 
wild-type study while 10 were unique, including protein kinases related to signal transduction 
regulating carbon metabolism in plants61. 
A phosphosite on a protein kinase related to energy sensing, CrSNF1 (T189/S190/S193:NL, 
Cre04.g211600.t1.1), was identified in this study as increasing by 1.73-fold following TOR 
inhibition. T189/S190/S193:NL is potentially the conserved site to T198 in Arabidopsis and 
T210 in yeast and is contained in the activation loop. This phosphorylation site regulates the 
catalytic activity of the kinase domain in Arabidopsis62-63 and yeast64 with rapamycin shown to 
induce an increase in phosphorylation at T210 in yeast65-66 with similar functionality possible in 
Chlamydomonas based on our vip1-1 findings. A site on another protein kinase, CrPDPK1 
(Cre11.g467568.t1.1), increased in phosphorylation following TOR inhibition. S403 on 
CrPDPK1, a site C-terminal to the kinase catalytic domain (Accession: cl21453), increased by 
2.56-fold and reports in mammalian studies have shown regulation of PDPK1 by inositol 
phosphates or pyrophosphates67.  
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5.3.5 Comparison of vip1-1 Mutant Study to Wild-Type TOR Inhibited Phosphoproteome 
Study 
To compare the phosphorylation sites modulated by TOR inhibition in this study to the wild-
type, fold-changes for differential sites were compared to wild-type fold-changes following TOR 
inhibition24. Of the 281 phosphopeptides changing, 97 (35%) of them overlap with sites 
identified in the previous wild-type work. This suggests most sites experimentally identified as 
TOR-regulated in the vip1-1 mutant were not detected in the wild-type study.  
For those that do overlap, Table 5.1 shows the fold-change comparison for TOR-associated 
proteins in Chlamydomonas and Table S2 provides this information on all differential sites. For 
TOR-associated sites, similar modulation following rapamycin treatment was observed across 
strains as demonstrated by S817 on LARP1 decreasing phosphorylation by 6.66-fold and 7.69-
fold in the vip1-1 mutant and wild-type strains, respectively. Additionally, heightened fold-
changes were observed in CrPRKAB which increased in phosphorylation abundance by 4.28-
fold in the vip1-1 mutant as compared to 2.27-fold in wild-type. This non-catalytic subunit of 
AMPK with a conserved 5'-AMP-activated protein kinase beta subunit, interaction domain 
(pfam: PF04739) serves as an energy sensor protein and the regulatory subunit monitoring 
cellular energy status activated under cellular metabolic stresses. Because of this, a larger 
modulation was observed in the rapamycin hypersensitive vip1-1 mutant. Other sites with 
heightened fold-changes include S155/157:NL on carnosine synthase protein 
(Cre13.g582800.t1.2), a protein with a conserved ATP-grasp domain (pfam: PF02655), that 
decreased 17.9-fold in vip1-1 mutant and 7.2-fold in wild type.  
Interestingly, numerous sites on phosphoproteins were identified with opposite trends in the 
mutant strain than were detected in wild-type (Table 5.2) such as Ser23/25:NL on pfkB-like 
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carbohydrate kinase protein (Cre06.g250500.t1.2). This protein has a conserved carbohydrate 
domain (pfam: PF01256) and ADP-dependent NAD(P)H-hydrate dehydratase activity based on 
gene ontology (GO:0052855). This site had a 1.78-fold increase following rapamycin treatment 
but in the mutant line, had a 2.56-fold decrease. Similarly, Ser481 of NAD(P)-binding 
Rossmann-fold superfamily protein (Cre06.g269050.t1.2), which has a conserved NAD(P)H-
binding domain conserved (pfam: PF13460), had a 2.38-fold decrease in wild-type but increased 
by 4.79-fold in the vip1-1 mutant. These sites, in addition to sites uniformly changing across cell 
lines, could help to increase the understanding between how the two kinase signaling pathways 
interact in Chlamydomonas. In combination with the previous work suggesting that InsPs play an 
essential role in cell growth through the discovery of interplay between these two pathways11, 
this work aims to better understand the relationship between TOR and InsPs through delineating 
overlapping targets and targets unique to both studies. 
5.3.6 Additional Proteins with Phosphosites Altered by TORC1 Inhibition 
Many of the sites changing from this study are from phosphoproteins not previously 
identified as TOR-regulated, including some phosphoproteins with numerous unique sites 
changing. For example, two proteins related to MAPK signaling, NPK1-related protein kinase 2 
(Cre10.g464100.t1.2) and a MAPKK-related protein (Cre06.g310100.t1.2), had two 
phosphosites each decreasing in phosphorylation (Table S2). Another protein, a rhodanese/cell 
cycle control phosphatase superfamily protein (Cre01.g003550.t1.1), had two sites, S763 and 
T764, increasing by 3.56- and 4.30- fold, respectively. While their function has not been 
explored in Chlamydomonas, cell cycle regulatory phosphatases are known to be critical as cell-
cycle checkpoint controls68. 
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The doubly phosphorylated phosphopeptide S1078-S1081 on the glycine-rich protein 
Cre12.g549150.t1.1 had the most significant fold change decrease of 55-fold following TOR 
inhibition. Additionally, two other phosphopeptides from this protein, the doubly phosphorylated 
S988-S991 and a monophosphorylated S1078, were also significantly decreasing, both by 4-fold. 
Glycine-rich proteins have been indicated in stress response in other plant species69 but there is 
limited site conservation to Chlamydomonas based on BLASTP analysis. While that limits the 
ability to infer biological significance on this finding, a previous phosphoproteomic study in 
Chlamydomonas identified S1078 as significantly decreasing following 72 hours of nitrogen 
depletion70, indicating that this site is potentially important for energy metabolism from both of 
these findings.  
5.3.7 Glycolysis-Related Enzymes Modulated by TOR Inhibition 
Key enzymes in the glycolytic pathway in Chlamydomonas have been reported to be under 
protein phosphorylation control71. A comprehensive study found seven of the ten enzymes of the 
late glycolytic pathway required for the conversion of fructose 1,6-bisphosphate to pyruvate to 
be phosphorylated56. In this study, we identified numerous sites on these enzymes and other 
proteins involved in glycolysis that were modulated following TOR inhibition including three 
pyruvate kinase family proteins (Cre03.g144847.t1.1 T34/36:NL, T88/S90:NL, T663/S665:NL, 
Cre05.g234700.t1.1 T63/S64:NL, Cre06.g280950.t1.2 S463/S466:NL) which are important 
regulatory enzymes since they perform irreversible steps in the pathway. Other phosphoproteins 
that had sites modulated include enolase (Cre12.g513200.t1.2 S417/T420:NL), an E1 component 
alpha subunit of the pyruvate dehydrogenase complex (Cre07.g337650.t1.2 S294/S296:NL), 
pyruvate orthophosphate dikinase (Cre17.g734548.t1.1 T535/S536:NL), and a 
phosphofructokinase (Cre06.g262900.t1.2 S81) that increased by 1.6-fold. Overall, these sites 
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were increasing following inhibition (Table S2) except T63/S64:NL on Cre05.g234700.t1.1, a 
pyruvate kinase family protein that decreased by 4-fold. Inositol pyrophosphates have been 
shown to participate in the control of intracellular ATP concentrations in yeast with mutants 
devoid of inositol pyrophosphates having increased glycolysis72. In this study, coverage on 
phosphosites that were not detected in the wild-type study on enzymes involved in glycolysis 
was obtained. The increases in phosphorylation following rapamycin treatment suggest a similar 
role of enhanced glycolysis and decreased ATP-consuming metabolic processes such as 
biosynthesis of macromolecules following TOR inhibition. 
5.4 Conclusion/Summary 
The objective of this study was to characterize the effect of TOR inhibition on the vip1-1 
Chlamydomonas mutant. The rapamycin-hypersensitive strain showed similarities with the sites 
modulated in the wild-type study while also providing other distinct groups of phosphosites not 
previously interrogated or without coverage in wild-type such as numerous sites on 
phosphoproteins related to glycolysis and energy metabolism. Common rapamycin-sensitive 
motifs such as RXRXXS/T and RXXS/T were not identified. A more pronounced acidic motif, 
S/TXEDE, was found in the mutant line over the wild-type, with implications to similar function 
to the critical sequence motifs found in inositol pyrophosphate signaling in yeast.  This could 
relate to the large subset of novel sites modulated just in the vip1-1 mutant study, however future 




Table 5.1 TOR targets identified with fold change values for rapamycin vs. control in the vip1-1 
mutant study compared to wild-type values from the study performed in wild-type24. Fold change 
values shaded red indicate a statistically signficant increase in phosphopeptide abundance for 
rapamycin versus control. Fold change values shaded blue indicate a statistically significant 
decrease in phosphopeptide abundance for rapamycin versus control. Sites that do not have a 
corresponding fold-change in the wild-type study because they were not identified are denoted 





Table 5.2 TOR inhibited sites in vip1-1 mutant with opposite trends from sites identified in the 
rapamycin study performed in the wild-type24. Fold change values shaded red indicate a 
statistically signficant increase in phosphopeptide abundance for rapamycin versus control. Fold 
change values shaded blue indicate a statistically significant decrease in phosphopeptide 
abundance for rapamycin versus control. Level of p-value statistical significance is denoted by p-







Figure 5.1 Quantitative coverage of the phosphoproteome of Chlamydomonas vip1-1 mutant 
following TOR inhibition. A pie chart showing the ratio of sites phosphorylated in this study 
with 82.4% pSer, 16.2% pThr, and 1.4% pY (A). From the sites detected in this study, a bar chart 
with the amount of phosphorylation events detected per peptide with >90% of phosphopeptides 




Figure 5.2 Volcano plot of phosphosites modulated by TOR inhibition in a vip1-1 
Chlamydomonas mutant. 149 sites significantly decreasing are shaded blue and 132 sites 
significantly increasing are shaded red. Differentially changing sites were determined using a 




Figure 5.3 Hierarchical clustering of differentially changing sites into 2 clusters (A). 
Visualization was performed in Perseus v1.6.0.0. Following data normalization and missing 
value imputation, intensity values were z-score normalized and grouped using k-means 
clustering with default parameters. Overall trends in site intensity were graphed and colored 
based on intensity (B). For each of the two clusters, motif analysis was performed (C): motif 
analysis on clusters 1 and 2 from hierarchical clustering. Sequence logo visualizations were 
performed using pLOGO with serine or threonine residues fixed at position 0. Positions with 
significant residue presence are depicted as amino acid letters sized above the red line. For 
cluster 1, there was significant enrichment for S/TXDEE motif with a significant amount of C-
terminal acidic residues in the +2, +3, and +4 positions. For cluster 2, there was significant 
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CHAPTER 6:  Conclusions and Future Directions 
6.1 Conclusions 
The overall goal of this work was to develop and implement label-free quantitative 
workflows to study the kinome and phosphoproteome in Chlamydomonas. This effort was 
derived from the limited understanding of the regulatory role post-translational modifications 
play in cellular signaling as it applies to kinase signaling pathways, specifically Target of 
Rapamycin kinase signaling, in Chlamydomonas. Prior to this work, a quantitative strategy to 
effectively probe dynamic protein phosphorylation following chemical inhibition in 
Chlamydomonas was limited, especially on the global scale.  
Phosphorylated protein detection in photosynthetic organisms has a history of almost three 
decades1. The ability to employ quantitative phosphoproteomic approaches using mass 
spectrometry, however, is relatively new, and at first traditionally focused on gel-based 
methods2. As advances in mass spectrometry continued to improve throughout the past few 
decades for proteomic applications3-4, detection of thousands of peptides or phosphopeptides in a 
single run became feasible. With this came the opportunity to solve complex biological questions 
requiring quantitative workflows. Efforts to employ quantitative phosphoproteomics in model 
mammalian systems benefitted extensively from this, creating workflows focused on improving 
human health. From this, high-quality, comprehensive, and freely accessible platforms for 
sharing functional information amongst the scientific community were furthered and continue to 
improve. During this time, significant advancements in the bioinformatic toolkit for studying 
plant-specific networks were also ongoing and helped push forward the significance behind   
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“omic” studies in plants as well. The extensive effort to integrate annotations from multiple 
protein analysis tools and protein homology across organisms, in addition to the advances in 
high-mass accuracy and high-resolving power instrumentation, allow for biological inference 
required to make sense of large-scale proteomic and phosphoproteomic data. While this process 
is constantly improving, the advancements in instrumentation and annotations into protein’s 
functionalities that are available permit quantitative label-free workflows such as the one 
developed in this work to exist. 
One of the primary advantages to using this label-free quantitative approach developed for 
investigating the kinome and phosphoproteome in Chlamydomonas is the ability to implement 
the platform on a wide array of potential experimental designs. In this workflow, >2,500 
phosphosites per experiment are consistently quantified with special attention focused on 
reproducibility both at the lab bench and in the data analysis processing post-acquisition. 
Development and implementation of this discovery-based method have led to a better 
understanding of TOR signaling in Chlamydomonas with new insights into the role of LARP1 in 
TOR signaling on downstream protein synthesis, evidence that carotenoid production is under 
TOR control, and further exploration into the interplay with inositol pyrophosphate signaling. 
Additionally, this work has guided follow-up efforts to continue to investigate the 
phosphorylation networks governed by the TOR kinase pathway in Chlamydomonas. This 
includes raising anti-phospho antibodies for site validation on targets of interest and follow-up 
affinity purification-mass spectrometry (AP-MS) experiments prioritized by tagging promising 
targets from this work to examine their interactome in Chlamydomonas through protein-protein 
interactions. 
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This workflow has been shown to successfully identify TOR-modulated phosphosites that 
play fundamental roles in TOR signaling in Chlamydomonas. Since this platform is discovery-
based and capable of optimization for a wide array of plant starting materials, future work in 
other kinase signaling networks in Chlamydomonas and in other photosynthetic organisms is 
possible moving forward. Through collaborative efforts, investigation into various other signal 
transduction pathways in Chlamydomonas and Arabidopsis are ongoing and while technology 
and informatics continue to improve, the ability to learn more from discovery-based methods 
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